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ABSTRACT 
The first aim of this thesis was to systematically review the literature to determine the 
diagnostic accuracy of ultrasound in the first trimester to screen for twin-twin transfusion 
syndrome (TTTS) and predict its outcome after diagnosis, as well as the effectiveness of its 
two main treatments.  Quantitative analysis revealed that a crown rump discordance or 
abnormal nuchal translucency in the first trimester was useful to screen for TTTS, but after 
diagnosis no single test could reliably predict outcome.  In both situations a negative test was 
not reliable for excluding TTTS or a poor outcome.  Fetoscopic laser ablation (FLA) is likely to 
confer a benefit both in terms of survival and morbidity in survivors.  
 The second aim was to determine what happened to biological markers in TTTS and 
how FLA affected them.  It appeared that TTTS may be associated with abnormal 
placentation as maternal serum -fetoprotein (MSAFP) approximately doubled and free -
human chorionic gonadotrophin (f-hCG) tripled. The balance of angiogenic factors i.e. 2-3 
fold increased angiogenin 2 and 1.5 fold increased soluble vascular endothelial growth factor 
receptor 1 appeared to favour angiogenesis in response to hypoxia or ischaemia in TTTS.  
Maternal cell-free messenger RNA was reliably detected and showed similar alteration in 
angiogenic markers.  Interestingly, TTTS was associated with minimal changes in cytokine 
levels.   In response to FLA there was an increase in transplacental haemorrhage (MSAFP 
increased 445%) rather than trophoblast destruction (f-hCG unchanged) as well as a 
transient increase in some anti-angiogenic markers.  Although, in general angiogenic factors 
and cytokines are altered little by this therapy.  If the biomarker changes detected precede 
the onset of clinically apparent disease, they may be useful to improve the performance of 
first trimester ultrasound screening.  Composite tests may be more useful to predict outcome 
and FLA should continue to be utilised to reduce morbidity.     
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 The epidemiology and aetiology of twin-twin transfusion 
syndrome 
 
The incidence of multiple pregnancy is increasing, with a rise in the use of assisted 
conception techniques and delayed child bearing1.  More specifically, in 2010, 11,053 
women gave birth to twins, equating to 1 in 32 babies being born a twin (this figure 
includes both live and stillbirths)2.  This is a considerable rise from 30 years ago, when 
the figure was 1 in 522, and of great significance to modern obstetric care as twin 
pregnancy, as with any multiple pregnancy, carries increased risks of maternal and 
perinatal complications1 3.  
 
1.1.1 The Relationship between zygosity and chorionicity 
Twin pregnancies can either result from fertilisation of a single ovum by a single sperm, 
monozygous (MZ) twins, or from fertilization of two ova by two sperm, dizygous (DZ) 
twins.  Approximately one-third of twins are MZ and two-thirds are DZ.  Dizygous twins 
are non-identical and will always have separate placentae (dichorionic twins).  However, 
in MZ or identical twins the number of placentae that develop is dependent on the timing 
of the single fertilised egg (zygote) splitting (see figure 1-1).  In one-third the zygote 
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splits before 72 hours and two placental discs develop producing dichorionic (DC) 
twins4. In the remaining two-thirds splitting of the zygote occurs after 72 hours, when the 
inner cell mass has formed and then a single placenta develops (monochorionic (MC) 
twins), most commonly with two amnions, monochorionic diamniotic (MCDA) twins4.  
However, if the cellular mass splits after one week then the result is twins that share not 
only the same placenta but also the same amniotic sac, monochrionic monoamniotic 
(MCMA) twins (<1%)2.  Overall, approximately one-fifth of twins are MC and four-fifths 
are DC5. 
 
Figure 1-1 Diagrammatic representation of the development and placentation of 
monozygotic twins depending on the timing of the zygote splitting. 
 
Adapted from Wigglesworth JS. The Placenta in twins. In: Ward RH, Whittle M, editors. Multiple Pregnancy. 
London: RCOG Press. 1995. Pages 48 - 55
4
. 
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It is however, chorionicity rather than zygosity that determines perinatal risk in a twin 
pregnancy, such that perinatal mortality in MC twin pregnancies is up to five times 
higher than in DC twin pregnancies6 7.  This is important because chorionicity can be 
reliably diagnosed by first trimester ultrasound scan8-10 by noting the following features: 
a) The number of placental masses 
b) The presence of a triangular tissue projection extending from the base of the inter-
twin membrane, referred to as a -sign, or the absence of this, referred to as a T-sign.   
The pregnancy is diagnosed as MC in the presence of a single placental mass and 
evidence of a T-sign, and DC if a -sign or two separate placental masses are present.   
 
Figure 1-2 showing the difference between the T-sign in monochorionic twins and 
the λ-sign in dichorionic twins  
 
 
 
 
 
 
 
T - sign 
λ - sign 
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It is the case that all MC twins are monozygous, although the same cannot be assumed 
with respect to DC twins, as these can be either mono- or dizygous depending on the 
timing of the zygote splitting as described above. 
 
1.1.2 Definition of TTTS 
Twin-twin transfusion syndrome (TTTS) is a relatively unusual condition as genetically 
concordant (i.e. monozygous) twins develop phenotypically discordant features.  It is in 
MCDA twins that TTTS commonly develops, complicating 10-15% overall, of whom 
50% are severely affected with the clinical features being apparent by 22 weeks of 
gestation11.  TTTS is a clinical condition characterised by the development of discordant 
amniotic fluid volumes (usually in the diamniotic sacs).  The criteria for diagnosis are 
ultrasound based and require demonstration of a significant discrepancy in amniotic 
fluid volumes with the presence of oligohydramnios (defined as a maximal vertical pool 
(MVP) of ≤2 cm) in one sac, and of polyhydramnios (a MVP of 8 cm, or 10cm after 20 
weeks) in the other sac in a MC twin pair. TTTS is thought to be secondary to a chronic 
imbalance of inter-twin blood flow and haemodynamic pressures within the twin fetal 
circulations12 and the twins are described in terms of being either the ‘donor’ or the 
‘recipient’ in this imbalance.  The ‘donor’ is relatively hypoperfused and hypotensive with 
associated poor renal perfusion and subsequently urine output.  This makes ultrasound 
visualisation of a fetal bladder difficult and leads to significant oligohydramnios.  In the 
‘recipient’ twin, there is a hyperdynamic circulation, with associated increased renal 
perfusion, polyuria and polyhydramnios13.   
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1.1.3 Placental angioarchitecture in TTTS 
It was the German Obstetrician Friedrich Schatz who first described TTTS in 1875 
based on his work on monochorionic placentas14.  He discovered the presence of 
connections between twins, for which he coined the term the “third circulation”.  He 
recognised the vascular connections within the placenta that are now considered an 
anatomical prerequisite for the development of TTTS. Work since then has largely 
focused on the inter-twin angioarchitecture, with numerous complex variations having 
been described15.  In the second week of embryological development trophoblast 
invasion of maternal blood vessels occurs to form lucanae or intervillous spaces, 
between which villi begin to appear in branches16.  From the third week the intravillous 
vascular network develops and connects with the allantoic vessels to establish the feto-
placental circulation17.  All monochorionic placentae have vascular connections and the 
majority of connections will form appropriately from the vein to artery of the same 
embryo17.  However, where the expanding chorionic vessels from individual embryos 
overlap there is the potential for inter-twin connections to form17.  Attrition of chorionic 
villi is a normal process in placental development18, however, if an intertwin connected 
villous area is lost the overall pattern of the connections may change19.  TTTS has been 
postulated to develop where the random disruption of anastomoses, and regression of 
their associated villous districts, results in unequal loss of these placental 
anastomoses17.  It is therefore known that all monochorionic placentae have vascular 
anastomoses in two forms: either direct connections – arterioarterial (AA)/ venovenous 
(VV), or via a shared cotyledon where an artery from one twin drains into the vein of the 
other, so-called arterio-venous (AV) connections20.  However, flow between the twins is 
usually roughly balanced as there are AV anastomoses in both directions, and any 
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imbalance can usually be compensated for by AA/VV anastomoses21.  In particular AA 
anastomoses appear to have a ‘protective role’ given that where an AA anastomoses is 
detected the incidence of TTTS is 15% compared to 61% if no AA anastomoses are 
present22.  In summary, TTTS occurs when the pattern of anastomoses present 
facilitates an overall preponderance of flow from the donor to the recipient21.   
 
TTTS is uncommon, which, coupled with the lack of a suitable animal model have made 
studying the angioarchitecture of the placenta more difficult.  Specialists have 
traditionally had to limit themselves to in-utero assessment by ultrasound, with 
subsequent pathological examinations of the placenta.  More recently, Van Gemert’s 
group has performed work using mathematical modelling23-25.  They have suggested 
models incorporating different patterns of vascular connections, which seek to explain 
why only some MCDA placentae develop TTTS and why the severity varies23.  In the 
first model, MC twins with unidirectional AV anastomoses, the “net transfusion” from 
donor to recipient reduces the donor’s blood volume, blood pressure, urine production, 
blood osmolality and therefore colloid osmotic pressure (COP)25.  It follows that the 
donor becomes progressively growth restricted.  In addition, donor swallowing and 
intramembranous absorption of amniotic fluid declines in line with the blood 
osmolality/COP.  The reduction in COP will therefore eventually cause a decline in net 
flow to the recipient.  The size of the AV anastomoses will dictate the severity of the 
discrepancy between the donor and the recipient, such that large calibre AV 
anastomoses result in a more pronounced discordance in fetal size and amniotic fluid 
volumes.  
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In the proposed second model, compensating superficial anastomoses exist but the 
original net flow from the donor twin causes the same decrease in blood pressure as 
previously described.  However, this facilitates flow in the compensating AA 
anastomoses in the opposite direction25 and mitigates the decrease in the donor’s 
haemodynamic (blood) pressure so that urine production will be maintained, albeit at a 
lower rate (than in uncomplicated monochorionic twins).  In the third model, bi-
directional AV anastomoses are present such that the flow from the donor to the 
recipient is compensated by oppositely directed anastomoses, as is suggested to be the 
most common scenario in TTTS12.  The result is similar to that seen in AV anastomoses 
with compensating AA anastomoses, i.e. a steady haemodynamic state of relatively 
small net transfusion25.  Finally, the fourth model includes “unequal placental sharing” 
so the twins develop discordance in size and amniotic fluid volume.  However, if a 
compensating AV anastomosis exists from the larger to the smaller twin the onset of 
TTTS will be at a later gestational age and the earlier discordance in growth/amniotic 
fluid accounted for by the differences in placental mass will be reversed, with the larger 
twin becoming the donor and the smaller the recipient25.   
 
These models help to explain the differing clinical presentations and perinatal outcomes 
observed in twin pairs affected by TTTS.  In summary, they propose that unidirectional 
transfusion from donor to recipient causes progressive and irreversible fetal 
discordance because anastomotic blood flow increases faster than the natural growth 
rate expected for each fetus24.  In MC placentae with only unidirectional AV 
anastomoses this fetal discordance will continue until the driving anastomotic pressure 
difference becomes small, whereas in the presence of compensating anastomoses the 
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discordance will develop but the net twin-to-twin transfusion will then trend to zero as 
compensation occurs (and discordance will therefore persist but not increase)24.  
Conversely, where there is “unequal sharing of the placental disc” and compensating 
anastomoses, anastomotic blood flow will grow faster than natural fetal growth and this 
will reverse the discordant growth expected by the unequal placental masses24.   
 
Such theoretical, mathematical work has offered comprehensive and logical models, 
which describe and help to explain the varying timing and severity of clinical 
presentation in TTTS.  The authors of this work acknowledge that by necessity various 
simplifications and assumptions were necessary to account for gaps in our current 
knowledge and make the equations from which they worked feasible.  One of these 
simplifications relates to overlooking potential fetal compensatory mechanisms, as well 
as other humoural and endocrine components, which have been implicated in the 
pathophysiology of TTTS26. 
 
  
1.1.4 Ultrasound findings in TTTS 
The severity of TTTS, in terms of reflecting prognosis and outcome, has been outlined 
in a clinical staging classification first described by Dr. Ruben Quintero27.   
Stage I: The fetal bladder of the donor twin remains visible ultrasonographically. 
Stage II: The bladder of the donor twin is collapsed and not visible by ultrasound. 
Stage III: Critically abnormal fetal Doppler studies noted. This may include absent or 
reversed end-diastolic velocity in the umbilical artery, reverse flow in the ductus 
venosus and/ or pulsatile flow in the umbilical vein. 
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Stage IV: Fetal hydrops in either twin (most commonly the recipient). 
Stage V: Demise of either twin. 
 
Quintero staging27 describes the prerequisite inter-twin discrepancy in amniotic fluid 
volumes as well as inter-twin haemodynamic disturbance observed ultrasonographically 
in the MC pregnancy27.  Donor and recipient twin haemodynamic disturbance is 
therefore reflected in the amniotic fluid volumes and the presence or absence of a donor 
fetal bladder but ultrasound also allows measurement of blood velocities within the 
peripheral and intracardiac arterial and venous fetal circulations by Doppler insonation.  
In-utero, the right ventricle contributes 60-70% of cardiac output and this is achieved by 
flow being distributed through the ductus arteriosus, to bypass the lungs, and the 
foramen ovale, to shunt blood directly from the right atrium to the left atrium28.  The 
other fetal circulatory adaptation involves the ductus venosus, which is the shunt from 
the umbilical vein to the inferior vena cava that allows blood to bypass the liver28.  
Objective ultrasound measurements of fetal cardiac function (or dysfunction) include: 
cardiothoracic ratio; ventricular chamber dimensions and freewall thickness; valvular 
regurgitation (atrioventricular (mitral/tricuspid), aortic and pulmonary); and assessment 
of systolic and diastolic function29-31.  Systolic function describes ventricular contraction 
and ejection, whereas diastolic function refers to the ability of the ventricle to fill29.  
Abnormalities such as reversed flow in the ductus venosus and/or pulsatile flow 
umbilical vein are indirect measures of fetal diastolic dysfunction29.  In TTTS, the donor 
twin has been demonstrated to have a higher heart rate than the recipient, which is 
thought to be a compensatory mechanism for the decreased circulating volume32.  
However, it is in the recipient where abnormal cardiovascular changes correspond to 
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the severity of TTTS29.  In the recipient, there is an increase in cardiothoracic ratio, 
which is thought to be due to cardiac hypertrophy rather than dilatation29 32.  It has also 
been shown that ventricular hypertrophy and diastolic dysfunction precedes systolic 
dysfunction, and that there is greater compromise of the right ventricular rather than left 
ventricular function29.  This is exemplified by the higher incidence of tricuspid valve (the 
atrioventricular valve on the right side of the heart) than mitral valve regurgitation (the 
atrioventricular valve on the left side of the heart) (60% vs. 38%)29.  Right ventricular 
dysfunction, encompassed by hypertrophy and reduced RV ejection fraction, in 
combination with tricuspid regurgitation can contribute to anatomical right ventricular 
outflow obstruction and eventually hydrops29.   
 
Doppler assessment can also assess the feto-placental circulation.  Umbilical artery 
Doppler velocimetry reflects placental function and any abnormality can identify a 
placental lesion33.  Although it cannot predict the extent of fetal compromise abnormality 
does indicate a pregnancy at higher risk of perinatal mortality33 and it is therefore useful 
for monitoring in the setting of twin pregnancy, where perinatal mortality is known to be 
higher1.  Cardiovascular scores, which can include umbilical artery Doppler 
assessment, have been suggested to standardise the assessment of the changes seen 
in TTTS, and several have been described34-36.  The Children’s Hospital of Philadelphia 
(CHOP) score is the most widely used and encompasses 12 parameters, 11 in the 
recipient and one in donor, which are graded according to severity36. 
 
This thesis assesses the diagnostic accuracy of conventional ultrasound and Doppler 
insonation measurements.  Firstly, from measurements taken in the first trimester for 
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the prediction of which MC twins will develop TTTS and secondly, after TTTS has been 
diagnosed, which measurements can help to predict outcome. 
 
1.1.5 Treatment for TTTS 
In 1875 Freidrich Shatz made observations not only about the placental circulation in 
TTTS but also that it was condition not amenable to treatment and with very high 
perinatal loss rates.  Since that time, this condition has offered many academic 
challenges.  This is not only in terms of reaching a consensus on diagnosis and 
understanding the underlying pathophysiology, but also in attempting to alter the clinical 
course of the condition.  Work of vital importance, as TTTS is a condition that affects 
10-15% of MC twins but whose natural outcome would be at least 90% perinatal loss of 
both twins and very high (>50%) neuromorbidity in any surviving babies11 37.  Crucially, 
TTTS usually present prior to viability, most commonly less than 22 weeks of gestation, 
and results in miscarriage or extreme preterm birth of both twins38.  Where this is not 
the case in-utero demise of one twin can still lead to jeopardy for the surviving co-twin39 
40.  Treatment strategies have therefore focused on prolonging the pregnancy and have 
included interrupting the “third circulation” to minimise the harm to the surviving co -twin.  
Treatment to ameliorate the discrepancy in amniotic fluid between the two amniotic sacs 
has taken on two forms: intentional septostomy of the dividing membrane41 or removal 
of amniotic fluid from the recipient sac42 43.  Other options have been to perform 
selective termination of one twin44, or to interrupt the connecting vessels on the 
placental surface by fetoscopic laser ablation (FLA) 45-47.  However, the two main 
approaches that have been utilised have been serial, aggressive amnioreduction and 
FLA.  Briefly, these procedures are performed as follows: 
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a) Serial, aggressive amnioreduction42 43 - involves the repetitive removal of large 
volumes of amniotic fluid (usually in excess of 1-2 litres)43 48.  Under continual 
ultrasound assessment, an 18-G needle is inserted percutaneously into the recipient 
amniotic sac.  Amniodrainage is performed until the MVP is normal (usually 5-6cms) 
and repeated whenever polyhydramnios recurs. 
b) Fetoscopic laser ablation45-47 – is performed percutaneously under local or regional 
anaesthesia.  A 3.3-mm cannula with trocar is inserted under continuous ultrasound 
guidance and a 2mm fetoscope (Stortz, Germany) introduced.  Primarily, coagulation 
selectively targets superficial and deep anastomoses on the chorionic plate using a 
Diode laser system (30-50 W).  The total numbers of vascular anastomoses on the 
chorionic plate crossing the inter-twin membrane are counted prior to the coagulation.  
At the end of the procedure, excess amniotic fluid is drained to a MVP of 5-6cm. 
Although not widely performed septostomy involves intentional puncture of the intertwin 
membrane, usually at the junction of the donor and recipient twins’ sacs close to its 
attachment to the chorionic plate49.  Again this is performed percutaneously and under 
continual ultrasound guidance49.  
 
Serial, aggressive amnioreduction is a relatively simple and widely available treatment.  
The rationale of this technique is to prevent pre-term labour related to polyhydramnios 
and to improve fetal haemodynamics by decreasing pressure on the placental surface42.  
Until recently amnioreduction was the mainstay of treatment with overall survival rates 
of 60%50 but uncontrolled case series have indicated associated neurodevelopmental 
morbidity of 40%51.  Alternatively, FLA of the vascular anastomoses appears to have 
the potential to modify the underlying disease.  A Cochrane review52 of three studies: 
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two comparing FLA with serial amniodrainage (one randomised controlled trial, one 
observational); and one (observational) comparing serial amniodrainage with 
septostomy, showed there is evidence that FLA, to selectively coagulate all 
unidirectional vascular anastomoses, may be superior in terms of survival with up to 
80% of treated cases having at least one survivor and neurodevelopmental morbidity 
being as low as 5%.  This thesis assesses whether in light of further randomised 
controlled trial evidence this is still the case. 
 
 
1.2 Systematic reviews  
Systematic reviews are widely regarded as a robust form of evidence on which to base 
practice, as they aim to reduce bias by use of explicit and systematic methodology 53-55.  
The biases that can be reduced include: language bias (selective inclusion of studies 
published in English); availability bias (selective inclusion of studies that are easily 
accessible to the researcher); cost bias (selective inclusion of studies that are available 
free or at low cost); familiarity bias (selective inclusion of studies only from one’s own 
discipline), and outcome bias (selective reporting by the author of a primary study of 
some outcomes but not others, depending on the direction and statistical significance of 
the results)5. 
 
Systematic reviews are based on clearly formulated questions, from which all relevant 
studies can be identified and their quality appraised56.  They can summarise and 
interpret large quantities of information in an efficient and objective manner57.  They 
establish the generalisabilty of the findings and examine consistency in the data.  In 
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doing so they can explain any inconsistency and conflicts within the data. Where they 
include meta-analysis this can increase the precision and power of results57.  Overall 
these techniques need to be explicitly described to ensure that the systematic review is 
robust to allow the results to be interpreted in a clinical meaningful way and therefore 
inform practice.  It is also possible if there is a paucity of evidence that systematic 
reviews can highlight areas for subsequent research57. 
 
1.2.1 Existing evidence on accuracy of diagnostic tools 
Literature was identified by searching for existing evidence addressing the accuracy of 
ultrasound in investigation of TTTS.  This showed that in the last two decades there 
have been a number of publications indicating that ultrasound measurements firstly, 
from the first trimester may have a role in predicting which MC twins will develop TTTS, 
and secondly, once TTTS develops may have a role in predicting its outcome.  Tests in 
the first trimester include crown rump length discordance, nuchal translucency 
discordance, nuchal translucency > 95th percentile and absent/reversed flow in the 
ductus venosus.  Tests to predict outcome after diagnosis include abnormalities in flow 
in the umbilical artery, middle cerebral artery, ductus venosus and umbilical vein as well 
as single e.g. valve dysfunction and composite measures of fetal cardiac dysfunction.  
However, individual studies addressing the accuracy of these widely available 
ultrasound tools vary greatly in size and have produced heterogeneous and imprecise 
estimates of accuracy.  The reporting of conflicting data has led to confusion and 
therefore made clinical interpretation difficult.  The absence of a uniform strategy for the 
investigation of pregnancies at risk of TTTS, or risks once it has been diagnosed, 
reflects the lack of a rigorous assessment of these ultrasound tests. 
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No systematic reviews of the diagnostic accuracy of ultrasound tools in TTTS were 
available at the commencement of the research leading to this thesis.  Therefore the 
need to conduct high quality comprehensive reviews on this aspect of TTTS was clear. 
 
1.2.2 Existing evidence on effectiveness of interventions 
Literature was identified by searching for existing published evidence addressing the 
effectiveness of interventions for TTTS.  A previous systematic review58 found that of 
the four possible intervention options (serial amnioreduction, FLA, septostomy and 
selective feticide) only serial amnioreduction and FLA had been robustly evaluated.  A 
subsequent Cochrane review in 200852 has evaluated three interventions (serial 
amnioreduction, FLA and septostomy), but also concluded that serial amnioreduction 
and FLA were the only two treatment modalities that have been rigorously tested.  This 
review included one randomised controlled trial (RCT)59 and stated that FLA should be 
considered in treatment of TTTS to improve perinatal outcome.  Further study of 
interventions has focused on FLA and serial amnioreduction, including a second RCT60 
that was reported after the Cochrane review was produced.  As this is only the second 
RCT comparing FLA and serial amnioreduction it provides a substantial contribution to 
the total number of cases studied, and as systematic reviews of RCTs are considered 
the most robust form of evidence53 the need to include this in an up-to date and again 
comprehensive review is clear. 
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1.3 Existing evidence on biological markers in the pathophysiology of 
TTTS 
 
1.3.1 Markers of placental destruction (FP/hCG)  
-fetoprotein (AFP) is a glycoprotein produced by the fetal liver and gastrointestinal 
tract in the second trimester of pregnancy61.  It has a half life of approximately five 
days62.  It enters the maternal circulation by crossing the placenta, mainly by 
paracellular diffusion in a unidirectional manner 63 64, but can also diffuse across the 
fetal membranes65.  Elevated maternal serum AFP (MSAFP) is accepted to be 
associated with a number of complications including growth restriction, preterm birth, 
placenta praevia, placental abruption, fetal loss, gestational hypertension and pre-
eclampsia66.  Similarly low levels are also associated with complications such as 
miscarriage, stillbirth, preterm birth and macrosomia66.  Theoretical mechanisms for 
these abnormal maternal serum levels, particularly high levels, relate to placental 
vascular damage, feto-placental ischaemia or feto-maternal-placental barrier 
disruption66. Human chorionic gonadotrophin (hCG) has an  and a β subunit and has a 
half life of 24 to 36 hours67.  The biologically intact β–heterodimer, the “free β -subunit” 
is secreted by the trophoblast as syncytial differentiation occurs68.  Elevations of free 
βhCG (f- βhCG) have been associated with miscarriage, pre-eclampsia, fetal growth 
restriction and fetal loss69.  With a higher level associated with a greater risk of 
complications.  In common with elevated MSAFP, placental dysfunction appears to be 
the underlying cause and therefore MSAFP and f- βhCG are considered markers of 
placental function66.  As described previously some of the morphological changes 
evident in conditions such as pre-eclampsia and growth restriction are shared by TTTS; 
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therefore it may be that these placental markers may also be raised in TTTS.  Similar 
elevations of MSAFP and free β-hCG have also been described after multifetal 
reduction procedures70.  Additionally, placental microtrauma71 e.g. chorionic villous 
sampling (CVS) causes a transplacental haemorrhage releasing AFP normally stored 
for controlled transport between the fetal and maternal circulations64.  It has therefore 
been inferred that elevations in MSAFP after fetal blood sampling and CVS represent 
placental damage 72 73.  It is hypothesised that FLA may be associated with similar 
changes in MSAFP and free β-hCG.    
 
1.3.2 Angiogenic growth factors  
The vascular endothelial growth factor (VEGF)-family of proteins, comprising VEGF 
isoforms A-E and placental growth factor (PlGF), interact with various receptors 
including VEGFR-1 (formally known as Flt-1)74, see figure 1-3.  VEGF-A is a 
macrophage-derived angiogenic growth factor which, along with PlGF from the 
trophoblast, has been shown to be potent angiogenic factor, being critical for placental 
angiogenesis and also as a permeability factor leading to vascular leakage74 75.  VEGF-
C and VEGF-D arise from natural killer (NK) cells and are primarily involved in 
lymphangiogenesis, the process of creating new lymphatic vessels from previous ones, 
although they also possess some angiogenic properties75.  The Tie-2 receptor, a 
member of the receptor tyrosine kinase family76, and its ligands angiopoietins, 
Angiopoietin- 1 and -2 (Ang-1, Ang-2) produced by decidual endothelial cells77 78, play 
fundamental roles in angiogenesis and remodelling of vessel structure75.  Ang-1 does 
not induce endothelial cell proliferation in-vitro, but is chemotactic for human endothelial 
cells and promotes angiogenesis in-vivo79.  It acts to stabilise blood vessels as opposed 
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to the antagonist ligand for Tie-2, Ang-2 which plays a role in vessel remodelling 
through dilatation of vessels and disruption of vessel integrity79 80.  Transforming growth 
factor-β1 (TGF- β1) is a further angiogenic factor that binds to Endoglin (Eng) and plays 
an important role in trophoblast differentiation81.   In contrast to the angiogenic role 
these factors and their receptors play, soluble VEGFR-1 and Eng act as natural 
inhibitors of VEGF-A and TGF- β1 respectively, and are therefore considered anti-
angiogenic74 82.  These factors are likely to have their predominant effects locally as the 
tissues that synthesise these proteins are immediately adjacent.   
 
Figure 1-3 Diagrammatic representation of angiogenesis in the human placenta. 
 
 
 
 
 
 
 
 
 
 
 
 
Adapted from Dunk C, Ahmed A. Growth Factor Regulators of Placental Angiogenesis. In: Kingdom JCP & Baker PN, 
editors. Intrauterine Growth restriction: aetiology & management. Springer. 1999. Pages 149-162. 
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angiogenesis, the remodelling of existing blood vessels to create new ones75.  Both of 
these processes are vital to the fetus and the placenta to facilitate provision of nutrients 
and oxygen alongside removal of waste products.  In addition, optimal growth depends 
not only on the initial formation of maternal and fetal vasculatures but also on increased 
blood flow through these as gestation advances75.  The successful development of the 
human placenta and the necessary paracrine and autocrine “signals” that regulate the 
migration and organisation of the various cell types within the placenta (i.e. trophoblast, 
endothelial cells) are numerous and unsurprisingly complex.  The fetal vasculature of 
the placenta is thought to be dictated by the actions of angiogenic growth factors and 
their receptors, rather than the action of the trophoblast,83 and involves members of the 
vascular endothelial growth factor (VEGF) family as well as transforming growth factor-β 
1 (TGF-β 1)75.   Fetal vascularisation of placental villi begins three weeks after 
conception by the formation of haemangioblastic cords84.  This is followed by a period of 
branching angiogenesis from weeks four to 25, which involves high levels of VEGF in 
relation to more modest PlGF levels83, after which angiogenesis switches from 
branching to non-branching form75, associated with increased expression of PlGF and 
the soluble form of VEGF receptor 1 (sVEGFR-1)84.  Thus, in an uncomplicated 
pregnancy PlGF levels usually increase in the first two trimesters, peaking at 29 to 32 
weeks, before declining to term. sVEGFR-1 levels are usually constant until 33 to 36 
weeks, and then increase to term85.  It is thought that the balance of high PlGF and low 
sVEGFR-1 in the second trimester of uncomplicated pregnancy creates a pro-
angiogenic state85. Conversely, at term the balance favours high sVEGFR-1 and lower 
PlGF, thought to be a  reflection of a more anti-angiogenic state85.  Pre-eclampsia is 
associated with an earlier increase in sVEGFR-1and fall in PlGF, which has been 
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considered to represent early onset of the anti-angiogenic state seen in an 
uncomplicated term pregnancy85.  Furthermore, It has been shown that if an embryo 
lacks the VEGF receptor-1, there is a relative excess of its soluble form, the known 
VEGF antagonist, and this combination is lethal84.   
 
Angiogenic factors can all be regulated by local oxygen concentration and the normal 
partial pressure of oxygen in the intervillous space is known to vary with gestation; 
being low in the first trimester and then peaking at approximately 16 weeks, before 
declining gradually to term75 86.  However, there is a time lag between changes in 
oxygen tension and placental morphological changes and changes in the level of 
angiogenic factors75.  The overall environment for placental development is one of 
relative hypoxia compared to maternal tissues, although as gestation progressed 
intervillous oxygen tension increases87.  Peculiar to the placenta, when compared to 
most other developing organs, is the fact that advancing vascularisation i.e. increased 
numerical density of fetal capillaries, instead of improving oxygenation appears to be 
associated with a decrease in tissue oxygenation in placental villi88.  In conditions such 
as intrauterine growth restriction and pre-eclampsia there is an increase in the amount 
of branching angiogenesis resulting in malformation of terminal villi, and a reduction in 
the growth of capillaries, so that capillary volumes and surfaces may be limited89.   
 
Twin placentae have been shown to not only display abnormal villus maturation but also 
other pathological lesions such as subchiorial fibrin deposition, retroplacental 
haematoma and infarction90.  These pathological lesions are all more common in 
monochorionic than dichorionic placentae, with infarction and abnormal villus maturation 
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being twice as common90.  In addition, there is an increased incidence of non-central 
cord insertion in twin pregnancies, which is found almost twice as commonly in MC 
twins when compared with DC twins (31.5% vs. 17.1%)91.  Non-central cord insertion is 
thought to represent competition for suitable implantation sites because although the 
cord maintains its initial implantation site there is simultaneous proliferation of villi in 
regions of favourable endometrial blood supply and atrophy of villi in poorly perfused 
areas92.  This is significant as this is another feature of the placenta associated with 
pregnancy complications such as prematurity and fetal growth restriction93 94.  Specific 
to TTTS, it has been shown that the placental villi of the recipient are smaller and there 
is also advanced syncytiovascular membrane formation, the only physical barrier 
between the fetal ad maternal blood95, a feature also seen in pre-eclampsia96.  There is 
also evidence that where discordant growth exists in TTTS there is evidence of 
increased resistance in the spiral artery of the donor twin, a feature suggestive of 
impaired trophoblast invasion, which has been shown in singleton pregnancies with fetal 
growth restriction and/or pre-eclampsia to equate to abnormal placental development97.  
These placental findings help to explain why twin pregnancies, including those 
complicated by TTTS, are predisposed to maternal and fetal complications such as pre-
eclampsia and fetal growth restriction98.   
 
Pre-eclampsia and fetal growth restriction have been described as having abnormal 
placentation and are associated with uteroplacental hypoxia89.  It is suggested that it 
may be the relative constancy of oxygen at the different gestations, rather than the 
absolute value, which may be needed for normal placental development86.  There is 
controversy as to whether relative ischaemia and/or hypoxaemia is the causative 
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mechanism predisposing to abnormal angiogenic orchestration both within the placenta 
and at the site of trophoblast vascular endothelial cell interaction82 99.  However, 
placental expression, circulating levels of angiogenic growth factors and the circulating 
receptor sVEGFR-1 have been implicated in this process98.  Indeed, there is growing 
evidence that the homeostasis between angiogenic and anti-angiogenic growth factors 
released from the human fetoplacental unit is involved in the pathogenesis of pre-
eclampsia99-105, intrauterine growth restriction100-102 105-107 and conditions associated with 
fetal hydrops108.  A descriptive case study has also reported increased expression of 
mRNA encoding VEGFR-1 in the villous syncytiotrophoblast of the donor portion of the 
placenta in TTTS, as compared to that of the recipient109.  In addition, a cross sectional 
study has demonstrated an increased circulating maternal plasma sVEGFR-1 
concentration and reduced plasma PlGF concentration in TTTS as compared to 
uncomplicated, gestationally matched monochorionic pregnancies110.  These data raise 
the possibility that TTTS may be a relatively anti-angiogenic condition and therefore this 
thesis will address this question as well as determine the impact of FLA. 
 
1.3.3 Maternal cell-free messenger RNA for angiogenic growth factors  
Since 1997, when it was shown that fetal nucleic acids are present in maternal serum 
and plasma111, much work has been done to explore new avenues for non-invasive 
prenatal diagnosis and monitoring.  Cell-free fetal DNA is thought to originate from the 
trophoblast cells of the placenta112.  The majority results from turnover of villous 
trophoblasts, as occurs in normal pregnancy, and a smaller amount arises due to 
apoptosis of fetal nucleated erythrocytes in the maternal circulation113.  Cell free DNA is 
detectable in maternal plasma from the first trimester (from approximately seven 
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weeks)114.  However, it is cleared very rapidly and undetectable 24 hours after delivery, 
115 so can be considered as a biomaker for the current pregnancy, in contrast with intact 
fetal cells that circulate in the maternal blood for decades116.  It is known that cell-free 
DNA is fragmented, and that the maternal DNA fragments are markedly bigger than the 
corresponding fetal DNA fragments, and is easily extracted and quantified using real-
time polymerase chain reaction amplification techniques117.  Higher levels of cell free 
DNA have been noted in the plasma of women with conditions associated with 
abnormalities of the placenta such as placenta accreta118, as well as in pre-eclampsia, 
in which there is delayed clearance of fetal cell-free nucleic acids117   It has been shown 
that both monochorionic and dichorionic pregnancies have significantly higher free fetal 
DNA concentrations than singleton pregnancies, with a trend towards a higher 
concentration in MC than DC twins119. 
 
Analysis of plasma fetal DNA can indicate the presence and concentration of fetal 
genetic material in the maternal circulation111.  However, it is also possible to detect 
fetal messenger RNA (mRNA), as this is stable in maternal blood due to the fact that it 
circulates in apoptotic bodies117 or in association with subcellular particles120.  Studies 
have shown that mRNA of placental origin is detectable in maternal plasma by use of 
real-time quantitative polymerase chain reaction and that it is also rapidly cleared hours 
after delivery120 121.  Longitundinal studies have demonstrated that mRNA is present at 
varying levels during pregnancy but absent within hours of delivery allowing authors to 
conclude that the mRNA they are measuring is fetal rather than maternal in origin120 122.  
There is also evidence that there is unidirectional transfer of mRNA across the placenta 
into the maternal blood120.  It is thought analysis of plasma fetal mRNA can impart 
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valuable clues as to the gene expression patterns of fetal tissues123, and plasma levels 
have been suggested to reflect recent pathological or physiological events due to the 
rapid kinetics of circulating placental mRNA124.  It is therefore considered by leaders in 
this field that measuring fetal mRNA levels offers the possibility of providing non-
invasive real-time “fetal functional development information”117.  For example, changes 
in oxygen supply or demand, and therefore available concentration, lead to acute and 
chronic cellular responses75.  It is thought that chronic responses can be seen in mRNA 
transcription level changes and so measuring mRNA levels can give complementary 
information to measuring protein levels alone75 and that for most genes changes in 
mRNA are related to changes in protein levels125.  AGFs have received particular 
interest due to their link with conditions associated with abnormal placentation, and it 
was recently suggested that a panel of cell free mRNA (cf-mRNA) markers could be 
used in the prediction of pre-eclampsia126 127.  Given the association of MC twin 
pregnancies with abnormal placentation90, and that TTTS may be a relatively anti-
angiogenic condition110 it is possible that cf-mRNA for AGFs may be aberrant in TTTS.  
In addition, cf-mRNA has been demonstrated to be sensitive in defining prospective risk 
of malplacentation syndromes126 and it is possible that if cf-mRNA changes are 
demonstrated they could perform a similar role in TTTS as well. 
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1.3.4 Cytokines 
Cytokines are soluble glycoprotein messengers of the immune system, released 
predominantly by T lymphocytes.  More specifically, it is the T lymphocytes expressing 
CD4+, which may be further classified into TH1 and TH2 subtypes, that are the richest 
source of cytokines128.  TH1 cytokines are involved in pro-inflammatory responses that 
include release of interferon-gamma (IFN-), tumour necrosis factor-α (TNF-α) and 
interleukin (IL) subtypes: IL-2, IL-6, IL-12, IL-1β128.  TH2 cytokines are released by 
lymphocytes involved in anti-inflammatory and allergic immune responses and include 
interleukin sub-types: IL-4, IL-5, IL-10 and IL-13128.  Cytokines are known to be 
expressed in the placenta, decidua, and fetal membranes during normal pregnancy and 
are considered integral to the establishment and function of the placental/maternal 
interface129.  The trophoblast does not express classical major histocompatibility 
complex (MHC) molecules but instead a non-classical MHC to suppress maternal 
immune cells, and the immunological balance of pregnancy favours TH2 promoted 
humoural immunity in preference to TH1 cell-mediated immunity to facilitate this129.  
Disruption to cytokine balance has been implicated in conditions associated with failure 
of trophoblast invasion as well as placental hypoxia and vascular changes within the 
placenta, such as those seen in recurrent miscarriage, intrauterine growth restriction 
and pre-eclampsia129 130.  The TH1 inflammatory cytokines, particularly IL-1β and IL-6, 
are thought to stimulate the invasive and proliferative phenotypes of the placenta in the 
first trimester; however, in later pregnancy TH2 cytokines are thought to suppress the 
production of TH1 cytokines129.  Increased placental production of some TH1 cytokines, 
in conjunction with their interaction with growth factors, has been suggested to 
represent failure of trophoblast invasion in recurrent miscarriage129 and the continued 
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placental hypoxia seen in pre-eclampsia130.  Specifically increased amniotic fluid levels 
of IL-6 and IL-8 in the mid-trimester have been associated with the subsequent 
development of pre-eclampsia131 
 
In contrast parturition is associated with an increase in production of the TH1 pro-
inflammatory cytokines and the chemokine IL-8, which increase with gestation to a peak 
in labour129 130.  This is particularly relevant to amniotic and cervico-vaginal fluid levels 
of IL-1β, TNF-α, IL-6, which stimulate prostaglandin production130.  There is also 
evidence that increasing levels of TH2 cytokines IL-4 and IL-10 at term, usually 
associated with decreased prostaglandin production, may reflect a reversal in function 
of these usually anti-inflammatory agents to facilitate the cascade of events that 
precipitates labour130.  As well as stimulating prostaglandin production from the amnion 
cytokines also have a role in membrane remodelling and function130  Rupture of 
membranes occurs when there is digestion of the extracellular membrane by matrix 
metalloproteinases and trophoblast apoptosis, both of which are stimulated by 
inflammatory cytokines (IL-1β, TNF-α, IL-6) and IL-8130.  There is evidence that elevated 
levels of these same inflammatory cytokines in the extraplacental membranes and 
consequently amniotic fluid are also associated with spontaneous preterm labour and 
the associated reaction when infection is also implicated in this process130.  This is 
particularly important as levels of IL-1β, IL-6 and IL-8 in amniotic fluid are also 
considered risk factors for the development of white matter damage and cerebral palsy 
in the infant and child132 133. 
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There is little specific study of cytokines in multiple pregnancies, particularly reporting 
the effects of chorionicity.  However, a study looking at mid-trimester amniotic fluid 
cytokines in singleton and twin pregnancies (including four MC and 25 DC twins) 
reported higher levels of IL-1β, TNF-α and IL-4 in twins than in singletons and supposed 
that this represented evidence of increased fetal immune system activation in twins134.  
A further study, including two sets of twins, of 18 fetal blood samples showed evidence 
of expression of fetal mRNA for TNF-α and IL-1β from as early as 21 weeks although, 
as this was a small sample it did not try to show any quantitative differences between 
singletons and twins135.  Another study suggested a link between increased IL-8 in 
cervico-vaginal secretions and preterm birth in twins136, and this has since been 
supported by analysis of 523 blood spot specimens, which also reported a significant 
increase in IL-8 levels in twins who delivered prematurely137.  IL-6 is another cytokine 
that has received particular attention as a possible marker of spontaneous preterm birth 
and intrauterine infection130 and this has also been investigated in relation to TTTS138 
139.  It was measured in amniotic fluid before FLA and found to be higher than in 
singleton pregnancies138.  In another study it was measured after FLA but was not found 
to correlate with the risk of premature delivery139.  However, other cytokines in maternal 
plasma or amniotic fluid in relation to TTTS have not been described.  
 
It is known that in multiple pregnancies, there is an increased risk of abnormal 
placentation, predisposing to complications such as pre-eclampsia and fetal growth 
restriction98.  In addition, in TTTS there are numerous, asymmetric anastomoses17 
within the placenta, which account for the characteristic haemodynamic imbalance in 
the fetal circulations.  It is therefore possible that cytokine balance may be aberrant in 
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the condition itself.  FLA causes occlusion by coagulation of the anastomoses140 and 
there is some evidence of minimal increases in feto-maternal haemorrhage and 
trophoblast destruction141.  It is possible that such a ‘reaction’ leads to the local release 
of cytokines and these may have an effect both on decidual-myometrial interaction 
(affecting the risks of preterm delivery)130 and potentially also the risk of cerebrovascular 
morbidity.  This is particularly important as neurodevelopmental morbidity occurs in 
between 11-19% of survivors of TTTS, in spite of treatment142, and cytokines have been 
implicated in neonatal white matter lesions, and by extension cerebral palsy132.  The 
need to study a range of both pro- and anti-inflammatory cytokines in relation to TTTS 
and FLA is therefore clear. 
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1.4 Summary  
In summary there is an absence of a uniform strategy for the investigation of 
pregnancies at risk of TTTS, or risks once it has been diagnosed, and this reflects the 
lack of a rigorous assessment of the relevant ultrasound tests. This thesis assesses the 
diagnostic accuracy of conventional ultrasound and Doppler insonation measurements 
to provide such an assessment. Firstly, from measurements taken in the first trimester 
for the prediction of which MC twins will develop TTTS and secondly, after TTTS has 
been diagnosed, which measurements can help to predict outcome. 
Furthermore, a third systematic review will update the existing evidence, including the 
only two RCTs, to compare FLA and serial amnioreduction in the treatment of TTTS.  
As the existing contemporaneous Cochrane review predated the second of these RCTs 
the need to include both trials in an up-to date and again comprehensive review is clear.  
It was for this reason that the Cochrane review has also subsequently been updated 
and published in January 2014. 
 
With respect to the pathophysiology of TTTS and the effect that FLA has on biological 
markers several aspects need to be considered.  MSAFP and levels of free β-hCG have 
been associated with conditions associated with abnormal placentation such as pre-
eclampsia, fetal growth restriction and miscarriage69.   Elevations of MSAFP have also 
been described after CVS71, and elevations of both MSAFP and free β-hCG after 
multifetal reduction procedures70, suggesting FLA, as a further invasive procedure, may 
also cause changes in their levels. In addition, placental expression and circulating 
levels of AGFs and their receptors have been implicated in the pathogenesis of 
conditions associated with abnormal placentation such as pre-eclampsia99-105, 
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intrauterine growth restriction100-102 105-107 and conditions associated with fetal 
hydrops108. TTTS is also associated with abnormal placentation, and has been 
suggested to be a relatively anti-angiogenic condition110.  Information regarding AGF at 
the protein level can be supplemented by fetal nucleic acid study, as plasma fetal RNA 
can impart valuable clues as to the gene expression patterns of fetal tissues123.   
Cytokines are known to be expressed in the placenta, decidua, and fetal membranes 
during normal pregnancy and are considered integral to the establishment and function 
of the placental/maternal interface129.  Disruption to cytokine balance has been 
implicated in conditions associated with failure of trophoblast invasion as well as 
placental hypoxia and vascular changes within the placenta, such as those seen in 
recurrent miscarriage, intrauterine growth restriction and pre-eclampsia129 130.  This 
thesis will assess how these biological factors may contribute to the development of 
TTTS, as well as investigate what effect treatment by FLA has. 
 
The research presented in this thesis was undertaken with two overall aims: 
1. To systematically review and critical appraise the current evidence relating to the 
diagnostic accuracy of ultrasound in the prediction of TTTS and its outcome, as 
well as the effectiveness of the two principal treatments for TTTS.  
2. To investigate markers of placental destruction, angiogenic growth factor and 
cytokine levels in uncomplicated twins and twin pregnancies complicated by TTTS.  
In addition, in the TTTS cohort to investigate the effect of FLA on these same 
markers. 
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CHAPTER 2 
 
METHODS 
 
2.1 Systematic review methods 
 
To determine the accuracy of ultrasound tests in the prediction of TTTS and its 
outcome, and the effectiveness of its two principal treatments three quantitative 
systematic reviews were performed.  Each of the three systematic reviews followed a 
prospectively developed protocol and used widely recommended and comprehensive 
methodology143-145.  Broadly this involves five steps56:  
i) Framing the question – in terms of the population, the index test or intervention to be 
studied, the reference standard or outcome and the type of study needed to evaluate 
these elements.   
ii) Identifying relevant studies – a comprehensive search to identify all possibly relevant 
citations, from which the final studies were selected and the review based. 
iii) Assessing the quality of the literature – the confidence that measures were taken to 
minimize bias in the study design, conduct, analysis and reporting.  
iv) Summarising the evidence – collating the findings, including meta-analysis if 
appropriate. 
v) Interpreting the findings – to explore how the findings impact on decision making. 
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2.1.1 Framing questions 
a) What is the diagnostic accuracy of ultrasound in the first trimester for the prediction of 
which MC twin pregnancies will be affected by TTTS? 
b) What is the diagnostic accuracy of ultrasound in the prediction of outcome of TTTS 
after diagnosis? 
c) What is the effectiveness of FLA versus serial amnioreduction in the treatment of 
TTTS? 
These questions were formed a priori in terms of the population, index test/intervention 
and outcomes and these components are illustrated below, where they were integral to 
study selection. 
 
2.1.2 Identification of relevant studies 
The systematic reviews were designed and performed with careful attention to the need 
to avoid bias (as described in the introduction).  The studies relevant to each review 
were identified by searching: general bibliographic databases including MEDLINE, 
EMBASE, and Web of Science; as well as specialist electronic databases (the 
Cochrane Library - Cochrane Database of Systematic Reviews (2013: Issue 1), Centre 
for Reviews and Dissemination (2013) and Medion (2013).  Hand searching of specialist 
journals was also performed and reference lists of all known reviews and primary 
studies were searched.  Language restrictions were not applied during search or 
selection, and unpublished studies were sought.  This search informed the planned 
series of three reviews looking at several aspects of TTTS from screening, to outcome 
prediction after diagnosis, as well comparing its two main treatments.  The search 
strategy used is detailed in Appendix 1 and encapsulated term combinations with the 
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relevant population using relevant MeSH terms, text words, and their word variants.  
Methodological filters were also applied for identification of diagnostic, therapeutic and 
prognostic studies.  All databases were searched from inception until January 2013.  A 
comprehensive database of the literature was constructed (Endnote X5).  The electronic 
searches were examined, to enable initial study selection based on the title and/or 
abstract.  Full manuscripts of all potentially relevant citations were obtained.  The final 
inclusion/exclusion decisions were made after evaluation of the full papers using piloted 
proformas.  The proformas used for each of the three reviews are shown in Appendices 
2-4.  For multiple/duplicate publication of the same data set only the most recent and/or 
complete study was included.  Two reviewers performed the study selection process 
independently (see acknowledgments).  If there was ambiguity about duplicate 
publication, studies were initially included for close examination of the reports during 
data extraction and synthesis.  
 
For the diagnostic accuracy of ultrasound in the first trimester for the prediction of which 
MC twin pregnancies will be affected by TTTS study selection criteria included: 
a) Population   MC twins (single placental mass and presence of T sign) 
b) Index tests Test performed in the first trimester  (prior to 14 weeks of 
gestation) - crown rump length discordance, nuchal 
translucency discordance, nuchal translucency > 95th 
percentile and absent/reversed flow in the ductus venosus.   
c) Reference standard Development of TTTS (polyhydramnios surrounding the 
recipient (MVP > 8cm, or 10cm after 20 weeks) and 
oligohydramnios (MVP < 2cm) surrounding the donor). 
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d) Study design Trials or cohort studies were considered ideal but case-
control studies were included. 
 
For the diagnostic accuracy of ultrasound in the prediction of outcome of TTTS after 
diagnosis study selection criteria included: 
a) Population MC twins (single placental mass and presence of T sign) 
with TTTS (polyhydramnios surrounding the recipient (MVP 
> 8cm, or 10cm after 20 weeks) and oligohydramnios (MVP 
< 2cm) surrounding the donor). 
b) Index tests Test performed after diagnosis of TTTS –  
abnormalities in flow in the umbilical artery, middle cerebral 
artery, ductus venosus, umbilical vein or measures of fetal 
cardiac dysfunction.   
c) Reference standard Intrauterine or neonatal death 
d) Study design Trials or cohort studies were considered ideal but case-
control studies were included. 
For the diagnostic accuracy reviews studies that reported a series of less than five 
cases or failed to correlate the test with the outcome specified were excluded.  Although 
both of the diagnostic accuracy reviews aimed to assess ultrasound the search was not 
limited to exclude other diagnostic tests.  This was to ensure that if there were any 
additional tests that had been evaluated in robust studies these could be retrieved for 
detailed examination of their applicability to the prediction of TTTS or its outcome. 
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For the review of effectiveness of FLA and serial amnioreduction in the treatment of 
TTTS study selection criteria included: 
a) Population MC twins (single placental mass and presence of T sign) 
with TTTS (polyhydramnios surrounding the recipient (MVP 
> 8cm, or 10cm after 20 weeks) and oligohydramnios (MVP 
< 2cm) surrounding the donor). 
b) Interventions   Fetoscopic laser ablation and amnioreduction 
c) Primary outcome  Survival of at least one fetus.  
d) Study design Both cohort and randomised designs that compared the two 
interventions in a primary study were considered.  Studies 
that only reported a series of less than five cases or one 
intervention were excluded.  
 
2.1.3 Quality assessment 
All included studies were assessed for their methodological quality based on validated 
tools4 55 146-149.  For the diagnostic accuracy reviews the items considered important for 
a good quality study included prospective design with consecutive recruitment (to avoid 
selection bias), verification of the index test with reference standard (>90%) (to avoid 
verification bias), adequate description of the index test and, both appropriate and 
timely application of the reference standard.   
For the review of effectiveness items considered important for a good quality study 
included randomisation with concealment of allocation (to avoid selection bias), 
complete description of the intervention (to allow replication by others), blinding of 
participants, personnel and outcome assessors (to avoid performance and detection 
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bias), avoidance of deviations from protocol and complete (>90%) follow up (to avoid 
attrition bias) and examination of any possibility of selective outcome reporting (to avoid 
reporting bias).  
A detailed explanation of how quality was assessed in each review can be found in 
tables 2.1 and 2.2. 
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Table 2-1 Quality assessment and definitions for diagnostic accuracy reviews. 
 
Feature QUADAS 2 Domain Applicability and criteria 
fulfilled when 
Patient selection 
Risk of bias 
 
 
 
 
 
 
Concerns re applicability 
1 For the study to be classed 
as having a low risk of bias it 
should: have a consecutive 
or random sample, avoid a 
case control design and 
inappropriate exclusions. 
 
The patients included should 
match the review question 
(RV 1 – unselected MC twins 
in the first trimester, RV 2 – 
MC twins with TTTS) 
Index test 
Risk of bias 
 
 
 
 
 
 
 
Concerns re applicability 
2 For the study to be classed 
as having a low risk of bias 
the index test should be 
interpreted without 
knowledge of the reference 
standard and have a pre-
specified threshold. 
 
The index test should match 
the review question (RV 1 – 
test performed in the first 
trimester to predict TTTS, RV 
2 – test after TTTS 
diagnosed to predict 
outcome). 
Reference standard 
Risk of bias 
 
 
 
 
 
 
 
Concerns re applicability 
3 For the study to be classed 
as having a low risk of bias 
the reference test should 
correctly identify the target 
condition and be interpreted 
without the knowledge of the 
index test. 
 
 The target condition as 
defined by the reference 
standard should match the 
review question (RV 1  - 
development of TTTS, RV 2 
– in utero/neonatal death) 
Flow and timing 
Risk of bias 
 
4 For the study to be classed 
as having a low risk of bias 
there should be an 
appropriate time interval 
between the index test and 
reference standard, all 
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patients should receive the 
same reference standard and 
be included in the analysis.   
 
 
Table 2.2 Quality assessment and definitions for review of effectiveness.  
Feature Quality assessment  
Study design Randomisation with concealment of 
allocation was considered ideal. However, it 
is acknowledged that in observational studies 
use of adjustment for confounding in analysis 
is ideal for this type of study design, therefore 
was also accepted for assessment of quality.  
 
Data collection Prospective collection of data was 
considered ideal, retrospective collection was 
considered second best 
Patient selection Consecutive recruitment with the use of 
specific eligibility criteria was considered 
ideal. 
Definition of TTTS MC twins (single placental mass and 
presence of T sign) with TTTS 
(polyhydramnios surrounding the recipient 
(maximum vertical pool (MVP) > 8cm) and 
oligohydramnios (MVP< 2cm) surrounding 
the donor) was considered adequate.  
Description of intervention Complete and transparent description to 
allow replication by others was considered 
adequate. 
To include gestational age at intervention 
and number of procedures performed. 
Outcome ascertainment Complete (>90%) follow up of the original 
study population with adequate description of 
the outcome measures were considered 
ideal. Blinding of carers and patients was not 
considered essential for quality, however, 
blinding of outcome assessors was 
considered ideal. 
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Piloted checklists (based on QUADAS 2148 for the diagnostic accuracy reviews and the 
CASP checklists150 151 for the effectiveness review) were used to identify and record 
items relating to study quality.  This assessment was performed independently, in 
duplicate for each review.  Any disagreements were resolved by consensus.  Quality 
assessment was displayed on a bar chart.  An assessment of individual components of 
study quality was made to classify studies as high or low quality, and this was utilised in 
sub-group analysis, including meta-regression if the number of studies allowed.  This 
approach was utilised in preference to assigning a quality score as these can obscure 
the strengths and weaknesses of the study and have been shown to have little validity4 
152.  Diagnostic accuracy studies were considered high quality if they reported an 
independent, prospective comparison of the index test with the reference standard in an 
appropriate population of consecutive patients and moderate quality if they fulfilled all 
except the criterion for consecutive recruitment.  All other studies were considered low 
quality. 
 
2.1.4 Summarising the evidence 
Data extraction forms were devised and piloted and can be found in Appendices 2-4.  
All data were extracted independently and in duplicate.  For the diagnostic accuracy 
reviews this allowed construction of two-by-two tables detailing the result of the index 
test under scrutiny and the results of the reference standard, namely crown rump length 
(CRL) discordance, nuchal translucency (NT) discordance, NT > 95th percentile or 
absent/reversed flow in the ductus venosus (DV) against the development of TTTS for 
the prediction review, and abnormalities of flow in the umbilical artery (UA), middle 
cerebral artery (MCA), DV, umbilical vein (UV), estimated fetal weight discordance 
 40 
(EFW) or fetal cardiac dysfunction against in-utero/neonatal death for the review of 
outcome.  If the study reported different cut-off levels for an abnormal test result then 
separate two-by-two tables were constructed to reflect this.  For the effectiveness 
review two-by-two tables detailed survival after FLA and amnioreduction.  
 
For the diagnostic reviews the following measures of test accuracy, with their 95% 
confidence intervals (CI), were calculated from the two-by-two tables: sensitivity (true 
positive rate), specificity (true negative rate), and likelihood ratios (LR, summarising how 
many times more (or less likely) patients with the disease are to have a particular result 
than patients without the disease)153.  Where any of the cells in the two-by-two tables 
contained zero cells, a half (0.5) was added to each cell to enable calculations154.  The 
results from studies with similar characteristics and the same threshold for the index 
test, as well as the reference standard, were pooled.  Where bivariate meta-analysis 
was not possible (if there were less than four studies) analysis also included exploration 
of threshold effect, using Receiver Operating Characteristic (ROC) analysis and 
calculation of Spearman correlation coefficients155.  LRs were favoured for meta-
analysis as these are widely regarded as of most relevance clinically156 as they can be 
directly applied to give a probability that an individual has a disease157.  This was done 
using Bayes’ theorem and the formula: 
Post test probability = LR x pre-test probability / [(1-pre-test probability) x (1-LR)]158 
An estimate for pre-test probability was calculated from the prevalence of the pathology 
in the population studied.  If a study reported a prevalence that was markedly different 
from the other studies and inconsistent with the general literature this estimate was not 
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included.  To deal with the uncertainty in estimation 95% confidence intervals (CI) for 
each point estimate (LR) were calculated. 
 
For the effectiveness review the included studies had either randomised or cohort 
designs therefore effect estimates were computed using Relative risk (RR) as an effect 
measure, along with 95% confidence intervals159.  Intervention failure and complication 
rates were compared using Fisher’s exact test. 
 
The extracted data were tabulated to allow qualitative inspection for clinical and 
methodological heterogeneity.  Heterogeneity was also explored graphically and 
statistically.  Graphical assessment for the diagnostic accuracy reviews involved 
examining the distribution of sensitivities and specificities as points on a ROC plot157 
and LRs as a measurement of accuracy size using a Forest plot.  For the effectiveness 
review the distribution of effect estimates was explored graphically using Forest plots.  
All reviews also examined heterogeneity statistically using the χ2 test and I2 160.  Where 
there was evidence of heterogeneity e.g. χ2 p value < 0.05 then a random effects 
pooling method was used, conversely if the studies were homogeneous then a fixed 
effects pooling method was used.  The reasons for heterogeneity were explored using 
meta-regression and sub-group analysis. Where only a single study existed single 
estimates are reported. 
 
Sub-groups were planned a priori based on clinical criteria known to influence prognosis 
and study quality and were performed if there were at least two studies with those 
characteristics.  These included: 
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- study design – trials or cohort studies only 
- study quality 
- variations in index test e.g. type of test parameter, cut off used 
- variations in reference standard – e.g. in-utero or neonatal death 
 
Statistical analyses were performed using Meta-DiSc97 and STATA 11 (StataCorp., 
2009. Stata Statistical Software: Release 11. College Station, TX: StataCorp. LP) for 
meta-analysis (bivariate with the “metandi” command120 where sufficient (4) studies 
were available), meta-regression and plotting ROC curves, and Statsdirect (Statsdirect 
Ltd) for calculations and producing Forest plots.  In the diagnostic accuracy reviews 
sensitivity analyses were performed to check the robustness of all results.  Statistical 
significance was accepted at a P value of < 0.05 for all reviews. 
 
2.1.5 Interpreting the findings  
The interpretation of the review findings takes into account the credibility of the findings 
and their relevance to clinical practice.  This will involve exploration of publication bias 
both graphically, through the production of funnel plots, and statistically, using Egger’s 
regression method161.  Funnel plots are scatter plots of a measure of individual study 
size (i.e. precision, overall sample size or standard error) against accuracy or effect 
size161 162.  The smaller studies are distributed towards the bottom of the graph and, due 
to their estimates of accuracy/effect being more heavily influenced by random variation, 
across a range of values161.  If the funnel plot is asymmetric this implies publication bias 
is present, as the missing plots are likely to reflect the fact that smaller or non-significant 
studies are less likely to be published162.  Conversely, a funnel shape would be 
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expected if publication bias is absent.  Egger’s regression method is intended to 
quantify the bias depicted by a funnel plot by use of the studies’ accuracy/effect sizes 
and their precision87 161.  Using this method the presence of publication bias is evident 
when p<0.187.  However, both funnel plots and Egger’s regression method are more 
reliable if a large number of studies are being analysed as smaller studies are more 
likely to be of lower methodological quality and show larger treatment effects or 
accuracy, known as small-study effects87 161.  For this reason, when there was evidence 
of small-study effects this was considered in the reporting of any meta-analysis to aid 
interpretation of the review findings.  The use of sub-group analysis based on study 
quality was also performed to ensure this process was explicit.  This allowed 
recommendations for practice to reflect the strengths and weakness of the assimilated 
evidence56. 
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2.2 Investigation of biological markers in the pathophysiology of TTTS 
methods 
 
2.2.1 Study design 
A cohort of monochorionic (MC) twins complicated by TTTS (n=23) was prospectively 
studied at a single Fetal Medicine Unit, between October 2006 and December 2007141 
163-165.  Twins were eligible for inclusion if they were confirmed by ultrasound scan (in 
the first trimester) to be MC (there was a single placental mass and only a thin dividing 
membrane (T-sign)) and subsequently presenting with a diagnosis of TTTS but no other 
fetal or maternal condition.  The diagnosis was made according to internationally 
accepted ultrasound criteria: a MC twin pregnancy with polyhydramnios (maximum 
vertical pool (MVP) >8cm) in the recipient (or >10cm from 20 weeks onwards) and 
oligohydramnios (MVP <2cm) in the donor27.  Recruitment was consecutive and all 
those recruited were available for follow up to birth. 
 
The stage of TTTS was reported based on: the presence of the donor twin’s bladder 
(stage I); the absence of the donor twin’s bladder but no Doppler abnormalities (stage 
II); Doppler abnormalities present (stage III); the presence of hydrops (stage IV); demise 
of one or both twins (stage V)27.  In addition the inter-twin and amniotic fluid volume 
difference were reported as these give useful clinical information regarding the severity 
of the condition166 167.  Severe polyhydramnios was defined as a MVP > 12cm, as this is 
the level above which a reduction in utero-placental blood flow and increased local 
hypoxemia has been described167.  The percentage estimated fetal weight difference 
(ΔEFW) was calculated as the difference in weight, divided by the larger twin's weight, 
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multiplied by 100, with growth defined as concordant if the ΔEFW was less than 25%166.  
Fetal ultrasound and echocardiography were performed with curvilinear array 
transducers with variable frequencies (7-3.5MHz) on a Siemens Antares (Siemens Ltd, 
Erlangan, Germany).  These were performed by a single operator (MDK). 
 
A relatively small comparison group of uncomplicated dichorionic (n=12) and 
monochorionic (n=7) twin pregnancies was also studied.  All of these twin pregnancies 
were appropriately grown for gestation with normal amniotic fluid volumes in each of the 
diamniotic sacs.  All uncomplicated twins were designated as DC or MC at ultrasound 
between 11-14 weeks.  Monochorionicity was based on the whether there was a single 
placental mass and only a thin dividing membrane (T-sign).  They were recruited in the 
second trimester and used for basal plasma comparison only.  They did not undergo 
any form of treatment and all delivered > 34 weeks. 
 
This study had Ethical approval from Birmingham Black Country Local Research Ethics 
Committee (No: 06/Q2702/71) and all participants gave informed consent. 
 
2.2.2 Sample collection and assay 
Maternal peripheral venepuncture was performed under basal conditions (several hours 
prior to any fetal therapy in the TTTS cohort, and at an antenatal visit in the 
uncomplicated twins) and then intervals of 6, 24 hours and one week post-treatment in 
the TTTS cohort.  Venous blood was collected either into a Sarstedt Lithium heparin 
7.5ml tube and placed on ice (for plasma samples) or into a Sarstedt Serum Gel S 
7.5ml tube and allowed to clot for at least one hour at room temperature (for serum 
 46 
samples).  Plasma samples were centrifuged within one hour, and serum samples were 
centrifuged after they had been allowed to clot.  Centrifugation occurred at 3000 rpm for 
10 minutes at 4°C (Heraeus Labofuge 400).  A sample of amniotic fluid was collected 
from the recipient twin sac just prior to fetoscopic laser ablation or amniodrainage and 
again at the end of the procedure.  
Briefly, the procedures were performed as follows: 
i). Fetoscopic laser ablation.  This was performed percutaneously under regional 
anaesthesia by a single operator (MDK)46.  A 3.3-mm cannula with trocar was inserted 
under continuous ultrasound guidance and a 2mm fetoscope (Stortz, Germany) 
introduced.  Primarily, coagulation selectively targeted superficial and deep 
anastomoses on the chorionic plate using a Diode laser system (30-50 W)46.  The total 
numbers of vascular anastomoses on the chorionic plate crossing the inter-twin 
membrane were counted prior to coagulation.  At the end of the procedure, excess 
amniotic fluid was drained to a MVP of 5-6cm (median 1500mL; range 900-4300mL).  
This was the primary treatment if stage II-IV TTTS was diagnosed. 
ii) Amniodrainage.  Under continual ultrasound assessment, an 18-G needle was 
inserted percutaneously into the recipient amniotic sac.  The initial 5mls sample was 
discarded and then 5mls of amniotic fluid taken for assay.  An amniodrainage was 
performed until the MVP was measured as 5-6cms (median 2500 mL; range 1700 – 
5100 mL).  This was the primary treatment if stage I TTTS was diagnosed. 
All treatment was performed within 24 hours of diagnosis. 
Both maternal plasma/serum and amniotic fluid samples were divided into 1000l 
aliquots and stored at -80°C until assay (all within 16 months of collection [range 1.2 – 
15.3 months]).  Where appropriate, the optimal concentration for plasma and amniotic 
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fluid for each analyte was determined by assay of a range of concentrations against the 
appropriate standard and if necessary diluted in accordance with manufacturer’s 
instructions.  All samples for any given analyte were assayed in duplicate at the same 
time using the same standard curve to minimize inter-assay variation.  The methodology 
has previously been described previously168-170.  All angiogenesis and cytokine assays 
were performed by the author and Dr Gendie Lash (see acknowledgements)164. 
 
AFP and free β-HCG   
Maternal serum and amniotic fluid samples were analysed for AFP and free β-HCG 
using solid phase, two site fluoroimmunometric assays (Delfia free β -HCG, Perkin 
Elmer Ltd, Finland).  Intra-assay and inter-assay coefficient of variation was 1% and 
1.9%141.  All values for AFP and free β-HCG are given as multiples of the median 
(MoM) to correct for the fact that they are known to change with gestational age171.  The 
reference ranges utilised to calculate these MoM were supplied by Dr Francoise Muller 
at the Service de Biochimie-Hormonologie Hôpital Robert Debré (Paris, France) for free 
β-HCG and Ian Mills at the Clinical Chemistry laboratory, Birmingham Women’s 
Hospital (England) for MSAFP. However, where the analysis is limited to the TTTS 
cohort undergoing FLA AFP and free β-HCG are analysed as absolute values to allow a 
percentage change to be seen. 
 
Angiogenic growth factors 
Maternal plasma and amniotic fluid samples were analysed for Ang-1 (sensitivity 
312.5pg/ml), PlGF (sensitivity 31.25pg/ml), VEGF-C (sensitivity 93.75pg/ml), VEGF-D 
(sensitivity 31.25pg/ml), sTie-2 (sensitivity 31.25pg/ml) and sVEGFR-1 (sensitivity 
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31.25pg/ml) by enzyme-linked immunosorbent assay (ELISA) (R&D Systems, 
Abingdon, UK).  In addition, samples were analysed for VEGF-A (sensitivity 27.4pg/ml) 
and Ang-2 (sensitivity 137pg/ml) using a FAST Quant human angiogenesis array 
(Whatman Schleicher & Schuell, Dassel, Germany).  The intra-assay coefficients of 
variation using these methods ranged from 4.2% to 10.1%. 
 
Multiplex analysis and cytokines 
Plasma and amniotic fluid samples were analysed for the TH1/TH2 cytokines: IFN-γ, 
TNF-α, IL-2, IL-6, IL-1β, IL-4, IL-5, IL-10, and IL-13; as well as keratinocyte growth 
factor (KGF), platelet derived growth factor-BB (PDGF-BB), fibroblast growth factor-
basic (FGF-basic), tissue inhibitor of matalloproteinases-1 (TIMP-1) and intercellular 
adhesion molecule-1 (ICAM-1) by Human TH1/TH2 or Human Angiogenesis 
FASTQuant kits (Kerafast, NC, USA).  IL-8 was measured by enzyme-linked 
immunosorbent assay (ELISA) (R&D Systems, Abingdon, UK).  The sensitivity of all 
assays ranged between 3.04pg/ml and 15.2pg/ml, and these values were utilised if the 
assay result was outside the reference range.  The intra-assay coefficients of variation 
using these methods ranged from 2.7% - 16.5%. 
 
Cell free mRNA 
Molecular analysis was performed in the Department of Obstetrics and Gynaecology at 
Showa University School of Medicine in Tokyo, Japan (see acknowledgements).  
Processing of blood samples has been described previously165 172.  Total RNA was 
extracted from 1ml of maternal plasma using the following technique165.  The plasma 
was mixed with 3ml of Trizol LS reagent (Invitrogen, Carlsbad, CA) and 0.25ml of 
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chloroform to disrupt the plasma cells and allow isolation of high quality RNA.  This 
mixture was centrifuged at 12,000 times gravity for 15 min at 4 C, and then the 
aqueous layer was extracted as this contains the RNA.  After 1 volume of 700ml/l 
ethanol was added to 1 volume of aqueous layer and the RNA precipitated out, the 
mixture was applied to a QIAamp MinElute Virus column (Qiagen, Hilden, Germany), 
causing the RNA to bind, and processed according to the manufacturer’s instructions.  
Total RNA was then eluted with 20µL of RNase-free water and directly reverse-
transcripted using an Omniscript RT kit (Qiagen) according to the manufacturer’s 
instructions.  The resulting complementary DNA (cDNA) products were amplified by 
real-time quantitative polymerase chain reaction (PCR) according to the manufacturer’s 
instructions (QuantiTect Probe PCR kit; Qiagen) using a 2µL aliquot of cDNA and the kit 
components in a reaction volume of 20µL.  TaqMan PCR analyses for VEGF-A, 
VEGFR-1 (Flt1), endoglin (Eng), PlGF and glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) were performed using pre-developed and commercially available primers and 
probe sets (Cat # Hs00167155_m1 for PAI-1, Cat # Hs00263492_m1 for tPA, Cat # 
Hs00900054_m1 for VEGFA, Cat # Hs01052936_m1 for FLT1, Cat # Hs00923997_g1 
for ENG, Cat # Hs00182176_m1 for PlGF and Cat # 4310884E for GAPDH; Applied 
Biosystems, Foster City, CA, USA).  TaqMan polymerases are thermostable 5’3’ 
exonuclease assays which cleave 5’ terminal nucleotides to release mono and 
oligonucleotides which can be used as probes173.  The PCR reaction utilises the 5’ 
nuclease activity of the TaqMan DNA polymerase to cleave a Taqman probe174.  
Attached to the probe are a reporter dye at the 5’-end and a quencher dye at the 3’-end. 
The reporter will not fluoresce while both are attached however, during the reaction 
cleavage of the probe separates the reporter and quencher dyes allowing the reporter 
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dye to fluoresce174.  The increase in fluorescence signal is only detected if the target 
sequence is complementary to the probe and is amplified during the PCR.   To verify 
that each PCR assay was specific to mRNA and not to genomic DNA the primers used 
all spanned an exon junction and would therefore only amplify cDNA from mRNA 
transcripts and not genomic DNA.  Amplification data were collected and analysed with 
an ABI Prism 7900T Sequence Detector (Applied Biosystems).  Each sample was 
analysed in duplicate, and multiple negative water blanks were included in every 
analysis.  The thermal profile used was as follows: 15 min of denaturation at 95 C, 15 
seconds of annealing at 94 C and 1 min of extension at 60 °C.  Quantification of gene 
expression was performed by investigators blinded to the outcome of pregnancy.  
Amounts of mRNA were calculated using both absolute value (copies/mL) and relative 
value (by comparison of the target nucleic acid threshold cycle with a calibrator nucleic 
acid threshold cycle), amounts of mRNA samples were expressed in term of copies per 
ml.  It is known that there is variation in amounts of starting material across samples175, 
therefore several genes were investigated for use as internal controls and the gene with 
the least variation selected for expressing relative value as previously utilised176-178.  
However, in line with previous studies of fetal mRNA178-181 and as the more consistent 
result in this study gene expression values are given in copies per ml. 
To quantify mRNA concentrations, we prepared plasmid DNA for calibration curves as 
previously described182.   
 
2.2.3 Statistical analysis 
Statistical analysis was performed using Graphpad Instat® and graphs generated using 
Graphpad Prism version4 (Graphpad Software Inc, CA, 2004).  As data did not fit a 
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normal distribution, values are expressed as median and inter-quartile ranges (IQR) and 
non-parametric statistical tests used.  The unpaired Mann Whitney U test was used to 
compare numerical variables where there were two groups and for comparison of three 
or more groups the Kruskal-Wallis test with Dunn’s post-hoc testing.  For analysis of 
‘paired’ plasma and amniotic fluid samples the Wilcoxon Signed rank test was used.  
Correlations were performed using Spearman’s rank correlation coefficient.  A multiple 
regression model was used to look at associations between biomarkers and duration 
after FLA, with particular reference to the influence of gestational age, operation time, 
amount of amniotic fluid drained at the end of the procedure, and the number of 
chorionic vessels coagulated.  A P value of < 0.05 was considered statistically 
significant. 
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CHAPTER 3 
 
 
RESULTS 
 
 
3.1 Systematic review results  
 
3.1.1 Diagnostic accuracy review of ultrasound in the first trimester to 
predict TTTS in uncomplicated MCDA twins 
 
3.1.1.1 Question 
What is the accuracy of ultrasound in the first trimester for the prediction of TTTS in 
uncomplicated MCDA twins? 
 
3.1.1.2 Identification of relevant studies 
The electronic and hand search relevant to all three planned reviews generated 25140 
citations, of which 3322 183-214 were thought to be relevant: 31 were published in English, 
one in Chinese and one in German.  After independent review of the full manuscript of 
these 33 articles, 10204-213 were selected for inclusion in this review (figure 3-1).  The 
characteristics of the included studies are shown in table 3-1.  The list of excluded 
studies is included in Appendix 5. 
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Figure 3-1 Study selection process for a diagnostic accuracy review of ultrasound 
in the first trimester to predict development of TTTS in uncomplicated MCDA 
twins.  
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Table 3-1 Study Characteristics for a diagnostic accuracy review of ultrasound in the first trimester to predict development 
of TTTS in uncomplicated MCDA twins.  
Study  Population 
(country/study design) 
Reference standard Index test/s 
Casabuenas et al 
(2008) 
Inclusion – 27 MCDA twin 
pregnancies and 3 triplet 
pregnancies with 1 set of MC fetuses 
(2 diamniotic, 1 monoamniotic) 
evaluated in the first trimester. Time 
period unspecified. 
No exclusions. 
Method of confirmation of chorionicity 
– USS. 
(Chile) (retrospective cohort) 
 
Development of second trimester TTTS 
– defined as the polyhydramnios/ 
oligohydramnios sequence (as 
described by Quintero). 
NT  20% 
CRL  10% 
 
NT and CRL measurements followed the 
UK Fetal Medicine Foundation 
recommendations. NT and CRL 
discrepancies were calculated as a 
percentage of the larger twin. 
All scans were performed 
transabdominally by maternal-fetal 
medicine specialists.  
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El Kateb et al 
(2007) 
Inclusion – 103 consecutive MCDA 
twin pregnancies followed up from 
11-14 weeks between June 2002 and 
February 2006.  
Exclusions – cases with 
chromosomal or congenital 
malformation. 
Method of confirmation of chorionicity 
– NS. 
(France) (Prospective cohort) 
Development of TTTS- defined by the 
association of polyuric polyhydramnios 
in one sac with a DVP of at least 8 or 10 
cms before and after 20 weeks 
respectively together with oliguric 
oligohydramnios in the other sac with a 
DVP of at most 2 cm. 
CRL  10% 
NT > 95
th
 percentile. 
 
CRL and NT were measured to the 
nearest millimeter in a sagittal section of 
the fetus with the head in a neutral 
position. 
Fratelli et al 
(2011) 
Inclusion – 136 consecutive MCDA 
twin pregnancies in the first trimester 
assessed between February 2001 
and April 2009. 
Exclusion – 1 case with trisomy 21 in 
both fetuses. 
Method of confirmation of chorionicity 
– USS. 
(Italy) (retrospective cohort) 
Development of severe TTTS – defined 
by the presence of DVP < 2cm in the 
donor and  8 cm (or 10cm if after 20 
weeks) in the recipient 
 
NT > 95
th
 percentile in the pregnancy. 
 
NT was measured in a sagittal section of 
the fetus with the head in a neutral 
position. Reference values for NT 
measurement 
Percentiles were those provided by the 
Fetal Medicine Foundation. The 
ultrasound examinations were 
performed by experienced sonographers 
accredited by the Fetal medicine 
Foundation. 
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Linskens et al 
(2009) 
Inclusion – 61 consecutive MCDA 
twin pregnancies that were referred 
for Down’s syndrome screening and 
had serial follow up ultrasonography. 
Taken from the fetal database at a 
tertiary centre between 2004 and 
2008. 
Exclusion – 3 cases IUD, 3 cases 
born immaturely. 
Method of confirmation of chorionicity 
– USS. 
(Netherlands) (retrospective cohort) 
Development of TTTS according to the 
Quintero staging system. 
NT  20% 
 
NT was measured on an early first 
trimester scan according to the 
standards defined by the Fetal Medicine 
Foundation. 
 
Maiz et al (2009) Inclusion – 733 diamniotic twin 
pregnancies undergoing USS at 11 
0/7 to 13 6/7 weeks gestation 
assessed between January 2006 and 
January 2008. 
Exclusion – 5 unable to get DV 
waveforms, 33 with a missing 
outcome  
516 DC, 179 MC. Only MC included 
in this review. 
Method of confirmation of chorionicity 
– USS. 
(United Kingdom) (prospective 
cohort) 
Development of TTTS. Reversed a wave in the DV 
The Doppler studies were undertaken 
during fetal quiescence. The image was 
magnified and a right ventral mid-sagittal 
view of the fetal trunk was obtained, and 
color flow mapping was used to 
demonstrate the umbilical vein, ductus 
venosus, and fetal heart. The insonation 
angle was less than 30°, the filter was 
set at allow frequency (50–70 Hz) to 
allow visualization of the whole 
waveform, and the sweep speed was 
high (2–3 cm/s) so that the waveforms 
were spread widely, allowing better 
assessment of the a-wave. 
Transabdominal USS by sonographers 
with the appropriate Fetal medicine 
Foundation Certificate of Competence. 
 57 
Matias et al (2010) Inclusion – 103 MCDA twin 
pregnancies assessed at 11-14 
weeks gestation between December 
1997 and October 2008  
Exclusions – 2 cases with congenital 
malformations, 2 cases with single 
IUD prior to development of TTTS 
Method of confirmation of chorionicity 
– USS and placental histology. 
(Portugal) (prospective cohort) 
Development of TTTS - defined by the 
presence of oligohydramnios and non-
visible bladder in the donor in 
combination with polyhydramnios and 
dilated bladder in the recipient, along 
with different stages of Doppler 
deterioration. 
Abnormal flow in the DV 
DV measurements were measured 
during fetal quiescence, the image was 
magnified and a right ventral mid-sagittal 
view of the fetal trunk was obtained. The 
insonation angle was systematically kept 
below 30 the high-pass filter was set at 
50–60 Hz and the sweep speed was 
high (2–3 cm/s) to better visualize the A-
wave. An average of five consecutive 
high-quality waveforms was used to 
qualitatively assess the flow in the DV, 
which was considered to be abnormal if 
the A-wave was absent or reversed. 
Transabdominal and transvaginal 
approaches as required. 
Experienced sonographers accredited 
by the Fetal medicine Foundation 
performed the ultrasound examinations.  
Matias et al (2005) Inclusion – 50 MCDA pregnancies 
referred to a single centre between 
11-14 weeks. 
No exclusions. 
Method of confirmation of chorionicity 
– USS. 
(Portugal) (prospective cohort) 
Development of TTTS - was defined 
sonographically based on the presence 
of anhydramnios and non-visible bladder 
in the donor in combination with 
polyhydramnios and dilated bladder in 
the recipient. 
NT  20% 
 
NT thickness was measured at a 
maximum magnification of the fetus and 
plotted against crown-rump length. 
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O’Kagan et al 
(2007) 
Inclusion – 560 MCDA twin 
pregnancies at 11- 13+6 weeks 
between January 2001 and April 
2006. 
Exclusions – 28 chromosomal or 
major structural defects, 20 no 
pregnancy outcome data, 42 with 
IUD one or both twins. 
Method of confirmation of chorionicity 
– USS. 
(United Kingdom) (prospective 
cohort) 
Development of severe TTTS treated 
with laser coagulation. The indication for 
laser being ultrasound diagnosis of 
polyhydramnios/anhydramnios and 
absent or reversed flow in either the 
umbilical artery or ductus venosus in 
one or both fetuses. 
CRL  10% 
NT  20% or NT  30% 
Inter-twin discordance in NT and 
CRL was calculated as the difference in 
each measurement between the two 
fetuses (NT1−NT2 and CRL1−CRL2, 
respectively) expressed as a percentage 
of the larger measurement. 
 
Sebire et al (2000) Inclusion – 303 consecutive MC twin 
pregnancies examined at 10-14 
weeks identified from September 
1992 and estimated to deliver by 
June 1999. 
Exclusions – 16 pregnancies with 
structural or chromosomal 
abnormalities. 
Method of confirmation of chorionicity 
– USS. 
(United Kingdom) (prospective 
cohort) 
Development of severe TTTS - was 
defined by the ultrasound features of 
anhydramnios and non-visible bladder in 
the donor in combination with 
polyhydramnios and dilated bladder in 
the recipient, which resulted in either 
miscarriage or fetal death or required 
intrauterine treatment or post-mortem 
evidence that the cause of death was 
TTTS. 
NT > 95
th
 percentile in the pregnancy. 
 
 59 
Tai et al (2007) Inclusions – 178 twin pregnancies 
scanned between 7 and 14 weeks of 
gestation and subsequently delivered 
between June 2000 and March 2006 
at a single centre. 
Exclusions - Fetuses with known 
chromosomal or major congenital 
anomalies, women who underwent 
first- or second-trimester pregnancy 
termination, those pregnancies that 
were monoamniotic. 
Only 43 MC twin pregnancies 
included in this review. 
Method of confirmation of chorionicity 
– USS. 
(USA) (retrospective cohort) 
Development of TTTS CRL >11% 
The CRL was calculated as the 
difference in the twin CRLs divided by 
the CRL of the larger twin and 
expressed as a percentage. 
 
 
CRL = Crown-rump length, DC = dichorionic, DV = ductus venosus, DVP = deepest vertical pool, GA = gestational age, MC = monochorionic, MCDA = 
monochorionic diamniotic, NS= not specified, NT = nuchal translucency, USS = ultrasound scan.
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Data relating to 1451 pregnancies were reported in the ten included studies, and 
included evaluation of 4 diagnostic tests – crown rump length discordance (646 
pregnancies), NT discordance (605 pregnancies), NT > 95th percentile (555 
pregnancies) and abnormality in the ductus venosus (278 pregnancies).  
 
3.1.1.3 Quality assessment 
Quality assessment for the included studies is summarised in Figure 3-2.  Recruitment 
was prospective in six (60%) of the studies, but only two of these studies (20% overall) 
also employed consecutive patient selection, and thus were considered to have avoided 
selection bias.  All ten studies (100%) avoided verification bias by ensuring that 
verification of the index test with the reference standard took place in >90% of cases.  
The index test was adequately described in eight (80%) of studies.  Appropriate and 
timely application of the reference standard was also present in eight (80%) studies, 
with two studies (20%) failing to provide an adequate description of what they meant by 
development of TTTS.  In considering the assessment made using the QUADAS 2 
checklist148, the risk of bias with regard to the applicability of patient selection to the 
review question was the only domain that was universally low, conversely blinding of 
the reference standard was not reported by any study.  Two studies207 210 were found to 
be of high quality, three studies204 208 213 of moderate quality and five studies205 206 209 211 
212 of low quality. 
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Figure 3-2 Bar chart showing quality of evidence in relation to the diagnostic 
accuracy of ultrasound in the first trimester to predict development of TTTS in 
uncomplicated MCDA twins.  
 
Data presented as 100% stacked bar chart with numbers in bars representing numbers 
of studies. (see methods for details of quality items) 
 
3.1.1.4 Summarising the evidence 
The results are summarised in figure 3-3 – 3-7 and table 3-2. 
A CRL discordance of  10% predicted the development of TTTS with a pooled positive 
likelihood ratio (LR+) of 2.82 (95% CI 1.75 – 4.55) and a negative likelihood ratio (LR-) 
of 0.89 (95% CI 0.76 – 1.05), with no significant heterogeneity (2 < degrees of freedom 
(df) p= 0.53, I2 =0%).  The area under curve (AUC) for the summary ROC analysis 
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suggested excellent accuracy for this test (0.92).  A NT > 95th percentile predicted the 
development of TTTS with a pooled LR+ of 2.45 (95% CI 1.15 – 5.19) and a LR- of 0.87 
(95% CI 0.73 – 1.02), although some heterogeneity existed, this was not significant (2 
> df p= 0.275, I2 =22.6%) and the AUC was fair/good at 0.80.  In the O’Kagan study212 it 
was possible to extract data for NT discordances of 20 and 30%.  Sub-group analysis 
was possible for discordance of 20%, as this was the same threshold utilised by the 
other three studies.  A NT discordance of  20% predicted the development of TTTS 
with a pooled LR+ of 1.98 (95% CI 1.23 – 3.19) and a LR- of 0.64 (95% CI 0.43 – 0.94), 
although some heterogeneity existed, this was not significant (2 > df p= 0.234, I2 = 
29.7%) and the AUC was good at 0.83.  In the Matias study204 it was possible to extract 
data for abnormalities in the DV for one fetus, both fetuses and at least one fetus.  As 
the only other study reporting DV measurement only reported data on abnormal DV flow 
in at least one fetus, this was the threshold that was utilised for meta-analysis, although 
there was still noted to be significant heterogeneity (2 > df p= 0.01, I2=84.8%) and the 
AUC revealed the test to be no better than chance.  An absent or reversed a wave in 
the DV in at least one twin predicted the development of TTTS with a pooled LR+ of 
4.80 (95% CI -1.44 – 11.03) and a LR- of 0.50 (95% CI 0.06 – 0.95).  Sensitivity 
analysis utilising the different thresholds for the index test e.g. NT discordance of 30% 
did not affect these estimates of diagnostic accuracy.  
 
When considering the possibility of publication bias it was noted that there were only a 
few studies in each analysis however, where assessment was possible funnel plot 
asymmetry was not detected (CRL discordance p=0.88, NT > 95th percentile p= 0.40, 
NT discordance p= 0.29). 
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All tests showed poor sensitivity but better specificity.  This is reflected in the LRs and 
subsequent post-test probabilities, as those for a negative test show little change from 
the underlying prevalence, whereas those for a positive test were more discriminating.    
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Table 3-2 Pooled analysis of ultrasound in the first trimester to predict development of TTTS in uncomplicated MCDA 
twins.  
 Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
LR+ (95%CI) LR- (95% CI) Pre-test 
probability %  
Post-test probability % 
(range) 
Test + Test - 
CRL 
discordance  
 10% 
0.23 (0.14 – 
0.33) 
0.92 (0.90 – 
0.94) 
2.82 (1.75 – 
4.55) 
0.89 (0.76 – 
1.05) 
13.8 (9.69 – 
17.9) 
31.1 (21.9 – 
42.2) 
12.5 (10.9 – 
14.4) 
NT > 95th 
percentile 
0.21 (0.01 –  
0.37) 
0.92 (0.87 –  
0.95) 
2.45 (1.15 – 
5.19) 
0.87 (0.73 – 
1.02 
13.8 (9.69 – 
17.9) 
28.2 (15.6 – 
45.4) 
12.2 (10.5 – 
14.0) 
NT discordance 
 20% 
0.53 (0.38 – 
0.68) 
0.73 (0.65 – 
0.80) 
1.98 (1.23 – 
3.19) 
0.64 (0.43 – 
0.94) 
13.8 (9.69 – 
17.9) 
24.1 (16.5 – 
33.8) 
9.30 (6.44 – 
13.1 
DV a wave 
absent or 
reversed 
0.5 (0.33 – 
0.67) 
0.88 (0.83 – 
0.91) 
4.77 (1.34 – 
17.04) 
0.49 (0.17 – 
1.41) 
13.8 (9.69 – 
17.9) 
43.3 (17.7 – 
73.2) 
7.28 (2.65 – 
18.4) 
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Figure 3-3 Forest plots of positive and negative likelihood ratios for ultrasound in 
the first trimester to predict development of TTTS in uncomplicated MCDA twins.  
a) Crown rump length discordance 
 
b) Nuchal translucency >95th percentile  
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c) Nuchal translucency discordance 
 
d) Absent or reversed flow in the ductus venosus in  1 fetus  
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Figure 3-4 Summary ROC curve for CRL discordance of  10% to predict 
development of TTTS in uncomplicated MCDA twins.  
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Figure 3-5 Summary ROC curve for NT >95th
 
to predict development of TTTS in 
uncomplicated MCDA twins.  
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Figure 3-6 Summary ROC curve for NT discordance of  20% to predict 
development of TTTS in uncomplicated MCDA twins.  
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Figure 3-7 Summary ROC curve for absent/reversed a wave in the DV in  1 fetus 
to predict development of TTTS in uncomplicated MCDA twins.  
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3.1.2 Diagnostic accuracy of tests after diagnosis to predict outcome 
of TTTS 
 
3.1.2.1 Question 
 What is the diagnostic accuracy of ultrasound in the prediction of outcome of TTTS 
after diagnosis? 
 
3.1.2.2 Study selection 
The electronic and hand search relevant to all three planned reviews generated 25140 
citations, of which 6223 27 34 36 38 185 197 202 215-268 were thought to be relevant: 57 were 
published in English, one in Serbian, one in Italian, one in German, one in Japanese 
and one in Chinese.  After independent review of the full manuscript of these 61 
articles, 11 were selected for inclusion in this review (figure 3-8).  The characteristics of 
the included studies are shown in table 3-3.  The list of excluded studies is included in 
Appendix 6. 
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Figure 3-8 Study selection process for a diagnostic accuracy review of 
ultrasound after diagnosis of TTTS to predict outcome. 
Potentially relevant citations identified and 
screened  (n=25140)*
Studies included in systematic review (n=11)
Umbilical artery n=7+
Umbilical vein n=4+
Ductus venosus n=4+
Middle cerebral artery n=2+
Tricuspid regurgitation n=2+
CVS score n=3+
Removal of duplicates (n=6045)
Primary articles retrieved for detailed 
evaluation (n=62)
References excluded after screening 
titles and/or abstracts (n= 19034)
Articles excluded (n=51) with reasons
•Not test accuracy n= 6
•Case series<5 n=7
•Reviews/opinion n=2
•Insufficient data to allow construction 
of 2x2 tables n=17
•No correlation with outcome n=13
•Not TTTS n=5
•More complete dataset in later paper 
n=1
*Overarching search encompassing three TTTS reviews +Some articles included more than one test
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Table 3-3 Study characteristics for a diagnostic accuracy review of ultrasound after diagnosis of TTTS to predict outcome. 
Study  Population 
(country/study design) 
Reference standard Index test/s 
IUD/NND 
Bruner et al (1997) Inclusion – 9 pregnancies with second 
trimester twin gestations with identical 
twins, MC placenta and co-existent 
polyhydramnios of larger twin and 
oligohydramnios of smaller twin. 
Single centre. 
Treatment was by serial amnioreduction. 
Method of confirmation of chorionicity – 
USS and placental histology. 
(USA) (cohort) 
IUD 
Test and outcome data only available for 6 
pregnancies  
 
UA abnormal  
Duplex pulsed-wave Doppler measurements 
of UA from a free-floating loop of cord. 
Calculations of the flow velocity waveform 
systolic-diastolic (S-D) ratio were performed 
on three to five sequential normally shaped 
waveforms. Results were reported as means 
and plotted against a normogram of age-
corrected S-D values. 
All measurements by a single examiner. 
Other parameters recorded  - EFW  
Ishii et al (2007) Inclusion – 55 pregnancies diagnosed 
with TTTS and underwent SLPCV at four 
centres between July 2002 and February 
2005. 
Exclusion - 2 Donor fetuses (one 
miscarriage and one IUD due to cord 
entanglement) 
3 Recipient fetuses (one miscarriage and 
two IUD due to cord entanglement) 
All underwent SLPCV Median GA 21 
(range from 16 - 25). 
Method of confirmation of chorionicity – 
USS. 
IUD 
 
Test and outcome data only available for  
53 donors and 52 recipients. 
 
 
Critically abnormal Doppler studies: 
UA – AREDV 
UV – pulsatile flow 
DV – absent or reversed flow during atrial 
contraction 
 
Colour and pulsed Doppler studies within 
24hrs of surgery. 
3.5-MHz or 5-MHz curved array transducer 
with spatial peak temporal average 
intensities of <100mW/cm
2
. The high-pass 
filter was set at the lowest level. Doppler 
measurements were obtained in the absence 
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(Japan) (cohort) of fetal breathing or movements. UA/UV 
measurements were recorded from a free 
loop of cord or at the placental insertion site. 
The sample volume for the DV was 
determined from its inlet portion at the UV. 
Kontopoulos et al 
(2007) 
Inclusion – 401 pregnancies referred to a 
single centre between August 2001 and 
August 2005 
Exclusion – triplets and higher order 
pregnancies, monoamniotic twin 
pregnancies 
All patients underwent SLPCV. Median 
GA donor survived 20.3; donor died 19.7 
(range for both 16 – 26) 
Method of confirmation of chorionicity – 
placental histology. 
(USA) (retrospective cohort) 
Donor IUD  UA – AEDV 
Pre-operative ultrasound examination 
included Doppler examination of the UA in a 
free loop of cord. The angle of insonation 
was kept at <30. The wall motion filter was 
kept at <100MHz and Doppler energy output 
levels were <50 mW/cm
2
. Doppler 
measurements were obtained in the absence 
of fetal breathing. If intermittently absent 
EDV considered to have positive EDV. None 
with reversed EDV 
Martinez et al (2003) 
 
Inclusion – 110 consecutive pregnancies 
undergoing SLPCV for TTTS at a single 
centre between October 1997 and 
February 2001. 
All underwent SLPCV. Median GA 20.7 
(range, 16.1 – 25.7) 
Method of confirmation of chorionicity – 
IUD 
Outcomes reported separately for donor 
and recipient 
Not all measurements and outcomes 
available pre/post op (indicates numbers of 
fetuses with data available) 
Critically abnormal Doppler studies: 
UA – AREDV 
UV – pulsatile flow at the placental cord 
insertion or umbilical loop 
MCA – PI < 5
th
 percentile 
DV – reversed flow during atrial contraction 
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NS 
(USA) (cohort) 
UA – D=110, R=110/ D=90, R= 94 
UV – D=106, R=107/ D=89, R=95 
MCA – D=102, R=105/ D=81, R=91 
DV – D=108, R=109/ D=90, R=95 
TR – D= 81, R = 102/ D=67, R=71 
 
 
TR  
 
Colour and pulsed Doppler studies. Energy 
output levels were lower than 50 mW/cm
2
 
spatial peak temporal average, and the high 
pass filter was set at the lowest level.  
Doppler measurements were obtained in the 
absence of fetal breathing or movements. 
Measurements taken 6-24hrs pre-op and 
within 24hrs after surgery  
Murakoshi et al 
(2008) 
Inclusion – 138 pregnancies with severe 
TTTS treated with fetoscopic laser 
surgery at five centres between July 2002 
and August 2006.   
Exclusion – 7 pregnancies that 
miscarried, 49 twins with stage I, II or IV 
TTTS.  
All underwent fetoscopic laser ablation of 
all communicating vessels. 
Method of confirmation of chorionicity – 
NS 
(Japan) (prospective cohort) 
Donor IUD  
Test and outcome data only available for 82 
pregnancies with stage III TTTS 
UA Doppler studies – absent or reversed 
EDV 
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Quintero et al 
(1999) 
Inclusion – 80 patients referred with a 
diagnosis of TTTS between August 1993 
and January 1999. 
48 patients underwent LPCV or SLPCV.  
Other treatments included umbilical cord 
occlusion (n=17), serial amniocentesis 
(n=10) and 1 termination of pregnancy. 
4 patients were lost to follow up. 
(USA) (prospective cohort) 
Donor IUD 
 
Test and outcome data only available for 45 
pregnancies treated with LPCV 
EFW 
Shah et al 2008 Inclusion – 62 consecutive pregnancies 
from a single centre between January 
2004 and April 2006. 
Exclusions – pregnancies where either 
twin was known to have congenital heart 
disease, severe non-cardiac fetal 
anomalies and cases of selective feticide. 
30 underwent SLPCV, 32 underwent AR 
(of whom 8 also needed SLPCV). 
Method of confirmation of chorionicity – 
NS 
(USA) (retrospective cohort) 
 
Recipient NND (within 30 days of birth)  
 
 
 
Doppler studies were performed immediately 
pre-procedure (is SLPCV or AR) and 
considered to be abnormal if: 
UA – AREDV 
UV – pulsatile flow in a free loop of cord 
DV – atrial systolic flow reversal 
Other parameter correlated with outcome 
AVVR (mild/moderate/severe), abnormal RV 
MPI, abnormal LV MPI, hydrops, overall 
Cardiovascular profile score 
All measurements by a single investigator 
blinded to outcome status 
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Skupski et al (2010) Inclusion - 466 consecutive pregnancies 
from eight centres (part of North 
American Fetal Therapy Network) 
January 2002 – June 2009. 
All underwent SLPCV. 
Method of confirmation of chorionicity – 
USS or pathology of placenta 
 
(USA) (cohort - retrospective analysis of 
prospectively collected data) 
IUD and NND (within 30 days of birth) 
Outcomes reported separately for donor 
and recipient 
Not all measurements and outcomes 
available for all fetuses. The figures below 
indicate the number of fetuses with data 
available. 
Letter in brackets refers to twin in whom the 
measurement is taken.  
UA – AEDV – (D) – IUD D=R=462 / NND 
D=321, R=355 
UA – AEDV – (R) – IUD D=R=462 / NND 
D=322, R=356 
UA – REDV – (D) – IUD D=R=464 / NND 
D=323, R=357 
UA – REDV – (R) – IUD D=R=464 / NND 
D=319, R=351 
UV – pulsatile flow – (D) – IUD D=R=435 / 
NND D=306, R=336 
UV – pulsatile flow – (R) – IUD D=R=433 / 
NND D=305, R=334 
DV – absent a wave – (D) – IUD D=392, 
R=374 / NND D=281, R=311 
DV – absent a wave – (R) – IUD D=R=392 / 
NND D=280, R=310 
DV – reversed a wave – (D) – IUD D=R=400 
/ NND D= 286, R=316 
DV – reversed a wave – (R) – IUD D=R=398 
/ NND D=284, R=314 
TR or MR – (D) – IUD D=R=464 / NND 
D=324, R=358 
Doppler studies 
UA – AEDV*  
UA – REDV*  
UV – pulsatile flow 
DV – absent a wave*  
DV – reversed a wave* 
TR or MR 
*intermittent or persistent 
All tests were reported separately for donor 
and recipient fetuses 
Other parameter correlated with outcome 
Absence of fetal bladder, EFW discrepancy, 
ascites, pericardial/pleural effusion, skin/cord 
oedema, hydrops fetalis, global cardiac 
dysfunction [(abnormal tei index, ventricular 
dyskinesia, abnormal EF (either ventricle), 
abnormal cardiac "score" or other measure 
of cardiac dysfunction)] 
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TR or MR – (R) – IUD D=R=464 / NND 
D=322, R=355 
Global cardiac dysfunction – (D) – IUD D= 
R=463/ NND D=323, R=357 
Global cardiac dysfunction – (R) – IUD 
D=R=458/ NND D=320, R=352 
Stirnemann et al 
(2010a) 
Inclusion – 107 consecutive MC 
pregnancies complicated by severe TTTS 
and referred for prenatal care over a one-
year period. 
All underwent SLPCV. 
Cardiac profile and outcome data only 
available for 58 pregnancies (44 
incomplete data and 5 lost to follow up) 
Method of confirmation of chorionicity 
NS. 
(France/Canada) (prospective cohort) 
 
NND (within 28 days of birth) 
 
  
A six variable cardiac profile was defined for 
each recipient twin including:  
RV – SF, LV – SF, LV – MPI, RV – MPI, DV 
– PI and Cardiac Index. 
Profile 1 - considered close to normal, 
although DV-PI and RV-MPI slightly 
increased.  
Profile 2  - significantly increased RV and LV 
MPI with moderately increased DV-PI. 
Demonstrating diastolic and global 
myocardial impairment.  
Profile 3 - significant depression of LV+RV 
shortening fraction, very high DV-PI and 
increased biventricular MPI. Demonstrating a 
severe systolic, diastolic and overt global 
cardiac failure. 
Fetal echocardiography performed pre-
operatively by one highly trained sonologist 
blinded to outcome. The mean of three 
measurements was taken for each variable. 
For pulsed Doppler measurements, the angle 
of insonation was kept under 20°.  
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Stirnemann et al 
(2010b) 
Inclusion – 215 consecutive patients with 
TTTS treated with selective laser 
coagulation of placental vessels at a 
single centre between 2006 and 2008. 
Median gestational age 20 weeks (18+2 
– 22+3). Quintero stage I – 46, 2 – 31, 3 
– 134, IV – 2. 
 
Exclusion – fetal malformations, 
premature rupture of membranes prior to 
surgery and amniocentesis prior to 
surgery. 
 
25 patients were lost to follow up. 
 
All underwent SLPCV within 24hrs of 
echocardiography.  
 
 
Method of confirmation of chorionicity – 
pathology of the placenta 
 
 
(France) (prospective cohort) 
IUD/NND 
 
Pregnancy outcome was not available in the 
25 patients lost to follow up and CHOP 
evaluation was incomplete in 34 
pregnancies. 
There were 158 pregnancies available for 
prognostic evaluation of the CHOP scoring 
system. 
 
IUD (per pregnancy) 
CHOP 1 25/116, 
CHOP 2 3/36, 
CHOP 3 0/6 
 
NND (per fetus) 
CHOP 1 70/232 
CHOP 2 16/72 
CHOP 3 1/12 
 
(though reporting of NND figures was 
inconsistent) 
 
 
Echocardiograms were performed within 
24hrs prior to surgery and followed a 
predefined protocol based on the 
recommendations of the American College of 
Echocardiography.   
 
All measurements were performed using an 
Aloka ProSound Alpha 10, a GE Voluson 
730 or a GE Voluson E8. 
Pulsed Doppler measurements were 
performed with an angle of insonation of 
<20° and the mean of three consecutive 
measurements used for all quantitative 
parameters. 
 
The CHOP score was computed as the sum 
of 12 cardiovascular parameters (11 in the 
recipient and 1 in the donor) scored 
according to severity. It included 
measurements in the recipient relating to: 
Ventricular hypertrophy, cardiomegaly, 
ventricular systolic function, MR, TR, MV EA, 
TV EA, DV, pulsatile UV, PR, RV outflow 
tract obstruction; and in the donor: 
UA. 
Score – stage 1=0-5, 2=6-10, 3=11-15, 
4=16-20. 
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Trieu et al (2012) Inclusion – 86 consecutive pregnancies 
with TTTS treated with laser coagulation 
of the placental anastomoses at a single 
centre between 2004 and 2009. 
Exclusion – any patient in whom it was 
not possible to measure MCA  
(Pre-op – 11 D and 15 R, Post-op – 3 D 
and 5 R) 
All underwent laser coagulation GA 20.5 
2.9 
Method of confirmation of chorionicity – 
USS 
(France) (retrospective cohort) 
IUD within 7 days of laser 
 
Not all measurements and outcomes 
available pre/post op 
 
5 D and 2 R IUD prior to 48hrs so no post-op 
measurement possible 
 
Overall numbers 
Pre-op – D=75, R=71 
Post-op – D=67, R=66 
MCA-PSV by experienced operators before 
(within 24hrs) and 48hrs after laser 
treatment. 
The circle of Willis and the MCA were 
identified using B-mode and colour Doppler. 
The window was placed at the proximal 
segment of the MCA, close to the origin of 
the internal carotid artery with an angle as 
close to 0 as possible. An angle >30 was a 
criteria for exclusion. The values were then 
converted to MoM. 
The PSV was considered to be elevated if it 
was  1.5 MoM. 
 
AREDV = absent or reversed end-diastolic velocity, AR = amnioreduction, AVVR = atrioventricular valve regurgitation, D=donor twin, DV = ductus venosus, 
EDV = end-diastolic velocity, EFW = estimated fetal weight difference, GA = gestational age, IUD= intrauterine death, LPCV = laser photocoagulation of 
communicating vessels, LV = left ventricle, MC = monochorionic, MCA-PSV = middle cerebral artery peak systolic velocity, MoM = multiples of the median, 
MPI = myocardial performance index, NND= neonatal death, NS= not specified, PI = pulsatility index, R=recipient twin, RV = right ventricle, SF = shortening 
fraction, SLPCV = selective laser photocoagulation of communicating vessels, TOP= termination of pregnancy, TR = tricuspid valve regurgitation, UA = 
umbilical artery, UAD = umbilical artery Doppler, USS = ultrasound scan, UV = umbilical vein.
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Data relating to 1635 pregnancies were reported in the eleven included studies, and 
included evaluation of seven diagnostic tests – umbilical artery abnormality (absent or 
reversed EDV) (1182 pregnancies), MCA abnormality (PI<5th percentile or PSV>1.5 
MoM) (196 pregnancies), DV abnormality (absent or reversed a wave) (693 
pregnancies), umbilical vein (UV) abnormality (pulsatile flow) (693 pregnancies), 
tricuspid regurgitation (576 pregnancies), abnormal cardiac profile (384 pregnancies) 
and EFW (45 pregnancies). 
 
3.1.2.3 Quality assessment 
Quality assessment for the included studies is summarised in Figure 3-9.  Recruitment 
was prospective in five (45%) of the studies, but only three of these studies (27% 
overall) also employed consecutive patient selection, and thus were considered to have 
avoided selection bias.  Ten studies (91%) avoided verification bias by ensuring that 
verification of the index test with the reference standard took place in >90% of cases.  
The index test was adequately described in eight (73%) of studies.  Appropriate and 
timely application of the reference standard was present in all 11 (100%) studies; with 
seven studies utilising IUD (64%), one (9%) NND, and three (27%) both IUD and NND 
as outcomes.  In considering the assessment made using the QUADAS 2 checklist148, 
the risk of bias with regard to applicability of patient selection, index test and reference 
standard to the review question were the domains that was universally low, conversely 
blinding of the reference standard was not reported by any study.  Two studies34 221 
were found to be of high quality, six studies27 202 216 219 222 268 of moderate quality and 
three studies217 218 220 of low quality. 
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Figure 3-9 Bar chart showing quality of evidence in relation to the diagnostic 
accuracy of ultrasound after diagnosis of TTTS to predict outcome.  
 
Data presented as 100% stacked bar chart with numbers in bars representing numbers 
of studies. (see methods for details of quality items). No studies were judged to be at 
high risk of bias. 
 
3.1.2.4 Summarising the evidence 
The results are summarised in Figure 3-10 – 3-13 and Table 3-4  
With respect to prediction of intrauterine death (IUD), six tests were evaluated (see 
table 3-4 a).  No test performed well in terms of both sensitivity and specificity, although 
the trend was for much better specificity than sensitivity, with the exception of EFW 
difference.  An abnormal UA Doppler predicted donor IUD with a pooled positive LR+ of 
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2.29 and a negative LR- of 0.44, although there was significant heterogeneity noted (2 
> df, p=0.013 and I2 = 65.4%).  An abnormal UA Doppler predicted recipient IUD with a 
pooled positive LR+ of 1.07, a LR- of 1.00 and there was no significant heterogeneity 
(2 < df, p=0.91 and I2 = 0%).  An abnormal MCA Doppler predicted donor IUD with a 
pooled LR+ of 1.08, a LR- of 0.97 and there was no significant heterogeneity (2 < df, 
p=0.51 and I2 = 0%).  An abnormal MCA Doppler predicted recipient IUD with a pooled 
LR+ of 1.88  and a LR- of 0.90, and although there was some heterogeneity this was 
not significant (2 > df, p=0.11 and I2 = 61.1%).  An abnormal DV in the donor predicted 
donor IUD with a pooled LR+ of 2.12 and a LR- of 0.97, some heterogeneity was noted, 
although again this was not significant (2 > df, p=0.14 and I2 = 49.8%).  An abnormal 
DV in the recipient predicted recipient IUD with a pooled LR+ of 1.53, a LR- of 0.86  and 
there was no significant heterogeneity (2 < df, p=0.86 and I2 = 0%).  A pulsatile UV 
predicted donor IUD with a pooled LR+ of 1.02, a LR- of 1.00 and there was no 
significant heterogeneity (2 < df, p=0.89 and I2 = 0%).  A pulsatile UV predicted 
recipient IUD with a pooled LR+ of 1.29 and a LR- of 0.89, however some heterogeneity 
was noted but was not significant (2 > df, p=0.07 and I2 = 61.6%).  The presence of 
mitral or tricuspid regurgitation (TR/MR) predicted donor IUD with a pooled LR+ of 1.04, 
a LR- of 1.00 and no significant heterogeneity was noted (2 < df, p=0.93 and I2 = 0%).  
The presence of TR/MR predicted recipient IUD with a pooled LR+ of 1.12, a LR- of 
0.93 and no significant heterogeneity was noted (2 < df, p=0.44 and I2 = 0%).  An EFW 
difference of >20% predicted donor IUD with a LR+ of 0.75 and a LR- of 1.71.  As all 
classifications of CHOP score include some abnormality it was not possible to 
dichotomise this test into a positive or negative result, however increasing CHOP score 
was associated with decreasing IUD CHOP 1 21%, CHOP 2 8% and CHOP 3 0%. The 
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majority of tests performed poorly when the sROC curve was considered. However, 
with respect to donor IUD DV abnormality (AUC 0.99) and pulsatile UV (AUC 0.94) 
showed excellent accuracy, with UAD abnormality showing fair accuracy (AUC 0.78). 
 
In terms of prediction of neonatal death (NND) this outcome was not as commonly 
reported for the donor as the recipient and five tests were evaluated (see table 3-4b).  
Again these tests proved to have higher specificities than sensitivities, with the 
exception of cardiac profile and overall NND.  An abnormal UA Doppler predicted donor 
NND with a positive LR+ of 1.78 and a negative LR- of 0.80.  An abnormal UA Doppler 
predicted recipient NND with a pooled positive LR+ of 0.90 and a negative LR- of 1.00, 
however significant heterogeneity was noted (2 > df, p=0.06 and I2 = 72.4%).  
Reversed flow in the DV predicted recipient NND with a pooled LR+ of 1.18 and a LR- 
of 0.96, although some heterogeneity was noted it was not significant (2 > df, p=0.21 
and I2 = 37.9%).  A pulsatile UV predicted recipient NND with a pooled LR+ of 1.18  and 
a LR- of 0.96, although some heterogeneity was noted it was not significant (2 > df, 
p=0.20 and I2 = 38.2%).  The presence of TR/MR predicted donor NND with a LR+ of 
0.68 and a LR- of 1.01.  The presence of TR/MR predicted recipient NND with a LR+ of 
0.76 and a LR- of 1.19.  The presence of global cardiovascular dysfunction predicted 
donor NND with a LR+ of 0.71 and a LR- of 1.19.  The presence of global 
cardiovascular dysfunction predicted recipient NND with a LR+ of 1.03 and a LR- of 
0.99.  The presence of global cardiovascular dysfunction predicted overall NND 
(including donor and recipient deaths) with a LR+ of 0.95  and a LR- of 1.08 . When 
considering the use of the CHOP cardiovascular score and its relation to prediction of 
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NND the inverse relationship shown with IUD was again apparent: CHOP 1 30%, 
CHOP 2 22%, CHOP 3 8%. 
 
When considering the possibility of publication bias it was noted that none of the meta-
analyses contained more than six studies and many contained only two or three.  It was 
only possible to make a graphically and statistically assessment in relation to UA 
Doppler, where funnel plot asymmetry was not significant (p>0.1).  
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Table 3-4 Pooled and single estimates for ultrasound tests after diagnosis of TTTS to predict outcome. 
a) IUD 
 No. of 
studies 
No. of 
women 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
LR+  
(95%CI) 
LR-  
(95% CI) 
Pre-test 
probability 
% (95% CI) 
Post-test probability % (range) 
Test + Test - 
UA abnormal and 
donor IUD 
6 1118 0.69 (0.36 – 
0.89) 
0.70 (0.51 – 
0.83) 
2.29 (1.61 – 
3.25) 
0.44 (0.22 – 
0.88) 
23.3 (15.3 – 
31.4) 
41.1 (32.9 – 
49.7)  
11.8 (6.28 – 
21.1) 
UA abnormal and 
recipient IUD 
4 634 0.08 (0.02 – 
0.25) 
0.93 (0.73 – 
0.98) 
1.07(0.10 – 
12.1) 
1.00 (0.81 – 
1.22) 
23.3 (15.3 – 
31.4) 
24.6 (2.95 – 
78.7) 
23.3 (19.8 – 
27.1) 
MCA abnormal 
and donor IUD 
2 196 0.22 (0.12 – 
0.37) 
0.81 (0.73 – 
0.87) 
1.08 (0.58 – 
2.02) 
0.97 (0.82 – 
1.14) 
23.3 (15.3 – 
31.4) 
24.7 (15.0 – 
38.1) 
22.8 (20.0 – 
25.8)  
MCA abnormal 
and recipient IUD 
2 196 0.33 (0.18 – 
0.52) 
0.67 (0.59 – 
0.75) 
1.88 (0.31 – 
11.2) 
0.90 (0.75 – 
1.08) 
23.3 (15.3 – 
31.4) 
36.4 (8.62 – 
77.3) 
21.5 (18.6 – 
24.7)  
DV abnormal and 
donor IUD  
3 629 0.08 (0.04 – 
0.14) 
0.95 (0.93 – 
0.97) 
2.12 (0.37 – 
12.2) 
0.97 (0.87 – 
1.08) 
23.3 (15.3 – 
31.4) 
39.2 (10.1 – 
78.8) 
22.8 (20.9 –  
24.7) 
DV abnormal and 
recipient IUD 
3 628 0.33 (0.16 – 
0.55) 
0.79 (0.63 – 
0.89) 
1.53 (1.12 – 
2.08) 
0.86 (0.72 – 
1.02) 
23.3 (15.3 – 
31.4) 
31.8 (25.4 – 
38.8) 
20.8 (18.0 –  
23.7) 
UV-P and donor 
IUD 
3 629 0.04 (0.02 – 
0.09)  
0.96 (0.94 – 
0.98) 
1.02 (0.42 – 
2.52) 
1.00 (0.96 – 
1.04) 
23.3 (15.3 – 
31.4) 
23.7 (11.3 – 
43.4) 
23.3 (22.6 –  
24.1)  
UV-P and recipient 
IUD 
3 629 0.34 (0.25 – 
0.45) 
0.70 (0.65 – 
0.74) 
1.29 (0.73 – 
2.27) 
0.89 (0.62 – 
1.27) 
23.3 (15.3 – 
31.4) 
28.2 (18.2 – 
40.9) 
21.3 (15.9 – 
27.9)  
TR/MR and donor 
IUD 
2 576 0.02 (0.002 
– 0.05) 
0.98 (0.97 – 
0.99) 
1.04 (0.25 – 
4.30) 
1.00 (0.97 – 
1.03) 
23.3 (15.3 – 
31.4) 
24.1 (7.07 – 
56.7) 
23.3 (22.8 – 
23.9)  
TR/MR and 
recipient IUD 
2 576 0.44 (0.33 – 
0.54) 
0.61 (0.56 – 
0.65) 
1.12 (0.87 – 
1.45) 
0.93 (0.77 – 
1.12) 
23.3 (15.3 – 
31.4) 
25.4 (20.9 – 
30.6) 
22.1 (19.0 –  
25.4) 
EFW 1 45 0.56 (0.31 – 0.26 (0.11 – 0.75 (0.47 – 1.71 (0.76  - 23.3 (15.3 – 18.6 (12.5 – 34.2 (18.8 – 
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difference>20% 
and donor IUD 
0.79) 0.46) 1.20) 3.89) 31.4) 26.8 54.2)  
 
b) NND 
 No. of 
studies 
No. of 
women 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
LR+ 
(95%CI) 
LR-  
(95% CI) 
Pre-test 
probability 
% (95% CI) 
Post-test probability % (range) 
Test + Test - 
UA abnormal and 
donor NND 
1 466 0.36 (0.22 
– 0.51) 
0.80 (0.75 
– 0.85) 
1.78 (1.10 
– 2.74) 
0.80 (0.62 
– 0.97) 
14.5 (9.70 
– 19.3) 
23.2 (15.7 – 
31.8) 
12.0 (9.52 – 
14.1) 
UA abnormal and 
recipient NND 
2 528 0.04 (0.01 
– 0.12) 
0.93 (0.90 
– 0.96) 
0.90 (0.03 
– 26.30) 
1.00 (0.83 
– 1.20) 
14.5 (9.70 
– 19.3) 
13.3 (0.51 – 
81.7) 
14.5 (12.0 – 
16.9) 
DVRF and 
recipient NND 
2 498 0.25 (0.15 
– 0.37) 
0.71 (0.66 
– 0.76) 
1.18 (0.52 
– 2.69) 
0.96 (0.80 
– 1.14) 
14.5 (9.70 
– 19.3) 
16.7 (8.11 – 
31.4) 
14.0 (12.0 – 
16.2) 
UV-P and 
recipient NND  
2 498 0.23 (0.14 
– 0.35) 
0.74 (0.69 
– 0.78) 
1.18 (0.51 
– 2.71) 
0.96 (0.81 
– 1.14) 
14.5 (9.70 
– 19.3) 
10.4 (7.97 – 
31.5) 
14.0 (12.1 – 
16.2) 
TR/MR and 
donor NND 
1 436 0 (0 – 0.08) 0.99 (0.96 
– 1.00) 
0.68 (0.04 
– 12.35) 
1.01 (0.97  
- 1.04) 
14.5 (9.70 
– 19.3) 
11.4 (0.67 – 
67.7) 
14.6 (14.1 – 
15.0) 
TR/MR and 
recipient NND 
1 436 0.33 (0.20 
– 0.50) 
0.56 (0.50 
– 0.62) 
0.76 (0.48 
– 1.18) 
1.19 (0.94 
– 1.51) 
14.5 (9.70 
– 19.3) 
 10.8 (7.53 – 
16.7) 
16.8 (13.8 – 
20.4) 
CVS dysfunction 
and donor NND 
1 436 0.26 (0.14 
– 0.41) 
0.64 (0.58 
– 0.70) 
0.71 (0.42 
– 1.21) 
1.17 (0.96 
– 1.42) 
14.5 (9.70 
– 19.3) 
14.9 (6.65 – 
17.0) 
16.6 (14.0 – 
19.4) 
CVS dysfunction 
and recipient 
NND 
1 436 0.37 (0.22 
– 0.531) 
0.64 (0.59 
– 0.70) 
1.03 (0.67 
– 1.58) 
0.99 (0.77 
– 1.26) 
14.5 (9.70 
– 19.3) 
13.9 (10.2 – 
21.2) 
14.4 (11.6 – 
17.6) 
CVS dysfunction 
and NND overall 
1 58 0.58 (0.41 
– 0.75) 
0.39 (0.28 
– 0.50) 
0.95 (0.69 
– 1.32) 
1.08 (0.67 
– 1.73) 
14.5 (9.70 
– 19.3) 
13.9 (10.5 – 
18.3) 
15.5 (10.2 – 
22.7) 
CHOP score not included in the above table as it was not possible to dichotomise the results into a positive or negative test.
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Figure 3-10 Forest plots of positive and negative likelihood ratios for ultrasound 
after diagnosis of TTTS to predict outcome 
a) UA Doppler and donor IUD 
 
b) UA Doppler and recipient IUD 
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Figure 3-11 Summary ROC curve for UA abnormality to predict donor IUD a 
diagnosis of TTTS. 
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Figure 3-12 Summary ROC curve for donor DV abnormality to predict donor IUD 
after diagnosis of TTTS.  
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Figure 3-13 Summary ROC curve for pulsatile UV to predict donor IUD after 
diagnosis of TTTS.  
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3.1.3 Effectiveness review of FLA and serial amnioreduction for the 
treatment of TTTS.  
 
3.1.3.1 Question 
What is the effectiveness of FLA versus serial amnioreduction for the treatment of 
TTTS? 
3.1.3.2 Study selection 
The electronic and hand search relevant to all three planned reviews generated 25140 
citations, of which 19 articles59 60 269-284 were thought to be relevant: 18 were published 
in English and one in German.  After independent review of the full manuscript of these 
19 full articles, five were selected for inclusion in this review (figure 3-14).  Thus, a total 
of five primary studies (all in English language), including 495 twin pregnancies, were 
selected for review (Table 3-5).  Two randomised trials (185 twin pregnancies) and 
three observational studies (310 twin pregnancies) were identified.  
The list of excluded studies is included in Appendix 7. 
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Figure 3-14 Study selection process for a systematic review of effectiveness of 
FLA and serial amnioreduction for the treatment of TTTS.  
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Table 3-5 Study Characteristics for a systematic review of the effectiveness of FLA and serial amnioreduction for the 
treatment of TTTS.  
(unless otherwise stated all interventions are carried out with continuous US guidance, and all twins undergoing laser also 
underwent a single amnioreduction as part of the procedure) Where survival differences are known to be significant p values are 
stated.  
Study Population Interventions Outcomes (survival) 
Follow up 
Length 
(Months) 
% 
Crombleholme et 
al (2007) 
 
43 monochorionic twin pregnancies 
complicated by TTTS (prior to 22 
weeks) who had failed to respond to 
initial qualifying amnioreduction.  
 
1 withdrew prior to randomisation 
and 2 dropped out after 
randomisation but prior to treatment 
(one from each arm). 
 
Ultrasound was used to determine 
chorionicity. 
 
Selective laser (n=20) performed in 3 
units 
Under epidural anaesthesia with 
intravenous sedation. 
Technique: most through a single 
percutaneous port, however some with 
an anterior placenta required a mini-
laparotomy. 3.3 mm 3 port fetoscope, 
one for the 600µ laser endostat and a 
second for rapid infusion of physiologic 
saline if needed to clear the amniotic 
cavity. Selective coagulation using 60 
Watt power with Endostat 1cm from the 
surface of the vessel, after the chorionic 
plate of the placenta was mapped 3 
times. All procedures digitally recorded 
and independently reviewed.  
Overall at 30/7 
Laser 18/40 (45%) 
AR 24/40 (60%) 
 
At least one twin at 
30/7  
Laser 13/20 (65%) 
AR 15/20 (75%) 
 
Donor at 30/7 
Laser 11/20 (55%) 
AR 11/20 (55%) 
 
Recipient at 30/7 
Laser 6/20 (30%) 
AR 9/20 (25%) 
 
NS >90% 
Randomised 
controlled 
trials 
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All treatments were performed prior 
to 24 weeks but mean gestation for 
laser and amnioreduction not 
specified. 
Initial recruitment planned to 146 but 
trial stopped early at investigators 
request and the Trial Oversight 
Committee’s recommendation based 
on interim analyses. 
Amnioreduction performed to a deepest 
vertical pocket (DVP) of <5cm. 
Antibiotics were instilled into the 
amniotic cavity prior to trocar removal. 
Vs 
Aggressive Amnioreduction (AR) 
(n=20) 
Ultrasound performed thrice weekly and 
AR performed whenever the DVP in the 
recipient twin sac was 8cm.  
Technique: 20 gauge needle and 
vacuum suction bottle to a DVP of ≤5cm. 
USS to assess for inadvertent 
septostomy 1hr post-procedure. 
No. of procedures NS 
Treatment failures Laser (n=0), AR 
(n=7).  
None of these 
differences were 
statistically significant 
 
 
 
 
 
Senat et al (2004) 
 
142 monochorionic twin pregnancies 
complicated by TTTS (15-26 weeks) 
 
Gestational age at treatment not 
specified but all randomised prior to 
24 weeks. 
 
Postnatal examination of the 
placenta confirmed monochorionicity 
Selective Laser (n=72) performed in 3 
units 
Under local/regional anaesthesia 
Technique: through recipient sac, 
3.3mm cannula with trocar, 2mm 
fetoscope, 400 or 600 µm diameter 
Nd:YAG or diode laser fibre. Selective 
coagulation by non-touch technique 
using an output 30-60 Watts. 
Post-laser amniotic fluid drained until 
Overall at 6/12 
Laser 81/144 (56%),  
SA 54/140 (39%)  
 
At least one twin at 
6/12   
Laser 55/72 (76%),  
SA 36/70 (51%) p=0.002  
 
Donor at 6/12 
Laser 39/72 (54%), 
SA 28/70 (40%) 
 
Median 20 
Range 6-42 
>90% 
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in all but 1 case (in SA group). 
 
Initial recruitment planned to 172 but 
trial stopped early after second 
interim analysis. 
maximum pool depth 5-6cm.  
n=3 didn’t undergo procedure (n=2 didn’t 
meet selection criteria; n=1 IUD both 
fetuses) Primary treatment failures 
within 2 weeks n=3 (n=2 had repeat 
laser, n=1 underwent additional 
amnioreduction) 
Vs 
Serial amnioreduction (SA) (n=70) 
performed in 17 units 
Technique: 18 gauge needle syringe 
aspiration or wall suction, until maximum 
pool depth 5-6cm.  
Mean no. of procedures 2.6 
n=2 didn’t undergo the procedure (n=1 
withdrew consent, had laser instead; 
n=1 IUD both fetuses) 
Primary treatment failures n=6 so also 
underwent laser. 
Prophylactic tocolytics and antibiotics 
were given. 
Recipient at 6/12 
Laser 42/72 (58%),  
SA 26/70 (37%) 
 
Without major 
neurological 
complications at 6/12 
Donor Laser 36/72 
(50%), SA 25/70 (35%) 
p=0.09 
Recipient Laser 39/72 
(54%), SA 19/70 (27%) 
p= 0.003 
 
TOP Laser 0/72, SA 
11/70 
 
Delivery<24wks Laser 
24/144, 16/140 
 
IUD 24 wks Laser 
27/144, SA 29/140 
 
NND/infant death  
Laser 12/144, SA 41/140 
Middeldorp et al 
(2007) 
 
 
 
21 consecutive monochorionic 
pregnancies complicated by TTTS 
(after 26 weeks) 
 
Ultrasound was used to determine 
chorionicity. 
Laser (n=10)  
Median gestational age at treatment 27 
weeks. 
Technique: maximum power used 70 
watts and post-procedure 
amnioreduction median 1800ml amniotic 
fluid removed. 
Overall (liveborn) 
Laser 20/20 (100%) 
SA 22/22 (100%) 
 
At least one (liveborn) 
Laser  20/20 (100%), 
SA 22/22 (100%) 
 
NS 
 
 
 
 
>90% 
 
 
 
 
 
Observational  
studies 
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All cases were seen at a single 
tertiary referral centre. 
 
 
 
 
 
 
n=1 had amniodrainage 3/7 prior to 
laser. n=1 laser abandoned due to poor 
visualisation.  
Vs 
SA (n=11) 
Technique: not described 
Median gestational age at treatment 27 
weeks. Mean no. of procedures 1.6. 
NND 
Laser 0/20 (0%), 
SA 3/22 (14%) 
 
Any adverse outcome 
Laser 3/20 (15%), 
SA  8/22 36%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Quintero et al 
(2003)  
173 consecutive monochorionic 
pregnancies complicated by TTTS. 
All treated prior to 27 weeks. 
 
Selective Laser (95) 1 centre 
Median gestational age at treatment 
21.6 weeks. 
Under General anaesthesia  
Technique: 2.7-3.3mm fetoscope with 
3.5mm trocar, 600 µm diameter non-
contact Nd:YAG using 10-40 Watts.  
Prophylactic antibiotics and tocolysis 
were given. 
Vs 
SA (78) 3 centres 
Median gestational age at treatment 
20.7 weeks. 
 
Overall (to NN period) 
Laser 122/190 (62.4%),  
SA 90/156 (57.7%) 
 
At least one twin  
Laser 79/95 (83.2%),  
SA 52/78 (67.7%)  
 
Donor  
Laser 60/95 (63.2%), 
SA 45/78 (57.7%) 
 
Recipient  
Laser 63/95 (66.3%),  
SA 45/78 (57.7%) 
 
Miscarriage<24wks 
Laser 8/95, SA 8/78 
 
IUD Laser 43/190 
(includes 1 pregnancy 
with IUD of D and 2 
NS 
 
>90% 
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Technique: sterile aspiration to MVP 6-
7cm. Weekly scanning and repeat 
procedures if  MVP 8cm 
No of procedures NS 
pregnancies with IUD of 
D+R before 
miscarriage), SA 12/156 
(includes 1 pregnancy 
with IUD of D and 1 
pregnancies with IUD of 
R before miscarriage) 
 
NND Laser 14/190 (6=D, 
8=R), SA 40/156 
(21=D,19=R) 
Hecher et al 
(1999)
 
 
116 consecutive monochorionic 
pregnancies complicated by TTTS. 
(17-25 weeks gestation) 
Laser (73) 1 centre 
Technique: through recipient sac, 
1.9mm fetoscope in 9.8F sheath, 400 
µm diameter Nd:YAG. Selective 
coagulation using an output 50-60 Watts 
from 1cm. 
n=1 also underwent SA   
Vs 
Serial Amnioreduction (43) 1 centre 
Technique: 18 gauge spinal needle, until 
normal amniotic fluid volume in recipient 
sac 
Median no of procedures 3 (range 1-15) 
 
Amniotic fluid drained after laser was 
significantly more than that removed at 
1
st
 amniocentesis in SA group (median 
2500ml vs 1990ml) 
Overall 
Laser 89/146 (61%),  
SA 44/86 (51%)  
 
At least one twin  
Laser 58/73 (79%),  
SA 26/43 (60%)  
 
Donor  
Laser 38/73 (52%), 
SA 21/43 (49%) 
 
Recipient  
Laser 51/73 (70%),  
SA 23/43 (53%) 
 
TOP Laser 2/73, SA 
1/43 
 
SF (of donor) Laser 
1/73, SA 4/43 (all 
resulted in death of co-
twin as well) 
 
IUD of 1 fetus Laser 
NS >90% 
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24/73,  
SA 3/43 
 
NND Laser 6/95, SA 
7/51 
 
D=donor twin, DVP = deepest vertical pocket, IUD= intrauterine death, MVP = maximum vertical pool, NND= neonatal death, NS= 
not specified, R=recipient twin, SA= serial amnioreduction, SF = selective feticide, TOP= termination of pregnancy 
 
 
See Appendix 8 for a summary of morbidity, gestational age and birth weight data for review of effectiveness of FLA and serial 
amniodrainage for treatment of TTTS 
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3.1.3.3 Quality assessment 
Details of the study characteristics, methods, populations, interventions (including failed 
procedures) and outcomes (including complications) are shown in Table 3-5 and quality 
assessment in Figure 3-15.  All included pregnancies had ultrasonic evidence of 
monochorionic twins and oligo-polyhydramnios, however, only one of the RCTs 59 also 
made postnatal examinations of the placenta, which revealed one placenta to be 
dichorionic.  In the majority of studies 59 269-271 recruitment was based on the presence 
of TTTS, however in one of the RCTs60 all patients were required to undergo a 
“qualifying” amnioreduction and it was only if this did not resolve the features of TTTS 
that patients were eligible for randomisation.  As the rationale of a randomised 
controlled trial is to eliminate bias it is considered that the two randomised controlled 
trials 59 60 provided ideal control for confounding factors, however in an attempt to 
minimise bias two of the observational, comparative studies 270 271 used statistical 
adjustment for differences between the groups (TTTS stage was recorded for both 
treatment groups and was not found to be significantly different- Quintero; gestational 
age and abdominal biometry was not significantly different between treatment groups - 
Hecher).  Method of data collection was prospective in 3/5 studies (60%) and in 2/5 
(40%) it was either retrospective or unreported.  All of the studies employed consecutive 
patient enrolment.  The majority of studies 59 60 270 271 reported intervention for TTTS 
prior to 26 weeks gestation, whereas Middeldorp et al 269 reported intervention after 26 
weeks.  Description of intervention was considered incomplete in 3/5 (60%) of the 
studies.  Although all studies provided detailed descriptions of the technique and 
equipment used, this detail was undermined in several instances: two studies 59 60 did 
not report the gestation at which the first intervention occurred, and another 270  failed to 
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provide numerical data for the mean or median number of amnioreductions performed 
in its serial amnioreduction cohort.  The remaining 2/5 (40%)269 271 provided adequate 
detail of both interventions.   
 
It was possible to extract data on overall survival, survival of at least 1 twin and 
differential survival of donor and recipient twins in all trials (5/5).  However, the timing of 
the definition of survival varied from birth 269 271, to the perinatal/neonatal period (28/30 
days respectively)60 270 and 7-12 months 59.  Data on neurological abnormality or 
morbidity in survivors were available in 4/5 (80%) 59 269-271.  Data relating to maternal 
morbidity were available in 3/5 (60%)59 60 269  
 
Figure 3-15 Bar chart showing quality of evidence in relation to the effectiveness  
of FLA and serial amnioreduction in the treatment of TTTS.  
 
 
Data presented as 100% stacked bar chart with numbers in bars representing numbers 
of studies. (see methods for details of quality items)
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3.1.3.4 Summarising the evidence  
Data from all studies are grouped, unless otherwise specified, to allow overall 
descriptive comparisons to be made. 
Survival outcomes (see figure 3-16 for relative risk calculations) 
All twins survived in both the FLA and the AR arms of the Middeldorp study269, so 
relative risk calculation was not performed and these figures have been excluded from 
the following ranges to avoiding masking the results from the other studies.  
When considering the primary outcome of this review, FLA conferred better survival of 
at least one twin in all except one trial60, with values ranging between 53.2-83.2%.  This 
trend was also repeated in relation to the secondary outcome of overall survival, range 
45.0% -62.4%.  However, with respect to differential survival of donor and recipient 
twins all studies showed equivalent or improved survival with FLA, ranges 52%-63.2% 
and 30-70% respectively.  This is in comparison with amnioreduction, which resulted in 
survival ranges: 51%-75% for survival of at least one twin, 39%-60% for overall survival, 
with differential survival of 40%-57.7% and 25%-57.7% for donor and recipient twins 
respectively.  Meta-analysis was not performed on all the studies as clear differences 
noted in inclusion criteria meant the populations included were not comparable. The 
reasons for not including a meta-analysis in this evidence summary are explained in 
further detail in the discussion. 
 
Intervention Failures and Complications  
Of the 270 patients scheduled to receive FLA nine (3.3%) either did not get FLA or had 
treatment failures.  Of these four did not undergo the planned treatment (1.5%), one 
(0.4%) underwent amnioreduction prior to FLA, and failure occurred in a further four 
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(1.5%); necessitating two patients to undergo repeat laser coagulation, and two 
additional amnioreduction.  Of the 222 patients who were scheduled to receive 
amnioreduction 15 (6.8%) either did not get the treatment or had treatment failures.  Of 
these two (0.9%) did not undergo the planned treatment (one requested laser instead 
and one had a double in-utero death prior to treatment), six (2.7%) required FLA as well 
and there were seven (3.2%) treatment failures.  There was no statistically significant 
difference between FLA and AR in terms of treatment failures (p=0.09). 
 
Four studies 59 269-271 also reported more specific data regarding complications including 
fetal and neonatal deaths, as well as fetal morbidity.  There were statistically fewer 
TOPs and NNDs in twins treated by FLA than amnioreduction, 2/155 (1.3%) vs 12/ 124 
(9.7%) (p=0.002), and 32/449 (7.1%) vs 91/369 (24.7%) (p<0.0001) respectively.  There 
were similar numbers of miscarriages and IUDs in both the FLA and amnioreduction 
groups, 25/250 (10.0%) vs 19/202 (9.4%) (p=0.87) and 74/500 (14.8%) vs 57/404 
(14.1%) (p=0.78) respectively.  All four studies reported fewer central nervous system 
(CNS) complications in relation to FLA.  Two studies reported survival with no CNS 
complications and showed a significant benefit with FLA: FLA 75/144 (52.0%) vs 
amnioreduction 44/140 (30.5%) p=0.00559; FLA 75/95 (78.9%) vs amnioreduction 40/78 
(51.3%) p=0.002270.  
 
Serious maternal complications were reported in three studies and were infrequent.  
Placental abruption necessitating delivery occurred in 1/72 (1.4%) who underwent FLA, 
as opposed to 2/70 (2.9%) who underwent amnioreduction 59 and this difference was 
not statistically significant (p=0.67).  The two other studies reported no serious maternal 
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complications in either group 60 271.  Minor maternal complications were more frequent 
with FLA and included a spinal headache (1/20; 5%) and a mini laparotomy (required in 
seven women (7/20; 35%) to expose the surface of the uterus) in the Crombleholme 
study60.  
 
Individual patient data analysis 
Despite contacting all authors it was only possible to obtain individual patient data for 
two of the observational studies269 270.  Repeated attempts to contact the authors 
yielded replies from all other authors, except the Eurofetus group, who stated that 
original ethics or logistically constraints prevented them from being able to share their 
data.  It was therefore not possible to perform this analysis. 
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Figure 3-16 Forest plot showing the relative risks of FLA and serial amnioreduction for the treatment of TTTS. 
 
 106 
3.2 Results of investigation of biomarkers in the pathophysiology of 
TTTS 
 
3.2.1 Markers of placental destruction (AFP/hCG)  
a) Demographics of the twin pregnancy cohorts 
There were 31 potentially eligible MC twin pregnancies complicated by TTTS in the 
study period; however eight of these declined participation. Anonymised demographic 
data regarding these eight were however available and were not statistically different.  
All 23 recruited women were available for follow up.  The demographics and outcomes 
of the uncomplicated dichorionic and monochorionic twin pregnancies and the twins 
complicated by TTTS have been previously described141 164 165 and are shown in Table 
3-6.  The majority of cases had severe TTTS (21/23: 91.3%: with stage III 18/21 or IV 
disease 3/21), whereas only two cases (2/23, 8.7%) had stage I TTTS285.   
 
Overall, in 16/23 cases (69.6%), the recipient amniotic sac had a maximum pool depth 
that was less than 12cm and in 7/23 (30.4%) the maximum pool depth was >12cm.  In 
14/23 (60.8%) of cases of TTTS, the inter-twin EFW difference (∆EFW) was <25%, 
whilst 9/23 (39.1%) had an ∆EFW of >25%.  When considering only the severe cases 
(n=21): 18 (85.7%) had stage III disease and three (14.3%) had stage IV disease; 8/21 
(38.1%) of recipient twins had ultrasound signs of cardiac dysfunction alone; in 5/21 
(23.8%) the donors demonstrated AEDFV only and in 8/21 (38.1%) both recipient 
cardiac dysfunction and donor AEDFV were present.  One case was excluded from all 
but basal analyses as fetoscopic laser ablation was not performed due to major inter-
twin membrane disruption following a previous amniodrainage (at another centre). 
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Table 3-6 Demographics of uncomplicated di- and monochorionic twins and 
monochorionic twin pregnancies complicated by TTTS.   
 
 
DC twins (n=12) MC twins (n=7) 
MC twins with 
TTTS (n=23) 
Maternal age (y) 
 
33.5 (29.5 – 37) 35 (26 – 40) 32  (25 – 34) 
Parity 
 
0 (0 – 1) 1 (0 – 2) 1 (0 – 1) 
Blood pressure at 
diagnosis (MAP; 
mmHg). 
 
82 (80 – 84) 83 (79.5 – 87.5) 82.5 (79.5 – 87) 
Gestational age 
(wk) at recruitment 
 
20.5 (20.22 – 21.5) 22.14 (20 – 22.43) 21 (19 – 22.14) 
Gestational age 
(wk) at delivery of 
survivors 
 
37 (34.5 – 37.5) 35 (35 – 36) 
33.93 (31.29 – 
35.36) 
Birthweight 
(survivors) (g)   
 
 
Twin 1 2480 (1743 
– 2680) 
Twin 2 2180 (1674 
– 2580) 
Twin 1 2497 (2165 
– 2600) 
Twin 2 1900 (1830 
– 2497) 
Recipient 2370  
(1972 – 2693) 
Donor 1880 (1355 – 
1996) 
 
Data analysed by Kruskal Wallis test (p < 0.05), represented as medians (IQR). 
 
Of the TTTS cohort who were treated by either fetoscopic laser ablation (n=20; 90.1%) 
or amniodrainage (n=2) (cases with stage I TTTS only; 9.9%), the overall survival was 
68.2% live births (30/44) and an outcome of at least one twin survivor in 86.4% (19/22) 
of cases.  
 
b) Circulating MSAFP and f-hCG concentrations under basal conditions in 
uncomplicated multiple pregnancies and those complicated by TTTS 
The median MoM were not significantly different in uncomplicated DC twin pregnancies 
for MSAFP 1.85 (IQR 1.62 – 2.34) or f-hCG 1.66 (95%CI 1.21 – 2.04) as compared to 
uncomplicated MC twin pregnancies (MSAFP 1.40 (IQR 1.16 – 2.58 and f-hCG 1.70 
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(IQR 0.32 – 3.35)).  The median MSAFP MoM and f-hCG MoM in MC twin 
pregnancies complicated by severe TTTS were significantly increased (MSAFP 3.10 
(IQR 2.67 – 4.43); p<0.05 and f-hCG MoM 5.75 (IQR 5.22 – 9.12); p<0.001) compared 
to uncomplicated twin pregnancies (Figure 3-17A and B). These significant differences 
were also found on post hoc analysis of uncomplicated MC twins vs those affected by 
TTTS and uncomplicated DC twins vs those affected by TTTS. 
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Figure 3-17 Box and whisker plot showing basal comparisons of MSAFP and f-
hCG and the effects of chorionicity and TTTS.  
 
(Representing the median value, the IQR and the overall range. Analysed by Kruskal-
Wallis test.)   
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c) Sub-group analysis of circulating MSAFP and f-hCG in the cohort of MC twins 
complicated by TTTS 
In the TTTS cohort, there was no significant difference, including on post hoc analysis 
across all three groups, in median MSAFP MoM or f-hCG MoM between sub-groups 
where the recipient had signs of cardiac dysfunction only (MSAFP 3.15 (IQR 1.64 – 
6.19) and f-hCG 5.50 (IQR 3.91 – 9.18)), where the donor had AEDFV only (MSAFP 
2.70 (IQR 2.04 – 3.19) and f-hCG 3.21 (IQR 1.09 – 7.34)) or both recipient and donor 
had both abnormal cardiac and feto-placental velocity (MSAFP 3.20 (IQR 2.15 - 4.80) 
and f-hCG 6.80 (IQR 5.19 – 14.12)).  
 
No significant difference in median MSAFP MoM or f-hCG MoM was noted when 
subdivided by severity of inter-twin EFW difference (Figure 3-18) or severity of 
hydramnios in the recipient amniotic sac (Figure 3-19).  
 
 
 
 
 
 
 
 
 
 111 
Figure 3-18 Box and whisker plot showing the effect of EFW difference on the 
levels of MSAFP and f-HCG for the TTTS cohort.  
 
(Representing the median value, the IQR and the overall range. Analysed by unpaired 
Mann Whitney U test.)  
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Figure 3-19 Box and whisker plot showing the effect of severe hydramnios on the 
levels of MSAFP and f-hCG for TTTS cohort. 
  
(Representing the median value, the IQR and the overall range. (Analysed by unpaired 
Mann Whitney U test)   
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d) Changes in circulating MSAFP and f-hCG concentrations after FLA 
The median MSAFP increased by 445% (636.65 (IQR 616 – 1216.9 U/ml)) by six hours 
post-procedure and remained elevated at one week (553.4 (IQR 203.7 –3020.8U/ml); 
p=0.001) (Figure 3-20a).  No significant difference in median f-hCG was noted post-
FLA (p=0.36) (Figure 3-20b).  There was no difference in the increase in MSAFP 
concentration (∆MSAFP), whether there were two survivors or one or more deaths post-
FLA (Figure 3-21).  There was no significant correlation between the ∆ MSAFP between 
basal and 6 hours post-FLA and total energy used (Spearman r=0.251 (95%CI -0.216 – 
0.62), the total number of AVA coagulated (Spearman r=0.27 (95%CI -0.19 – 0.64), the 
duration of the procedure (r= -0.24 (95%CI -0.62 – 0.22) or the amniotic fluid 
drained/gestational age ratio) (r= -0.29 (95%CI -0.65 – 0.17).  There was no significant 
correlation between f-hCG and total energy used (Spearman r=-0.032 (95%CI -0.468 – 
0.417) or the total number of AVA coagulated (Spearman r=0.148 (95%CI -0.316 – 
0.554).  Multiple linear regression models demonstrated that the rise in MSAFP was 
independent of the effect of gestational age, operation time, amount of amniotic fluid 
drained at the end of the procedure, the amniotic fluid drained/gestational age ratio, and 
the number of chorionic vessels coagulated. 
 
 There was no significant difference in basal MSAFP or f-hCG (prior to or after 
treatment) noted in those twins who both died post-FLA (MSAFP 3.0 (IQR 0.23 - 5.96) 
and f-hCG 7.60 (IQR 5.87 – 21.18)), compared to those with one survivor (MSAFP 
3.10 (IQR 2.34 – 5.08) and f-hCG 6.80 (IQR 4.66 – 9.02)) or two survivors (MSAFP 
2.70 (IQR 1.39 – 5.09; p=0.66) and f-hCG 4.45 (IQR 1.97 – 10.7); MSAFP p=0.6652, f-
hCG p=0.28).   
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In the small number (n=2) of TTTS cases (stage I) treated by amnioreduction there 
were no significant changes in MSAFP and f-hCG after treatment (p= 0.6652, p= 
0.5083 respectively).   
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Figure 3-20 Box and whisker plot showing the changes in A) MSAFP and B) f-
hCG over time after FLA. 
 
(Representing the median value, the IQR and the overall range. (Analysed by Kruskal-
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Figure 3-21 showing the effect of the numbers of survivors on levels of MSAFP in 
those treated by amnioreduction and by FLA. 
 
  
 
 
 
Graph demonstrating the change of geometric mean MSAFP (+/-75th geometric centile) 
after fetoscopic laser ablation in a cohort where there are two fetal survivors (filled 
square) as compared to those pregnancies where there is at least one IUD (black 
square). No significant difference in MSAFP increase was noted over time in those 
treated with amnioreduction or with two survivors vs at least one IUD after FLA (black 
cross). 
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3.2.2 Angiogenic growth factors 
 
a) Demographics of the twin pregnancy cohorts. 
See 3.2.1 section a) for demographics 
 
b) Circulating plasma angiogenic factors and receptors, sVEGFR1 and sTie-2, 
concentrations in uncomplicated twin pregnancies and TTTS. 
The median (IQR) plasma concentrations for all the measured angiogenic factors and 
the receptors sVEGFR-1 and sTie-2 are shown in Table 3-7.  There was a significant 
difference in the plasma VEGF-C, Ang-2 and sVEGFR-1 concentrations between 
uncomplicated MC and MC twin pregnancies with TTTS.  Maternal plasma VEGF-C 
was significantly lower in TTTS cases (P< 0.0001) and this significance was confirmed 
on post-hoc analysis of uncomplicated DC vs TTTS and uncomplicated MC vs TTTS.  
Plasma Ang-2 was significantly higher in the TTTS cohort (P=0.0012), with post-hoc 
analysis showing a significant difference between uncomplicated DC twins and the 
TTTS cohort.  In terms of angiogenic growth factor receptors, only plasma sVEGFR-1 
was significantly higher in the MC twins with TTTS (P=0.042), but this significance was 
not seen on post-hoc analysis.  The sVEGFR-1/PIGF ratio was significantly higher in 
the TTTS cohort compared to MC and DC cohorts (P=0.0071), with post-hoc analysis 
showing a significant difference between uncomplicated DC twins and the TTTS cohort.  
.  
VEGF-C was higher in uncomplicated MC twins than uncomplicated DC twins, and 
lowest in TTTS (P<0.0001), while Ang-2 and sVEGFR-1 was highest in TTTS 
(P=0.0012 and P=0.042 respectively).   
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Table 3-7 Plasma concentrations (pg/ml) of angiogenic growth factors and their 
receptors in uncomplicated di- and monochorionic twins and twins complicated 
by TTTS. 
 DC twins 
(n=12) 
MC twins (n=7) MC twins with 
TTTS (n=23) 
P value 
VEGF-C 
 
1500, 1300 – 
1800  
1700, 1500 – 
1800  
190, 190 – 
1300 (↓) 
<0.0001 
VEGF-D  
 
98, 81 – 140  240, 63 – 3900  79, 63 – 140  0.1277 
VEGF-A 
 
1100, 480 – 
1700  
1400, 450 – 
25000  
1600, 700 – 
5100  
0.2499 
Ang-1 5038, 4736 – 
6126  
5314, 4779 – 
5811  
4478, 2519 – 
5273  
0.0576 
PlGF 280, 230 – 420  310, 150 – 560  170, 100 – 320  0.1181 
Ang-2 7100, 3500 – 
12000  
9300, 4300 – 
20000  
22000, 16000 
– 31000  (↑) 
0.0012 
sVEGFR-1 3700, 3100 – 
6300  
3900, 3000 – 
4700  
5700, 4200 – 
11000  (↑) 
0.042 
sTie-2 8100, 7100 – 
8400  
9000, 7800 – 
9200  
7200, 6000 – 
8900  
0.1440 
sVEGFR-
1/PlGF 
12.63, 9.52 – 
19.42  
14.92, 7.33 – 
20.73 
26.10, 18.07 – 
92.24 (↑) 
0.0071 
 
Data analysed by Kruskal Wallis test, represented as medians (IQR). 
 
c) Basal concentrations of angiogenic factors and sVEGFR-1 and sTie-2 
receptors in plasma and amniotic fluid in MC twins complicated by TTTS. 
There was a significant difference between plasma and amniotic fluid concentrations of 
all angiogenic factors, with the exception of VEGF-D.  VEGF-C (P< 0.0001) and Ang-1 
(P=0.0004) were significantly elevated in amniotic fluid samples compared to ‘paired’ 
maternal plasma samples shown in table 3-8.  In contrast, PlGF (P=0.0003) and Ang-2 
(P<0.0001) were significantly higher in maternal plasma compared to amniotic fluid 
samples in TTTS.  Concentrations of the angiogenic growth factor receptor sTie-2 were 
higher in plasma than amniotic fluid (P<0.0001), whereas sVEGFR-1 was higher in 
amniotic fluid compared to maternal plasma in TTTS (P=0.0002).  These significant 
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differences were also noted on multivariate analysis correcting for stage of TTTS (P< 
0.001).  Again, we compared sVEGFR-1/PlGF in plasma and amniotic fluid and found 
this to be significantly higher (P=0.0018) in amniotic fluid compared to maternal plasma. 
  
No significant association (using Spearman’s correlation) was noted between any 
maternal plasma and amniotic fluid angiogenic factors.  
 
Table 3-8 Concentrations (pg/ml) of angiogenic growth factors and their receptors 
VEGFR-1 and sTie-2 receptors in plasma and amniotic fluid in MC twins 
complicated by TTTS. 
 Plasma Amniotic fluid P value 
VEGF-C 
 
187.5 (187.5 – 
1170) 
7209 (6043 – 
8429) 
<0.0001 
VEGF-D  
 
71 (63  - 130) 76 (66 – 85) 0.716 
VEGF-A 
 
1600 (870 – 
5300) 
15000 (8500 – 
25000) 
0.0038 
Ang-1 4300 (2500 – 
5200) 
7400 (5400 – 
11000) 
0.0004 
PlGF 210 (100 – 
330) 
65 (60 – 69) 0.0003 
Ang-2 25000 (18000 
– 32000) 
11000 (7000 – 
14000) 
<0.0001 
sVEGFR-1 5400 (4300 – 
10000) 
21000 (11000 
– 34000) 
0.0002 
sTie-2 7300 (6000 – 
9000) 
1600 (1500 – 
2000) 
<0.0001 
sVEGFR-
1/PlGF 
25.5 (18.0 – 
34.1) 
319.0 (173.8 – 
536.4) 
0.0018 
 
Data analysed by Wilcoxon signed rank test, represented as medians (IQR). 
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d) Sub-group analysis of plasma, amniotic fluid angiogenic factors,  sVEGFR-
1 and sTie-2 receptor concentrations in MC twin pregnancies complicated by 
TTTS.  
There was no significant difference in median plasma or amniotic fluid angiogenic 
factors or receptors when the TTTS cohort was subdivided by Quintero stage of TTTS.  
There were significant differences in the following angiogenic factors and their receptors 
when the TTTS cohort was analysed by sub-group: 
(i) Severity of polyhydramnios in recipient sac (median values). 
In maternal plasma VEGF-C (MPD< 12cm 1000pg/ml vs. MPD≥ 12cm 190pg/ml; P< 
0.01) and Ang-1 (MPD< 12cm 4700pg/ml, vs. MPD≥ 12cm 2300pg/ml; P< 0.05) were 
lower in the sub-group of TTTS complicated by severe hydramnios. 
In amniotic fluid, concentrations of VEGF-A (MPD< 12cm 17000pg/ml, vs. MPD≥ 12cm 
9100pg/ml, P= 0.0299), Ang-2 (MPD< 12cm 13000pg/ml vs. MPD≥ 12cm 6400pg/ml; 
P= 0.0083) and sTie-2 (MPD< 12cm 1800pg/ml vs. MPD≥ 12cm 1400pg/ml; P= 0.0148) 
were significantly lower in the sub-group of TTTS complicated by severe hydramnios 
(MPD ≥ 12cm). 
(ii) Severity of haemodynamic changes in Donor and Recipient twins. 
In stage III or IV TTTS maternal plasma VEGF-D concentrations were significantly 
different when the severity of hemodynamic changes was considered.  VEGF-D was 
significantly elevated where there was evidence of either absent umbilical artery 
Doppler velocimetry in the donor alone or absent umbilical artery Doppler velocimetry in 
the donor and signs of cardiac dysfunction in the recipient. (P= 0.0061), and post-hoc 
analysis showed a significant difference if there was recipient cardiac dysfunction only 
vs recipient and donor dysfunction- figure 3-22. 
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Figure 3-22 Box and whisker plot showing that the severity of haemodynamic 
changes in TTTS causes a significant difference in basal plasma VEGF-D levels.  
 
(Representing the median value, the IQR and the overall range. Analysed by Kruskal-
Wallis test.)   
 
(iii) Inter-twin estimated fetal weight difference (at diagnosis) of ≥ 25%.  
Multivariate analysis correcting for stage of TTTS, gestational and maternal age noted 
that VEGF-A and sVEGFR-1 concentrations were significantly higher in maternal 
plasma when the cohort was subdivided by ΔEFW at diagnosis (≥ 25%) (P= 0.045). 
 
e) Changes in plasma and amniotic fluid angiogenic factors and sVEGFR-1 
and sTie-2 receptor concentrations after FLA in MC twin pregnancies complicated 
by TTTS.  
Plasma PlGF was the only factor that was significantly different after fetoscopic laser 
ablation.  Maternal plasma PlGF was transiently decreased after this therapy returning 
to baseline by one week (P= 0.0314) (basal 210- IQR 100-330, 6hr 130 IQR 65-210, 
24hr 120 IQR 40-230, 1 week 210 IQR 170-590).  The plasma sVEGFR-1/PlGF ratio 
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was also affected by FLA, with a transient increase after therapy, followed by a 
significant reduction to below basal concentrations by one week (P= 0.0102).  Only 
VEGF-D was significantly different (+8.3%; P=0.0155) in amniotic fluid immediately after 
completion of FLA.  Multiple logistic regression analysis was also performed.  These 
observed changes in both maternal plasma and amniotic fluid, in response to fetoscopic 
laser ablation appeared to be independent of the number of AVA ablated, the volume of 
amniotic fluid removed at amniodrainage, the duration of surgery, the gestation at which 
surgery was performed or the outcome of the surgery in terms of fetal survival.   
 
3.2.3 Maternal cell-free mRNA for angiogenic growth factors  
 
a) Demographics of the twin pregnancy cohorts. 
See 3.2.1 section a) for demographics 
 
b) Percentage of maternal plasma samples that express cf-mRNA 
We found that cf-mRNA was detectable for a number of angiogenic factors and 
receptors.  In uncomplicated DC, MC and TTTS pregnancies respectively the proportion 
of samples with detectable cf- mRNA were as follows: GAPDH - 80%, 100% and 96%; 
VEGFR-1 - 10%, 0% and 26%; VEGF-A- 80%, 71% and 96%; Endoglin – 60%, 71% 
and 91%; PlGF – 70%, 57%, 22%; Tie-1 0%, 43%, 0%; Ang-1 71%, 50% and 60% and 
Ang-2 83%, 50% and 89%.  The median (IQR) plasma concentrations for all the 
measured angiogenic factors and the receptors VEGFR-1, Endoglin and Tie-1 are 
shown in Table 3-9. There is no IQR for Ang-2 as insufficient samples had detectable 
levels to enable this calculation, so the overall range is shown.
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Table 3-9 Maternal cell-free mRNA levels (copies/ml plasma) in uncomplicated 
twin pregnancies and those complicated by TTTS.  
 DC twins 
(n=12) 
MC twins  
(n=7) 
MC twins with 
TTTS (n=23) 
P value 
GAPDH 44.7 (1.9 – 
163.4) 
176.1 (37.7 – 
240.4)  
140.4 (7.9 – 
283.9) 
NS 
VEGFR-1 0.0 (0.0 – 0.0) 0.0 (0.0 – 0.0)  0.0 (0.0 – 2.5) NS 
VEGF-A 337.7 (0.0 – 
595.1) 
390.8 (0.0 – 
795.8) 
618.6 (418.3 – 
4279) 
0.024 
Endoglin 14.5 (0.0 – 
3457) 
1171 (0.0 – 
1517) 
2896 (1365 – 
6187) 
0.027 
Tie-1 0.0 (0.0 – 0.0) 0.0 (0.0 – 17.9) 0.0 (0.0 – 0.0) NS 
PlGF 106.7 (0.0 – 
126.0) 
114.6 (0.0 – 
119.6) 
0.0 (0.0 – 
71.47) 
NS 
Ang-1 3.1 (0.0 – 8.3) 1.6 (0.0 – 8.5) 5.1 (0.0  - 17.2) NS 
Ang-2 13.7 (2.3 – 
23.4) 
8.5 (0.0 – 23.2) 44.8 (26.8 – 
76.7) 
0.007 
 
Data analysed by Kruskal-Wallis test, represented as medians (IQR), except Ang – 2 
shown as median and overall range. 
 
c) Changes and differences in expression with chorionicity and in TTTS 
There was a significant difference in VEGF-A (medians DC -337.3, MC - 390.8, TTTS - 
618.6 copies/ml plasma p=0.024), Endoglin (medians DC-14.49, MC-1171, TTTS - 
2896 copies/ml plasma p=0.027) and Ang-2 (medians DC-13.66, MC-8.49, TTTS 44.80 
copies/ml plasma p=0.007) (figure 3-23). On post-hoc analysis significant differences 
were found in VEGF-A between uncomplicated DC twins and the TTTS cohort and in 
Ang-2 between uncomplicated DC or MC twins and the TTTS cohort. 
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Figure 3-23 Box and whisker plot showing significant differences in VEGF-A, 
Endoglin and Ang-2 between uncomplicated twin pregnancies and pregnancies 
complicated by TTTS.  
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(Representing the median value, the IQR and the overall range. Analysed by Kruskal-
Wallis test.)   
 
3.2.4 Cytokines 
 
a) Demographics of the twin pregnancy cohorts. 
See 3.2.1 section a) for demographics 
 
b) Circulating plasma cytokine concentrations in uncomplicated twin 
pregnancies and those complicated by TTTS. 
The median (IQR) plasma levels for all the measured cytokines are shown in Table 3-
10.  There was a significant difference in the plasma PDGF-BB and TIMP-1 
concentrations noted between uncomplicated MC and MC twin pregnancies 
complicated by TTTS (Figure 3-24).  Median maternal plasma PDGF-BB was lower in 
uncomplicated MC twins (479.6 pg/ml) than in TTTS pregnancies (1071 pg/ml) and DC 
twin pregnancies (1368 pg/ml) (P=0.049) and no groups were significantly different on 
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post-hoc analysis.  However, TIMP-1 was higher in TTTS pregnancies than in 
uncomplicated twins (P=0.003), with uncomplicated DC twins vs TTTS significant on 
post-hoc analysis.    
 
Table 3-10 Basal circulating plasma cytokine concentrations (pg/ml) in 
uncomplicated twin pregnancies and in the cohort of MC complicated by TTTS. 
 
 
DC twins (n=12) MC twins (n=7) MC twins with TTTS 
(n=23) 
P value 
IL-6 
 
6.1, 6.1 – 6.1 6.1, 6.1 – 50.5  6.1, 6.1 – 43.2 0.079 
IL-1β 
 
6.1, 6.1 – 14.9 38.5, 6.1 – 215.0 6.1, 6.1 – 85.5 0.297 
IL-10 
 
30.4, 30.4 – 669.6 1179, 30.40 – 10870 30.4, 30.4 – 3484  0.178 
IL-2 
 
10.25, 6.6 – 23.6 37.70, 6.10 – 213.8 9.9, 6.1 – 188.2 0.600 
IL-13 
 
69.15, 37.8 – 208.9  220.9, 111.1 – 2392  40.2, 30.4 – 5528  0.415 
IL-4 
 
6.1, 6.1 – 6.1  6.1, 6.1 – 71.0  6.1, 6.1 – 267.6  0.308 
IFN- 
 
45.25, 30.40 – 170.4  392.8, 30.4 – 1057  62.2, 30.4 – 3337  0.510 
IL-5 
 
23.7, 9.35 – 63.0  218.6, 11.6 – 690.3  17.5, 6.1 – 529.8 0.521 
TNF- 
 
7.2, 6.1 – 39.3 40.2, 6.1 – 144.6 8.2, 6.1 – 141.2 0.539 
KGF 
 
133.9, 78.68 – 200.5 
  
272.9, 210.8 – 3670  212.1, 106.5 – 1962 0.090 
PDGF
-BB 
 
1368, 684.3 – 1906 
  
479.6, 342.5 – 799.3  1071, 523.1 – 2158 0.049 
FGF-
basic 
 
552.7, 304.9 -  2247  2448, 1337 – 22530  1115, 389.0 – 6512   0.106 
TIMP-
1 
 
1911, 1860 – 2085  2110, 1561 – 3683  2615, 2196 – 3118 0.003 
ICAM-
1 
 
82700, 71010 – 
86190  
85610, 83810 – 
88080  
74510, 68050 – 
80800 
0.071 
Data analysed by the Kruskal-Wallis test and represented as medians (IQR) 
No IL-8 detectable in plasma 
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Figure 3-24 Box and whisker plot showing significant differences in basal plasma 
cytokines between uncomplicated di- and monochorionic pregnancies and 
monochorionic pregnancies complicated by TTTS. 
               
(Representing the median value, the IQR and the overall range. Analysed by Kruskal-
Wallis test.)   
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c) Basal concentrations of cytokines in plasma and amniotic fluid in MC twins 
complicated by TTTS. 
There was a significant difference between basal plasma and amniotic fluid 
concentrations of IL-6, IL-10, IFN-γ, TIMP-1 and ICAM-1 (Table 3-11).  These cytokines 
were elevated in amniotic fluid samples as compared to ‘paired’ maternal plasma 
samples.  There were no significant differences noted between plasma and amniotic 
fluid concentrations of IL-2, IL-1, TNF-, IL-4, IL-5, IL-13, KGF, PGF-BB and FGF-
basic   
 
No significant association was noted between maternal plasma and amniotic fluid 
cytokines, with the exception of the trend noted for TIMP-1.  There was a significant 
correlation showing when plasma TIMP-1 increases, amniotic fluid TIMP-1 decreases 
(Spearman r= -0.464; 95%CI – 0.7417 to -0.05157; P=0.03).   
 129 
Table 3-11 Basal concentrations of cytokines (pg/ml) in plasma and amniotic fluid 
in the cohort of MC twins complicated by TTTS (n=23). 
 Plasma Amniotic fluid P value 
IL-6 6.1, 6.1 – 6.1 446.8, 148.3 - 1020  <0.001 
IL-1b 6.1, 6.1 – 85.5  16, 15.2 – 31.3  0.994 
IL-10 30.4, 30.4 - 3484  3119,  935.1 – 6260  0.032 
IL-2 9.9, 6.1- 188.2  46.8, 15.2 – 88.2 0.982 
IL-13 40.2, 30.4 – 5528  986.9, 512.2 – 1352  0.958 
IL-4 6.1, 6.1 – 267.6  151.1, 46.5 – 318.9  0.277 
IFN- γ 62.2, 30.4 – 3337  7764, 1810 – 16380  0.010 
IL-5 17.5, 6.1 – 529.8  82.1, 32.2 – 106.8  0.589 
TNF-a 8.2, 6.1 – 141.2  61.9, 23.6 – 96 0.434 
KGF 212.1, 106.5 – 1962    282.5, 76 – 505.4   0.090 
PDGF-bb 1071, 523.1 – 2158    628.2, 76 – 1182   0.079 
FGF-basic 1115, 389 – 6512   2240, 1403 – 2895   0.131 
TIMP-1 2615, 2196 – 3118   124800, 109800 – 139000   <0.001 
ICAM-1 74510, 68050 – 80800   40560, 21300 – 55510   <0.001 
 
Data analysed by the paired Wilcoxon signed rank test and represented as medians 
(IQR) 
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d) Sub-group analysis of plasma and amniotic fluid cytokine concentrations 
in MC twin pregnancies complicated by TTTS.  
There was no significant difference in median plasma or amniotic fluid cytokines when 
the TTTS cohort was subdivided by Quintero stage.  There were significant differences 
in the following cytokines when the TTTS cohort was analysed by sub-group: 
(ii) Severity of polyhydramnios in recipient sac. 
In maternal plasma only ICAM-1 was significantly different (MPD <12cm median 75850 
pg/ml, 75% CI 70290-83210 pg/ml vs. MPD ≥12cm median 68241 pg/ml, 75% CI 
55520-74510 pg/ml; P=0.03).  ICAM-1 was lower in the sub-group of TTTS complicated 
by severe polyhydramnios. 
In amniotic fluid, concentrations of most cytokines were significantly different, except IL-
6, IL-1β, PDGF-BB and ICAM-1.  All were significantly lower in the sub-group of TTTS 
complicated by severe polyhydramnios (MPD ≥12cm). 
(ii) Severity of haemodynamic changes in Donor and Recipient twins. 
In severe TTTS (Quintero stage III or IV) we noted only maternal plasma PDGF-BB 
concentrations to be significantly different when the severity of hemodynamic changes 
was considered.  PDGF-BB was significantly elevated where there was evidence of 
cardiac dysfunction in the recipient, either in combination with absent umbilical artery 
Doppler velocimetry in the donor or alone. (P= 0.03; Figure 3-25). Post-hoc analysis 
showed significance for twins with recipient dysfunction only vs donor dysfunction only. 
 
  
 131 
Figure 3-25 Box and whisker plot showing that the severity of haemodynamic 
changes in TTTS causes a significant difference in basal plasma PDGF-BB levels.  
 
 
(Representing the median value, the IQR and the overall range. Analysed by Kruskal-
Wallis test.)   
 
 
There were no significant changes in cytokine concentrations in amniotic fluid on sub-
group analysis with respect to the severity of haemodynamic changes. 
(iii) Inter-twin estimated fetal weight difference (at diagnosis) of >25%.  There were 
no significant differences in any cytokine concentrations in maternal plasma with 
respect to sub-group analysis for inter-twin EFW difference.  There was however, a 
significant difference in ICAM-1 in amniotic fluid.  ICAM-1 was significantly lower with 
EFW difference  25% (<25% 52090 pg/ml, 38330- 57320 pg/ml vs. 25% 21530 pg/ml, 
16700 – 28010 pg/ml P=0.0033).  
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e) Changes in plasma and amniotic fluid cytokine concentrations after FLA in 
MC twin pregnancies complicated by TTTS.  
There was no significant change in cytokines in maternal plasma before and at six 
hours, 24 hours and one week after fetoscopic laser ablation.  However, KGF was 
significantly lower after FLA in amniotic fluid (pre laser median 349.9 (IQR 110.2 – 
554.7), post laser median 183.2 (IQR 76.0 – 322.8) p= 0.046). There was also a 
significant difference in IL-8, although the median values were the same the IQR 
showed a trend towards higher levels pre-laser. (Table 3-12) 
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Table 3-12 Cytokine concentrations (pg/ml) in the cohort of MC twins complicated 
by severe TTTS before and at specified intervals after treatment by FLA (n=20). 
a) Maternal plasma 
 Basal 6hrs 24hrs 1 week P value 
IL-6 
 
 6.4, 6.1 – 
52.5 
12.8, 9.3 – 
24.7 
10.5, 6.1 – 
56.8 
6.1, 6.1  - 
31.9 
0.192 
IL-1β 
 
6.1, 6.1 – 
107.6 
14.2, 6.1 – 
109.4 
20.5, 6.1 – 
131.9 
6.1, 6.1 – 
181.1 
0.828 
IL-10 
 
30.4, 30.4 – 
4071 
30.4, 30.4 – 
2279 
31.2, 30.4 – 
3008 
30.4, 30.4 – 
4407 
0.991 
IL-2 
 
8, 6.1 – 
207.9 
8.2, 6.1 – 
140.3 
17.1, 6.1 – 
195.6 
6.1, 6.1 – 
173.1 
0.851 
IL-13 
 
35.3, 30.4 – 
36100 
227.2, 30.4 
– 8663 
220.6, 30.4 
– 34340 
79.8, 30.4 – 
2760 
0.833 
IL-4 
 
 6.1, 6.1 – 
335 
6.1, 6.1 – 64 7.350, 6.1 – 
222.2 
6.1, 6.1 – 
165.7 
0.844 
IFN- 
 
46.3, 30.4 – 
4873 
30.4, 30.4 – 
676.9 
138.4, 30.4 
– 2665 
33.4, 30.4 – 
1692 
0.809 
IL-5 
 
17, 6.1 – 
623.8 
28.2, 6.1 – 
343.9 
42.3, 6.1 – 
476.9 
13.8, 6.1 – 
503.4 
0.976 
TNF- 
 
9.9, 6.1 – 
147.4 
11.7, 6.1 – 
68.1 
26.7, 6.1 – 
120.2 
11.9, 6.1 – 
115.9 
0.960 
KGF 
 
212.8, 109.5 
– 2063 
226.5, 94.7 
– 2007 
298.1, 109.8 
– 2856 
271.2, 108.9 
– 2324 
0.971 
PDGF-BB 945.4, 540.5 
– 1587  
970.5, 550.6 
– 2060 
1271, 249.5 
– 2213 
1238, 384.1 
– 1535 
0.963 
FGF-basic 
 
2168, 450.5 
– 14220 
1894, 478.0 
– 12780 
1774, 492.8 
– 25320 
2908, 266.9 
– 13630 
0.939 
TIMP-1 
 
2805 2440 – 
3176 
2923, 
2076.0 – 
3274 
 
2846, 2206 
– 3484 
2488, 1916 
– 3042 
0.487 
ICAM-1 74440, 
68040 – 
81950  
70130, 
59800 – 
77790 
74470, 
66930 – 
85310 
72660, 
38700 – 
79890 
0.670 
 
Data analysed by the unpaired Mann Whitney U test and represented as medians 
(IQR). 
No IL-8 detected in plasma 
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b) Amniotic fluid 
 
 
Pre - laser Post - laser P value 
IL-6 
 
363.9, 157.7 – 
806.2 
312.2, 192.5 – 
1027 
0.318 
IL-1β 
 
15.59, 15.2 – 
30.22 
15.2, 15.2 – 
22.9 
0.465 
IL-10 
 
2858, 705.7 – 
6095 
2669.0, 1241 – 
4208 
0.661 
IL-2 
 
44.2, 15.2 – 
83.9 
42.1, 16.4 – 
67.9 
0.561 
IL-13 
 
907.9, 530.3 – 
1295 
938.8, 558 – 
1120 
0.688 
IL-4 
 
 135.3, 42.4 – 
296.6 
113.7, 34.4 – 
213 
0.417 
IFN- 
 
7715, 1505 – 
15090 
7680, 1685 – 
11350 
0.801 
IL-5 
 
76.0, 35.2 – 
106.1 
51.5, 23.5 – 
88.9 
0.216 
TNF- 
 
58.5, 23.3 – 
91.1 
52.3, 29.2 – 
81.0 
0.333 
KGF 
 
349.9, 110.2 – 
554.7 
183.2, 76.0 – 
322.8 
0.046 
PDGF-BB 
 
613.4, 76.0 – 
1073.0 
640.0, 76.0 – 
1580.0 
0.712 
FGF-basic 
 
2300.0, 1518.0 
– 2898.0 
1911.0, 1605.0 
– 2430.0 
0.439 
TIMP-1 
 
123500.0, 
109200.0 – 
137300.0 
127900.0, 
109700.0 – 
141100.0 
0.439 
ICAM-1 
 
36670.0, 
20970.0 – 
51230.0 
31890.0, 
17780.0 – 
48850.0 
0.376 
IL-8 
 
1563.0, 1563.0 
– 2822.0 
1563.0, 1169.0 
– 1563.0 
0.130 
 
Data analysed by the Wilcoxon signed rank test and represented as medians (IQR). 
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CHAPTER 4 
 
DISCUSSION AND CONCLUSIONS 
 
4.1 Systematic reviews 
 
4.1.1 Diagnostic accuracy reviews of tests in the first trimester to 
predict TTTS and tests after diagnosis to predict outcome of TTTS 
The first diagnostic accuracy review examined the role of ultrasound in screening in the 
first trimester to predict the development of TTTS. It found that tests already commonly 
utilised for dating twin pregnancies and screening for Down’s syndrome such as crown 
rump length and nuchal translucency, could be applied for screening for TTTS if 
discordancy ≥ 10% or 20% respectively were calculated or nuchal translucency > 95th 
percentile noted.  The second review assessed the accuracy of ultrasound tests after 
diagnosis of TTTS to predict outcome in terms of IUD or NND.  The test that performed 
the best was donor DV abnormality in prediction of donor IUD.  With respect to IUD 
there was an association between an abnormal test result and worse rates of survival, 
however interestingly this was not the case with prediction of NND. Here, several 
abnormal tests, including cardiac predictors such as TR/MR or worsening CVS score, 
were associated with improved outcome. 
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The first review evaluated the accuracy of four first trimester ultrasound tests in a total 
of 1451 pregnancies.  For all four screening tests a positive test result had a high 
reliability for predicting the development of TTTS but a negative test result did not 
completely exclude TTTS, as the sensitivity of all tests was poor (ranging from 0.21 – 
0.53). This was particularly true for CRL discordance and NT > 95th percentile as they 
both had specificities of 92% and gave post test probabilities for a positive test of 31.1% 
and 28.2% respectively (more than doubling the pre-test probability).  Although no 
screening test demonstrated an ideal overall predictive accuracy, CRL discordance 
greater than 10% (based on analysis of four studies, including 646 pregnancies) 
appeared to be the best. This is of clinical relevance as all pregnancies, including 
multiple pregnancies, are recommended to have CRL performed as a routine test in the 
first trimester to date the pregnancy1 286.  So this test is already being performed but if 
the CRL discordance in the MC twin pair were routinely calculated (the difference in the 
CRLs of the twins divided by the CRL of the larger twin), where discordance was 
greater than 10% this pregnancy could be discussed with or referred on to a centre with 
expertise in treating TTTS. This would have the advantage that the TTTS may be 
treated at an earlier stage, and stage at treatment has been shown to be an 
independent predictor of neurodevelopmental outcome287.  In addition, all women are 
offered screening for Down’s syndrome including measurement of nuchal translucency1 
286, and NT > 95th percentile was the other test with the highest specificity and could be 
utilised for risk stratification of MC twin pregnancies. So these are both routinely 
available tests but currently not widely utilised for the purpose of screening for risk of 
TTTS.  This review suggests that these tests could be utilised for screening for TTTS, 
with the caveat that if the test is negative it does not exclude the condition. However, as 
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centres should monitor MC twins with scans every week or fortnight from 16 weeks1, so 
even if the screening test e.g. CRL discordance was negative, these pregnancies would 
still receive regular follow up.  However, as treatment for TTTS is only offered at 
regional and sometimes supra-regional centres, that are often a considerable distance 
from the referring unit, early referral could be reserved for women whose pregnancies 
screen positive on first trimester test as there is evidence that twins referred early (prior 
to 20 weeks) to a specialist centre have better outcomes than those referred later288.   
 
The clinical utility of the review findings has been explored further through consideration 
of the combination of these first trimester tests with the currently accepted treatment for 
TTTS, fetoscopic laser ablation289.  This is done by calculating the numbers needed to 
test (NNTest) with CRL/NT or DV scanning, and treat (NNTreat) with FLA to avoid 
death of both infants as shown in table 4-1.  The NNTest are 56, 52, 22 and 11 for CRL 
discordance, NT >95th percentile, NT discordance and DV abnormality in  1 fetus 
respectively and the NNTreat 5, 7, 8 and 5 respectively.  To describe these more fully, it 
would be necessary to test 56 pregnancies using CRL discordance of 10% to prevent 
death of both infants if all screen positive cases are treated by FLA.  The numbers are 
similar for NT > 95th percentile but lower at 22 needed to be tested and screen positve 
cases treated by FLA to avoid death of both twins.  This review considers that as CRL 
and NT are already being performed as routine practice, these figures add further 
weight to this review’s findings that they should now be utilised as predictors for 
development as TTTS as well to allow risk stratification and onward referral for MC twin 
pregnancies found to be at higher risk. 
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Table 4-1 Ultrasound screening in uncomplicated MCDA pregnancies and number of women needed to be tested and 
treated with FLA to prevent death of both infants. 
Test result Sensitivity 
% 
Specificity 
% 
Prevalence 
of TTTS (%) 
Probability 
of TTTS 
after testing 
positive (%) 
Risk of death of 
both infants after 
treatment* 
NNTest1 NNTreat2 
CRL discordance 
>10% 
 
22.5  91.9 
 
13.8 31.1 0.49 56 5 
NT>95th 
 
 
20.8  
 
91.5  
 
13.8 28.2 0.49 52 7 
NT discordance 
>20% 
 
53.2  73.1 13.8 24.1 0.49 22 8 
DV absent/reversed 
flow in  1 fetus 
 
50.0  87.5  13.8 43.3 0.49 11 5 
*RR 0.49 (95% CI 0.30 – 0.79) Roberts et al289. 
1NNTest is the number needed to test and treat with FLA to prevent death of both infants calculated by 1/ (proportion of true 
positives(TP) – (proportion TPxRR)). 
2NNTreat is the number needed to treat if only test positives are treated with FLA calculated by 1/ (probability of testing positive – 
probability after treatment). 
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The second diagnostic review assessed the accuracy of ultrasound tests after diagnosis 
of TTTS to predict outcome in terms of IUD or NND.  The test that performed the best 
was DV abnormality in prediction of donor IUD.  With respect to IUD all tests reported a 
trend between an abnormal test result and worse rates of survival, however interestingly 
this was not the case with prediction of NND. Here, several abnormal tests, including 
cardiac predictors such as TR/MR or worsening CVS score, were associated with 
improved outcome.  This may be due to the fact that these cardiovascular abnormalities 
are common in recipient twins and can be transient290, and that cardiovascular 
abnormalities can be amenable to treatment postnatally291.  It is acknowledged that this 
finding is inconsistent with a previous study in TTTS215, and information from singleton 
pregnancies 292 although singletons usually differ from recipient twins in that they are 
growth-restricted, however, this is an area that warrants further study of the 
physiological mechanisms at play. 
 
This review evaluated the accuracy of seven tests performed after diagnosis of TTTS to 
determine its outcome, including 1635 pregnancies.  Overall these tests showed poor 
predictive ability for either IUD (six tests) or NND (five tests).  No test showed high 
sensitivity for the prediction of outcome, so a normal test is not useful for excluding IUD 
or NND.  It is perhaps surprising that cardiovascular assessment denoting deteriorating 
cardiodynamic function, as represented by a higher CHOP score or cardiac profile, was 
associated with an improvement in survival in terms of NND.  In keeping with the 
findings of the review of tests in the first trimester some tests showed high specificities 
such that a positive test makes IUD or NND likely. With respect to donor IUD an 
abnormal DV, a pulsatile UV or the presence of TR/MR showed high specificity (DV – 
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93% - from 3 studies, UV – 96% - from 3 studies, TR/MR – 98% - 2 studies), whereas 
only TR/MR was useful for NND  (specificity 99% - 1 study).  For recipient outcomes: an 
abnormal UA Doppler showed high specificity for IUD (93% - 4 studies) and NND (93% 
- 2 studies).  As the likelihood of IUD and NND is very important for counselling in TTTS 
these tests with high specificities could be useful.  Unfortunately, it is only for an 
abnormal DV and its prediction of donor IUD that this is likely to be true. This was the 
only test that had both high specificity and a significant LR+ giving a clinically 
meaningful post-test probability for a positive test of 39.2% (compared with a pre-test 
probability of 23.3%).  This test also showed the best accuracy with an AUC of 0.99. 
This is logical as DV abnormality has been shown to be associated with fetal 
acidaemia293 and has been considered a late change in fetal Doppler assessments, 
therefore showing a higher association with perinatal death than for example umbilical 
artery Doppler abnormalities294.  Ultrasound assessment of both fetuses prior to 
treatment is ubiquitous and the likely accuracy of DV in predicting IUD, as shown in this 
review, leads to the recommendation that this should be a part of this routine 
examination and utilised in counselling regarding the possible outcome of treatment.   
 
The strengths and the validity of the findings of the diagnostic accuracy reviews of tests 
used to predict the development and outcome of TTTS are derived from the use of 
rigorous methodology, in accordance with accepted guidelines for performing 
systematic reviews56 145 157 295.  They were based on clear research questions from 
which prospective protocols were designed.  The search strategy was thorough and 
was performed without language restrictions.  The resulting articles underwent a 
detailed assessment of the quality of study design and reporting based on validated 
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tools4 146-149.  The evidence was summarised both descriptively and quantitatively, 
including reporting summary likelihood ratios on the basis of the recommendation of the 
Evidence Based Medicine Working Group156.  These likelihood ratios were utilised with 
Bayes’ theorem to calculate clinically meaningful post-test probabilities.  It is 
acknowledged that research has suggested that independently pooled likelihood ratios 
should be interpreted with caution, as positive and negative likelihood ratios, like 
sensitivity and specificity, are related statistics296.  However, sensitivity analysis with 
pooled sensitivity and specificity, as well as bivariate analysis,116 which not only 
preserves the two dimensional nature of the data but can acknowledge any possible 
correlation between these two measures, were also performed.  These additional 
analyses confirmed the interpretation of the results therefore confidence in the 
inferences made is likewise confirmed. 
 
The limitations of these reviews are predominantly related to the absence of clear 
reporting by the primary studies.  Initiatives to standardise the design and reporting of 
studies have become widely recognised and supported over the last decade149 286 295 297 
298 and this transparency is particularly important in relation to screening or diagnostic 
tests, as these are more prone to bias299.  However, it is known that study design can 
affect estimates of diagnostic accuracy and in particular that diagnostic performance 
can be overestimated if interpretation of the reference standard is not blinded300.  This is 
pertinent to these two reviews as none of the included studies (21 in total, 10 in the first 
review and 11 in the second) reported whether the reference standard was blinded.  
Ideally, meta-regression using items of study quality can assess the impact of study 
design300, however due to the small number of studies relating to each test this was not 
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possible297 although, where possible sub-group analysis using only high quality studies 
was performed, and this confirmed the diagnostic accuracy estimates.  
 
The review of first trimester ultrasound tests for the prediction of TTTS reported four 
tests, three of which (CRL discordance, NT >95th percentile and NT discordance) 
included analysis of four studies and one of which included review of only two (DV 
abnormality).  There was only evidence of heterogeneity in analysis of DV abnormality 
and this may be explained by the inclusion of studies reporting absent a wave in one 
and absent or reversed a wave in the other.  However, no significant heterogeneity was 
found in any of the other analysis, and these tests were the ones shown to be of greater 
value clinically.  It is acknowledged that the numbers of studies for each test are small 
but, due to the thorough literature search and the absence of evidence of publication 
bias, confidence can be had that the findings provide the best evaluation of the currently 
available evidence.  
 
The review of prediction of outcome (in terms of IUD or NND) of TTTS after diagnosis 
reported a range of different tests and although some studies reported more than one 
test not all tests included all of the participants.  This was apparent in all of the studies 
and although acknowledged no explanation was given as to whether the pregnancies 
that were unable to be included differed from those included.  So although several of 
the studies had been designed to avoid selection bias, by using prospective and 
consecutive recruitment34 221 268, the omission of analysis to confirm that the patients 
who had missing data were not statistically different from those included means that this 
bias may still exist.   These studies could therefore be considered equivalent to the 
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other studies in this review and in the review of prediction of development of TTTS, with 
non-consecutive and/or retrospective recruitment, but reassuringly these aspects of 
study design have not been shown to give different results in reviews of this type300. It is 
therefore reasonable to conclude that despite these limitations the results of these 
diagnostic accuracy reviews remain valid.  As the populations included reflect those 
encountered in everyday practice and ultrasound is a safe modality to employ clinicians 
can be reassured that the recommendations to incorporate routinely available first 
trimester tests as screening for TTTS, as well as DV assessment in prediction of its 
outcome can be implemented immediately. 
 
4.1.2 Effectiveness review of FLA and serial amniodrainage in the 
treatment of TTTS 
 
This systematic review examined the effectiveness of the two principal treatments for 
TTTS, FLA and serial amnioreduction.  It found that there was a lack of consistency 
between the studies as to the relative effects of these two treatments but in a previously 
untreated population it appears that FLA offers improved survival chances. 
 
It is considered that this review satisfied criteria for performing a rigorous systematic 
review144 301.  It examines both randomised controlled trials and observational studies 
and demonstrated that FLA and serial amnioreduction have been studied in 495 
pregnancies affected by TTTS.  However, the number of studies considered worthy of 
inclusion was small. These included four studies (2 randomised controlled and 2 
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observational) comparing FLA with serial amnioreduction in pregnancies complicated by 
twin–twin transfusion syndrome presenting before 26 weeks gestation59 60 270 271 and 
one observational study comparing the same treatments but after 26 weeks269. The 
quality of reporting of the studies included is a limitation of this review.  Of the five 
studies included in this systematic review, no study fulfilled all five aspects of quality 
assessment.   The only aspect universally well described and conducted was follow-up 
of >90% of subjects enrolled.  In considering other sources of bias three studies have a 
potential bias in that the laser procedure was performed in relatively few centres, 
whereas amnioreduction was performed by multiple operators in many centres59 60 270. It 
should also be recognised that the technique used in FLA differs between centres. 
Some using a non-selective technique with all vessels running across the intertwin 
membrane being ablated, whereas other groups are more selective in ablating 
communicating vessels270.   
 
Despite only a small number of studies reporting the effect of FLA versus 
amnioreduction there was considerable heterogeneity noted.  The most stark example 
of this is in the study inclusion criteria and relates to the differences noted between the 
two RCTs.  As the Crombleholme study60 required patients to fail to respond to a 
qualifying amnioreduction prior to randomisation to either FLA or AR, the 
generalisability of this study to an untreated TTTS population as included in the other 
RCT59 and two of the observational studies 270 271 is likely to be affected. This may 
explain why the treatment effects reported by the two RCTs were diametrically 
opposed.   The other major difference noted was in the timing of the measurement of 
the primary outcome of survival, which varied from birth to 6 months. It is noted that four 
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of the studies described how their planned analyses accounted for the impact of 
clustering within the twin pair, and that the study that did not all twins survived.  
Unfortunately, the planned individual patient data (IPD) analysis, which would have 
enabled this review to perform analyses accounting for these differences was not 
possible as the majority of studies, including the two RCTs, were unable to provide this 
data.  This was however considered in the design of this review so the primary outcome 
of survival of a least one fetus, a calculation possible from the extracted two-by-two 
data, could still be performed and interpreted.  
 
The two RCTs59 60 were both stopped early quoting the O’Brien-Fleming multiple testing 
procedure. This involves fixing the number of observations between tests and the 
number of tests in advance to allow a trial to be stopped early, with little impact on trial 
accuracy or power, if one treatment is markedly better than the other299.  However, this 
methodology is not accepted by all as it has been shown that even large effects seen 
early in a trial can be reversed or disappear over its duration302.  In the Senat trial the 
second interim analysis showed FLA to offer better survival for at least one fetus, hence 
the trial was stopped.  However, the Crombleholme trial was stopped at the 
investigators’ request as clinicians were increasingly unwilling to only offer patients FLA 
on a randomised basis.  Interestingly, this trial’s interim analysis showed better survival 
with amnioreduction, but the reliability of this analysis may well be affected by the 
uncertainty as to whether many eligible women were not referred because of their 
clinicians’ preconceptions that FLA was the better treatment.  Therefore despite 
reference to the O’Brien-Fleming procedure the fact that trials were both stopped early 
leads to less certainty regarding their results.  
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Systematic reviews and meta-analyses of data from observational studies are 
sometimes conducted to obtain evidence for practice, reflecting the relative paucity of 
experimental designs303.  Reviews of observational studies, therefore, have a role in 
evaluating medical effectiveness144 especially strengthened by being comparative, as in 
this series.  There is however controversy about the differences in effects observed in 
randomised and observational studies304. Although meta-analysis of observational data 
can sometimes provide more precise estimates, there is the potential for producing 
spurious results as a consequence of confounding and selection biases299.  It is for this 
reason, in combination with the heterogeneity noted particularly in relation to inclusion 
criteria and timing of outcome measure in the RCTs, that this review does not provide 
an overall meta-analysis, as it was not felt this would provide clinically useful 
information and may even be misleading.  It is acknowledged that both a previous 
review289 and an update to the Cochrane review (in press)286 have performed meta-
analysis of the two RCTs, however these papers recognise that significant 
heterogeneity exists and that the two trials appear to have opposite directions of effect.  
In view of this, comprehensive summaries of the characteristics and methodological 
quality of all included studies are reported.  To supplement this information sub-group 
analysis by inclusion criteria was performed so a pooled effectiveness estimate was 
obtained that could be generalised to the most common TTTS presentation 
encountered in clinical practice, i.e. prior to 26 weeks and without prior treatment.  This 
showed that the relative risk of survival of at least one twin was 1.33 (95% CI 1.17 – 
1.52), in favour of treatment with FLA and that these studies were statistically 
homogeneous.  With respect to differential survival of the donor and recipient this trend 
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was repeated, as was the evidence of homogeneity, although the confidence intervals 
for the donor crossed the line of no effect. 
 
In summary the evidence on which to base decisions regarding treatment for TTTS is 
not robust, although it is acknowledged that FLA is likely to confer improved survival 
chances for the pregnancy.  TTTS therefore remains a morbid condition and 
neurological morbidity remains a problem despite treatment305-307. However, as both 
RCTs were stopped early it seems unlikely that a further RCT will be funded but it 
should be acknowledged that trials stopped early provide less certainty with respect to 
treatment effect302 308.  
 
 
4.2 Biological markers for the investigation of the pathophysiology of 
TTTS 
 
4.2.1 Markers of placental destruction (AFP/hCG)  
Elevations in MSAFP and levels of free β-hCG have been associated with conditions 
associated with abnormal placentation such as pre-eclampsia, fetal growth restriction 
and miscarriage69.   Elevations of MSAFP have also been described after CVS71, and 
elevations of both MSAFP and free β-hCG after multifetal reduction procedures70.  This 
study is the first to investigate both the effect of TTTS and FLA on these same markers. 
It found there was no significant difference between median MSAFP and f-hCG MoM 
in uncomplicated DC and MC twin pregnancies in the mid-gestational period. However, 
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in TTTS there was a significant increase in median MSAFP and f-hCG MoM compared 
to uncomplicated twin pregnancies.  These data have also demonstrated a significant 
increase in MSAFP concentration post- FLA that persists until at least one week post-
procedure, with no associated increase in maternal f-hCG.   
 
A large cohort study309 has previously investigated the median MSAFP MoM in DC and 
MC twin pregnancies and is in agreement with these results.  However, this group noted 
a significant increase in median f-hCG MoM in monochorionic twin pregnancies, which 
this study did not find.  However, the previous study was focused mainly upon the role 
of second trimester analytes in screening for Down’s syndrome and there was limited 
information on the outcomes of these pregnancies.  It is possible that some of the 
cohort of twins may have suffered significant complications, such as TTTS and this may 
explain the inconsistency in Muller’s data309 and these data with respect to f-hCG.   
 
This study found that in TTTS, there is a significant increase in median MSAFP and f-
hCG MoM compared to uncomplicated twin pregnancies. Several hypotheses may be 
proposed to explain the difference in circulating maternal f-HCG in pregnancies with 
severe TTTS.  The polyhydramnios surrounding the recipient fetus may be associated 
with relatively impaired uteroplacental blood flow increasing the risks of hypoxaemia167. 
Several factors influence the placental production of HCG, including the total number of 
trophoblast cells, the degree of syncytialisation of cytotrophoblast302 and oxygenation 
within the placenta121.  The increase in maternal f-HCG may therefore reflect the large 
placental size in TTTS and changes in placental oxygen tension secondary to 
uteroplacental hypoperfusion. 
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Increased placental transfer of AFP may occur across fibrinoid deposits at 
discontinuities in the syncytiotrophoblast64 or by release from the decidua entering the 
maternal circulation300.  In syndromes with abnormal placentation, a prospective 
increase in MSAFP and hCG levels has been described297.  The increase in median 
MSAFP MoM in this cohort of pregnancies with severe TTTS may reflect the abnormal 
placentation in this condition.  It is not possible from this study to know whether the 
observed elevation in MSAFP and f-hCG in subjects with TTTS precedes the onset of 
the disease process.  If so, their measurement may be of use to aid prediction of TTTS, 
increasing the sensitivity of first trimester ultrasound screening212. 
 
Laser ablation of arterio-venous anastomoses ideally discontinues the inter-twin 
transfusion process. These data have demonstrated a significant increase in MSAFP 
concentration post- FLA that persists until at least one week post-procedure, with no 
associated increase in maternal f-hCG.  Immediate effects from laser have been 
described with coagulation necrosis from thermal injury observed around the 
coagulation site and complete cotyledon infarction caused by the arrest of blood flow310.  
The damaged cotyledon may continuously release trophoblast debris including DNA, 
RNA and proteins into the maternal circulation310. The number of chorionic vessels 
coagulated may reflect the number of ischaemic placental cotyledons but in this study, 
no association was noted between the rise in MSAFP and either the number of 
chorionic vessels coagulated or the total energy used during FLA.  MSAFP is selectively 
elevated compared to f-hCG levels suggesting a transplacental leak of fetal 
haematopoietic cells300.  Histological examination of the MC placentae post-FLA shows 
evidence of microvascular collapse with associated focal subchorionic haemorrhage310.  
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Feto-maternal transfusion from this surgery may increase placental permeability to AFP 
and lead to the observed rapid rise in MSAFP within six hours post-surgery.  This may 
indicate a continuing abnormality of transplacental AFP transport or clearance300 310.  
Despite abnormal fetoplacental blood flow being associated with at least one fetal death 
post-FLA, this study did not note any significant increase in MSAFP or f-HCG above 
twin pregnancies with dual survivors.  A rise in MSAFP has also been described where 
there is ‘microtrauma’ to the placenta, such as in chorionic villous sampling71 or in 
procedures where there is single fetal demise in multiple pregnancies311.  Deprest 
described a persistent elevation of plasma fetal DNA levels (but not RNA) after laser for 
up to 48 hours312 313 associated with longer operation time, number of chorionic vessels 
ablated and IUD of at least one twin after FLA for TTTS.  This indicates that the 
passage of proteins, RNA and DNA from the fetal to maternal circulations post-FLA may 
require a more complex explanation than simple ablative trophoblast damage or 
increased transplacental permeability.  
 
We have also investigated a small number of pregnancies complicated by mild TTTS 
where only amnioreduction was performed.  It is interesting to note that neither MSAFP 
nor f-hCG increase when this therapy was utilised, making it unlikely that 
amnioreduction is the stimulus to the observed rise in MSAFP after FLA (a procedure 
where amnioreduction is also performed). 
 
These data suggest that the basal rise in MSAFP and f-hCG associated with TTTS 
may be secondary to abnormal placentation, a process that precedes the onset of 
clinical disease.  Post-FLA there is a rise in MSAFP, with no corresponding rise in f-
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hCG, indicating an association with increased transplacental haemorrhage rather than 
trophoblast destruction.  This study therefore aids our understanding of the 
pathophysiology of TTTS as well as the effect of FLA, although it is acknowledged that 
these changes need to be confirmed to precede the onset of clinical disease as has 
been shown in relation to the pathophysiology of pre-eclampsia.  Of clinical relevance, if 
confirmed to precede disease onset, measurement of MSAFP and f-hCG may be 
useful adjuncts to ultrasound predictors of the development of disease.   
 
4.2.2 Angiogenic growth factors 
Placental expression and circulating levels of AGFs and their receptors have been 
implicated in the pathogenesis of conditions associated with abnormal placentation 
such as pre-eclampsia99-105, intrauterine growth restriction100-102 105-107 and conditions 
associated with fetal hydrops108. In addition TTTS, which is also associated with 
abnormal placentation, has been suggested to be a relatively anti-angiogenic 
condition110.  This study supports these findings by demonstrating a significant increase 
in median plasma sVEGFR-1 (and indeed the circulating sVEGFR-1/PlGF ratio) in 
those pregnancies complicated by severe TTTS as compared to uncomplicated di- and 
monochorionic twin pregnancies.  In addition, the amniotic fluid sVEGFR-1 
concentration was significantly higher than the maternal plasma concentration.  More 
comprehensively, it is the first study to also examined the circulating plasma and 
amniotic fluid concentrations of the VEGF isoforms (VEGF-A, VEGF-C and VEGF-D), 
PlGF and the angiopoietin/Tie complex in relation to the severity of TTTS and in 
response to FLA.  This showed that with more severe hydramnios angiogenesis in 
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response to hypoxic or inflammatory stimuli may be favoured.  Interestingly it did not 
show a marked change in AGFs and receptors in response to FLA. 
 
Angiogenesis and trophoblast/vascular interaction play an important role in human 
placentation75.  There is accumulating evidence that angiogenic factors, including those 
of the VEGF family, PlGF and the angiopoietins orchestrate materno-fetal circulatory 
interaction within the haemochorial placenta83 314.  Although there was no significant 
difference in the concentration of maternal plasma VEGF isoforms/sVEGFR-1 and 
angiopoietin/Tie-2 complex with increasing severity of TTTS (as denoted by Quintero 
staging alone), plasma VEGF-D was significantly increased in those pregnancies 
complicated by Stage III/IV TTTS when there was evidence of haemodynamic 
compromise in both the recipient and the donor, particularly in comparison with the 
recipient alone.  This is in keeping with the findings of other studies; in that maternal 
circulating angiogenic factors appear to be most altered when both utero- and 
fetoplacental blood flow are abnormal105.   
 
Interestingly, the expression of VEGF-A within the stromal core of the villi and 
syncytiotrophoblast is significantly increased when there is hydrops fetalis315, a situation 
mirrored within the fetal myocardium316.  Such an up regulation in these fetal organs is 
thought to be secondary to hypoxaemia.  There is some evidence that VEGF-A, 
expressed in amnion and chorionic, may control the intra-membranous absorption of 
fluid across fetal membranes and be involved in amniotic fluid regulation, a process that 
is abnormal in TTTS286 317. However, measured plasma VEGF-A did not appear to be 
significantly different in uncomplicated monochorionic twin pregnancies as compared to 
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those complicated by TTTS. Conversely, the plasma level of VEGF-C (a factor believed 
to orchestrate lymphangiogenesis) was significantly lower in twin pregnancies 
complicated by TTTS, as compared to uncomplicated MC twin pregnancies. 
 
These data demonstrate that maternal plasma concentrations of Ang-2 are increased in 
pregnancies complicated by TTTS compared to uncomplicated twin pregnancies, 
particularly uncomplicated DC twin pregnancies.  Physiologically, Ang-2 has the 
potential to favour angiogenesis in response to hypoxaemic or inflammatory stimuli, if 
concentrations are high relative to concentrations of Ang-1 and the VEGF isoforms318.  
Of interest is the observation from this study that in those MC twin pregnancies with 
TTTS in which there was severe hydramnios (as defined by the maximum pool depth > 
12cm), the amniotic fluid concentrations of VEGF-C and Ang-1 are significantly reduced 
compared to those with a maximum pool depth between 8-12cms, an observation 
independent of the effect of gestational age.  This is not thought to represent simply a 
dilutional effect as this would have been expected to affect all angiogenic factor 
comparisons. A previous study comparing amniotic fluid protein levels between non-
TTTS controls and TTTS recipients (by definition affected by polyhydramnios) showed 
higher overall protein levels in controls implying some dilutional effect but showed 
changes in markers of cardiac dysfunction despite this effect319, as is believed to have 
occurred here.   When gross polyhydramnios is present, a reduction in uteroplacental 
blood flow and increased local hypoxaemia has been reported167.  The observed 
changes in amniotic fluid VEGF-C and Ang-1 may be in response to this.  
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Abnormal placentation is associated with the development of excess rates of fetal loss, 
intrauterine growth restriction and maternal pre-eclampsia320, with associated 
uteroplacental ischaemia and endothelial cell dysfunction321.  The human placenta (and 
its underlying vasculature) appears to be a rich source of angiogenic factors, both the 
VEGF family314 322, the angiopoietins323 324 and their respective receptors.  Circulating 
plasma concentrations of angiogenic factors and the soluble VEGFR-1 are increased 
from early gestation, in at risk pregnancies, preceding the development of pre-
eclampsia85 105 325, intrauterine growth restriction101 105 326 327 and even fetal demise108 
328.  In addition, decreased plasma concentrations of sTie-2 have been reported in 
pregnancies complicated by pre-eclampsia and intrauterine growth restriction102, also 
implicating the angiopoietin/Tie system in the processes related to abnormal 
placentation.  The association of an anti-angiogenic process in severe IUGR appears 
strongest when abnormal blood flows, in both the uteroplacental and fetoplacental 
circulation, are noted105.  
 
Multiple pregnancies, and in particular monochorionic twin pregnancies, have 
significantly increased rates of pregnancy complications, especially pre-eclampsia and 
intrauterine growth restriction6 98.  In uncomplicated twin pregnancies, an elevation in 
maternal serum sVEGFR-1/PlGF ratio and sVEGFR-1 concentrations has been noted 
above singleton pregnancies98 329. Expression studies have indicated that it is the 
relative size of the placenta (compared to singletons) rather than an angiogenic 
response to relative hypoxaemia, which was responsible for this finding98.  However, 
expression of placental sVEGFR-1 is further increased if the twin pregnancy is 
complicated by intrauterine growth restriction330.  The effects of chorionicity are 
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unreported however, in TTTS, the placental size is significantly larger than in an 
uncomplicated monochorionic twin pregnancy331.  In this study there was no difference 
demonstrated between any of the circulating angiogenic factors or their receptors 
between uncomplicated dichorionic and monochorionic twin pregnancies at mid-
gestation, although it is conceded that the sample sizes are small, making a type 2 
statistical error possible. 
 
Kusanovic and colleagues110 have investigated maternal plasma circulating angiogenic 
factors PlGF and sVEGFR-1 in a cohort of monochorionic twin pregnancies complicated 
by TTTS (n=16).  Of this cohort 50% (8/16) had relatively mild TTTS with stage I/II 
disease.  Furthermore, in one of the other eight twin pregnancies, a co-twin death had 
already occurred (a process observed to increase sVEGFR-1 concentrations, 
irrespective of the underlying pathology)108.  It was noted that there was a higher 
median plasma concentration of sVEGFR-1 and a significantly lower PlGF 
concentration in the monochorionic twin cohort complicated by TTTS and the authors 
postulated that TTTS is associated with an ‘anti-angiogenic state’. This study has 
replicated their findings in relation to sVEGFR-1 and PlGF so could be taken to support 
this assertion.  More specifically, this study has shown that the balance of angiogenic 
factors i.e. higher angiogenin 2 and soluble vascular endothelial growth factor receptor 
1 appears to favour angiogenesis in response to hypoxia or ischaemia in TTTS.   
 
This study also investigated changes in maternal (and amniotic fluid) angiogenic factors 
in response to fetoscopic laser ablation, the treatment that appears to most consistently 
modify outcome in TTTS52. This process allows the prospective identification of 
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pathological arteriovenous anastomoses linking the cotyledonary circulations of both 
twins and the subsequent ablation of this placental abnormal angioarchitecture. The 
process inevitably causes some secondary trophoblast destruction and increased 
permeability between the maternal/fetal circulations141.  However, these data indicate 
that changes in maternal (and amniotic fluid) angiogenic growth factor concentrations in 
response to fetoscopic laser ablation are modest, if they occur at all.  They also appear 
to be independent of the number of AVA ablated, the amniotic fluid volume removed at 
the end of the procedure and as to the outcome of the pregnancy, in terms of fetal 
survival. 
 
Such data further aids understanding of the pathogenesis of the condition of TTTS, the 
responses to treatment and the relation to outcome. These data support that anti-
angiogenic activity is increased in severe TTTS. 
 
 
4.2.3 Maternal cell-free mRNA for angiogenic growth factors 
Analysis of plasma fetal DNA can indicate the presence and concentration of fetal 
genetic material in the circulation111.  In addition, plasma fetal RNA can impart valuable 
clues as to the gene expression patterns of fetal tissues123.  These data demonstrate 
that maternal cf- mRNA could be reliably detected for VEGF-A, Endoglin, PlGF, Ang-1 
and Ang-2 in twin pregnancies. This represents a broader range of cf-mRNA encoding 
genes than previously reported in twin pregnancies. Furthermore, a significant 
difference in VEGF-A, Endoglin and Ang-2 was demonstrated between uncomplicated 
twins and MC twin pregnancies complicated by TTTS.   
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Angiogenesis and trophoblast/vascular interaction play an important role in human 
placentation75.  There is accumulating evidence that angiogenic factors, including those 
of the VEGF family, PlGF, TGF- β1 and the angiopoietins orchestrate materno-fetal 
circulatory interaction within the haemochorial placenta81 83 314. There is some evidence 
that VEGF-A, expressed in amnion and chorion, may control the intra-membranous 
absorption of fluid across fetal membranes and be involved in amniotic fluid regulation, 
a process that is abnormal in TTTS286 317. The finding of elevated maternal cf-mRNA 
VEGF-A in TTTS, in comparison with uncomplicated twin pregnancies (particularly in 
comparison with uncomplicated DC twin pregnancies), supports this conclusion.  As an 
antagonist ligand for Tie-2, Ang-2 plays a role in dilatation of vessels and disruption of 
vessel integrity79 80. Physiologically, Ang-2 has the potential to favour angiogenesis in 
response to hypoxemic or inflammatory stimuli, if concentrations are high relative to 
concentrations of Ang-1 and the VEGF isoforms318. As TTTS is a condition associated 
with abnormal placentation, and there may be link with relative ischemia and/or 
hypoxemia, this could explain our finding of increased levels of cf-mRNA Ang-2.  The 
finding of increased Eng in TTTS is in keeping with previous work that has suggested 
that TTTS may be a relatively anti-angiogenic state110, as it is associated with 
endothelial dysfunction332 and its soluble form is known to inhibit the important role of 
TGF- β1 in trophoblast differentiation81. 
 
The number of twin pregnancies, complicated and uncomplicated, was relatively small 
but for certain cf-mRNAs significant differences were noted. However, the possibility 
that this represents a type 1 statistical error cannot be excluded.  It is also 
acknowledged that there are inherent difficulties in measuring fetal nucleic acids in the 
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maternal circulation and this is a field of ongoing advancement.  It is however, widely 
accepted that the placenta is the predominant source of fetal nucleic acid in the 
maternal plasma but that fetal nucleic acids only accounts for on average 3-6% of the 
cell-free nucleic acid present333.  For this reason the method used to detect this 
subpopulation of cell free nucleic acid must be able to differentiate this from the 
background maternal nucleic acid333.  Initially this was done by targeting genetic 
markers on the Y chromosome, but this was therefore only applicable in male fetuses.  
More recently several techniques have been developed to make prenatal nucleic acid 
evaluation relevant to all pregnancies.  As the size of fetal nucleic acid fragments is 
known to be smaller than maternal334, this size difference has been used to allow 
selectively enrichment of fetal nucleic acid335.  The main limitations of this approach are 
that the degree of enrichment possible is only moderate, and that the manipulations 
involved are liable to external contamination333.  Fetal epigenetic markers have also 
been used where methylation status differs between the fetus and the mother, but one 
marker tried336 involved techniques that can lead to destruction of a large proportion of 
the treated DNA337.  Due to these limitations the use of plasma RNA markers has also 
been explored after the discovery of placental specific mRNA120 338.  Reverse 
transcriptase PCR also has potential problems in quantitatively measuring RNA.  These 
include the need for a specific, sensitive and reproducible assay339.  Firstly, the use of 
mRNA-specific primers, as in this study, seeks to restrict the likelihood of background 
genomic DNA amplification339.  Secondly, there is a need to correct for any inter-sample 
variation by the use of an internal standard against which RNA values can be 
normalised339.  To find a reliable internal standard for this study experience from 
previous studies176-178 was utilised and after investigating a number of genes the one 
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with the least variation was chosen.  With a view to needing a method that was 
consistent Taqman was chosen as this has been shown to have a very low coefficient 
of variation340.  It was for these reasons that the analysis of fetal mRNA was conducted 
at a laboratory with proven expertise and reputation for previous work in this area.  A 
large prospective study measuring angiogenic factors in the late first trimester in all 
monochorionic twins, who could then be followed up to assess which were complicated 
by TTTS, would help to clarify the diagnostic possibilities of these plasma tests. 
 
Overall these findings aid the further understanding of the pathophysiology of the 
morbid condition of TTTS. In addition, if the alterations in maternal cf-mRNA precede 
the onset of clinically apparent disease, they may be useful as an adjuvant blood test to 
complement first trimester ultrasound screening.  
  
4.2.4 Cytokines 
Cytokines are known to be expressed in the placenta, decidua, and fetal membranes 
during normal pregnancy and are considered integral to the establishment and function 
of the placental/maternal interface129.  Disruption to cytokine balance has been 
implicated in conditions associated with failure of trophoblast invasion as well as 
placental hypoxia and vascular changes within the placenta, such as those seen in 
recurrent miscarriage, intrauterine growth restriction and pre-eclampsia129 130.  This 
study is the first to report a comprehensive range of cytokines in relation to severe 
TTTS, as well as the effect of treatment by FLA.  In addition, by the use of comparison 
groups of uncomplicated DC and MC twins it was found that TTTS is associated with 
minimal differences in cytokine levels. Treatment by FLA did not cause a significant 
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change in maternal plasma cytokine concentrations.  However, the amniotic fluid 
concentration of cytokines was significantly higher than those in maternal plasma in 
TTTS, for the TH1 inflammatory cytokines IFN-, IL-1β, IL-6, TNF-; the TH2 anti-
inflammatory cytokines IL-4, IL-10; the chemokine IL-8; as well as TIMP-1 and ICAM-1.  
 
The inclusion of both uncomplicated DC and MC twins in the basal comparison allowed 
examination of whether changes seen in TTTS were specific to this complication.  
TH1/TH2 cytokines were not significantly different in maternal plasma between the 
cases of uncomplicated MC and DC twins and those affected by severe TTTS.  This is 
in keeping with Huber’s study, which looked at AF IL-6, comparing TTTS pregnancies 
treated with laser with singleton pregnancies undergoing amniocentesis for 
karyotyping138, and did not find a significant difference either.  Only two cytokine related 
markers showed significant differences when uncomplicated MC and DC twins were 
compared with MC twins complicated by TTTS: these were PDGF-BB and TIMP-1. 
PDGF-BB is known to have a role in regulating cell growth and division341 as well as 
vessel stabilisation168 and was higher in twins with a DC placenta than those with a MC 
placenta (DC>TTTS>uncomplicated MC).  An increase in PDGF-BB has been observed 
in pregnancy-induced hypertension in association with diminished vascular 
remodelling168.  It is possible that there may be less vascular modelling in the DC than 
MC placenta, although given the association of vascular connections within the TTTS 
placenta17 one may have expected this level to be lowest, and as this finding only just 
reached significance further work is needed to evaluate the role of PDGF-BB.  TIMP-1 
is a member of the tissue inhibitors of metalloproteinase family known to modulate 
matrix metalloproteinase activity and suppress extracellular matrix turnover342.  It also 
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acts directly to inhibit cell growth and possibly induce apoptosis342.  The finding that 
TIMP-1 is higher in maternal plasma in TTTS than in uncomplicated twin pregnancies 
suggests usual cell proliferation and turnover may be disordered in TTTS.  Further work 
to evaluate the relevance of TIMP-1 to a causative mechanism would require a larger 
cohort, and possibly a broader range of members of the TIMP and MMP family, to be 
studied in MC twins prior to the onset of TTTS.  
 
In terms of sub-group analysis, there were modest changes. When considering the 
cytokines found to be significantly different when severity of polyhydramnios was 
considered it was evident that a more severe presentation was associated with lower 
concentrations of cytokines .e.g. recipient twin with polyhydramnios ≥12cm: maternal 
plasma ICAM-1 lower; AF IFN-γ, TNF-α, IL-2, IL-4, IL-5, IL-10, IL-13, KGF, FGF-basic, 
and TIMP-1 lower. As this level of polyhydramnios is associated with a reduction in 
uteroplacental blood flow and increased local hypoxemia167 it is possible that placental 
expression of cytokines is also reduced as a result.  With respect to EFW difference the 
trend for severity being associated with lower levels was continued but only AF ICAM-1 
was significantly different.  Increased AF ICAM-1 has been suggested to be associated 
with preterm birth343 but has not been studied in TTTS before.  With respect to the 
severity of haemodynamic changes, i.e. whether recipient cardiac dysfunction was 
absent or present, only maternal plasma PDGF-BB showed a significant difference, and 
this was higher.  Higher PDGF-BB has been associated with a reduction in vascular 
modelling168 and so we suppose that this may be contributing to worsening 
haemodynamics in TTTS. However, we consider these relatively isolated findings are 
currently of uncertain significance.  
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All cytokines, with the exception of PDGF-BB, were found in higher concentrations in 
amniotic fluid prior to FLA than maternal plasma. This difference was significant for the 
TH1 inflammatory cytokines IFN-, IL-1β, IL-6, TNF-; the TH2 anti-inflammatory 
cytokines IL-4, IL-10; the chemokine IL-8; as well as TIMP-1 and ICAM-1.  This is in 
keeping with a previous study describing the use of multiplex assays of inflammatory 
markers for analysis of different types of sample344.  It is known that the human placenta 
is a rich source of cytokines, as are the decidua and fetal membranes129. This may 
explain the higher concentrations in amniotic fluid compared to maternal plasma.  The 
lack of IL-8 in plasma is also of interest.  As IL-8 is thought to promote angiogenesis121, 
given the likelihood that TTTS is associated with anti-angiogenic activity110 163 its 
absence in TTTS is perhaps not surprising; however it absence, despite ELISA testing, 
in uncomplicated twins in this study and previous reports of higher levels in conditions 
associated with abnormal placentation, such as pre-eclampsia300, suggests this is an 
area that merits further study. 
 
There were no significant differences found in plasma cytokine levels before and after 
FLA. KGF was the only amniotic fluid marker to change and this was lower after FLA.  
KGF is an epithelial growth factor that is known to be expressed by endometrial 
epithelium and is thought to modulate PLAC1 (a trophoblast-specific gene) to promote 
trophoblast growth or differentiation345. It may also be involved in regeneration of the 
endometrium346, as well as the interaction between the decidua and chorion in early 
pregnancy347. It has also been studied in relation to preterm birth but no significant 
difference found between those delivering preterm or term343.  Animal studies have 
investigated its role in lung abnormalities in relation to prematurity348 349.  There is some 
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evidence that KGF may protect against the development of pulmonary hypertension349.  
Given the possibility that TTTS may be associated with abnormal placentation, a 
process known to be associated with abnormal trophoblast invasion, it would be 
interesting to study the role of KGF in TTTS further, including the significance of the 
change in amniotic fluid levels noted.  
 
FLA does not appear to be associated with significant trophoblast destruction141 and 
this may explain why cytokines levels in maternal plasma and amniotic fluid are not 
affected by such treatment.  The only previous study investigating cytokines in TTTS 
treated by fetoscopy measured IL-6 levels and their relation to very preterm birth but did 
not find any association in this cohort of 166 MC pregnancies complicated by TTTS139.  
As TTTS is associated with neurological morbidity in surviving infants, whether treated 
or not, it is important to investigate whether cytokine levels increased post treatment. It 
was particularly reassuring that amniotic fluid levels of inflammatory cytokines 
previously shown to be associated with cerebral palsy (IL-1β, IL-6 and TNF-)132 did not 
change. However, it cannot be assumed that such an association is causal.  It is 
acknowledged that amniotic fluid samples were collected immediately after FLA and 
there may be a greater time lag before changes in cytokine levels are apparent. 
However, ethical constraints prevented us from obtaining later amniotic fluid samples 
and we have obtained maternal plasma samples up to one week to provide as detailed 
information as possible with regard to the effect of FLA. 
 
This study reported the use of predominantly multiplex assays, which have the 
advantage of giving a broad picture of the immune response.  It is noteworthy that this 
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study found TTTS is associated with minimal changes in cytokine levels when 
compared to uncomplicated twins, although the majority of cytokine levels were higher 
in amniotic fluid than maternal blood. Through the use of assays providing sensitivities 
for cytokines akin to levels reported by previous studies138 139 350 351 it does not appear 
that FLA provokes a significant cytokine response. It is acknowledged that where 
differences were not found with multiplex assays it may be worthwhile conducting 
ELISA testing to confirm these findings and that the numbers of twin pregnancies 
studied was small so a type 2 error is possible.  
 
This study provides a novel insight into cytokines in relation to TTTS and some 
reassurance regarding treatment with FLA. To shed further light on the pathophysiology 
of TTTS it would be useful to measure cytokines in a large cohort of MC twins prior to 
the onset of TTTS. 
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4.3 Conclusions  
 
CRL and NT measurement in the first trimester is routine practice in twin pregnancies.  
Calculation of CRL discordance of ≥ 10% is the best screening tool for TTTS, with 
nuchal translucency > 95th percentile and calculation of nuchal translucency 
discordance of ≥ 20% also of value.  These tests are useful for showing those at high 
risk of TTTS but all MCDA twins still need regular follow up as a negative test does not 
exclude TTTS.  Donor DV abnormality showed moderate predictive accuracy for 
predicting donor IUD after diagnosis of TTTS and should be incorporated into routine 
assessment.  Again a negative test does not ensure a good outcome and all TTTS 
pregnancies require regular follow up regardless of whether treated.  FLA appears to 
offer both survival and morbidity advantages over serial amniodrainage in the treatment 
of TTTS.  Unfortunately, TTTS remains a high-risk condition with considerable morbidity 
despite treatment. 
 
In terms of the pathophysiology of TTTS the changes seen in relation to markers of 
placental destruction and angiogenesis support the understanding that TTTS is one of a 
number of conditions associated with abnormal placentation.  It seems that in TTTS the 
balance of angiogenic factors appears to favour angiogenesis in response to hypoxia or 
ischaemia however, it is associated with minimal changes in cytokine levels.  FLA 
appears to be associated with transplacental haemorrhage rather than trophoblast 
destruction.  Interestingly, FLA does not seem to provoke much, if any, response in 
angiogenic growth factors or cytokines. 
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4.4 Recommendations for future research in TTTS 
 
Ultrasound tests in the first trimester seem to be of value in screening for TTTS.  
However, further research to evaluate the use of a combination of tests, such as the 
both CRL and NT discordance, may be able to improve on the current sensitivity of 
individual tests.  This supposition could also relate to ultrasound tests to predict 
outcome of TTTS after diagnosis. There are currently no tests that can reliably predict 
either a good or poor outcome however, any combination test utilised in further 
research should include DV assessment as this was the test that showed the most 
promise. 
 
In terms of treatment for TTTS it seems unlikely future randomised trials to evaluate 
FLA and serial amnioreduction would be funded, given that both RCTs were stopped 
early. It appears that FLA does offer survival and morbidity advantages but individual 
patient data analysis could increase clinicians’ certainty.  Although some authors were 
not able to provide data for this review it has been indicated that with further time and 
the possibly the establishment of a collaborative group of experts in this area the 
difficulties encountered could be overcome. 
 
With respect to the work on biomarkers in TTTS several exciting prospects in terms of 
angiogenic growth factors and markers of placental function have been highlighted.  
Further research should focus on conducting a large prospective cohort study in 
monochorionic twins in the first trimester.  This would allow biomarkers to be measured 
prior to the onset of TTTS and noting any differences evident in twins that went on to 
develop TTTS in comparison with those that did not.  This would test the hypothesis 
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that the changes noted in this thesis are part of the pathogenesis of the condition.   This 
study could employ both individual ELISA and multiplex assay testing.  If biomarker 
changes are confirmed to pre-date the onset of clinical disease, as this is diagnosed on 
ultrasound, these biomakers could be incorporated into first or early second trimester 
testing utilising ultrasound, more specifically CRL and NT, to produce a combination 
test with greater sensitivity and specificity than ultrasound alone. 
 
 
 
 
 
 
 
 
  
 168 
APPENDICES 
Appendix 1  
 
Search strategy for reviews 
 
1. Twins/ or Diseases in Twins/ 
2. Fetofetal Transfusion/ 
3. fetofetal transfusion.mp. or Fetofetal Transfusion/ 
4. Twin Oligohydramnios-Polyhydramnios Sequence.mp. 
5. twin to twin.mp. 
6. feto fetal.mp. 
7. twin twin.mp. 
8. feto feto.mp 
9. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 
10. limit 9 to "therapy (sensitivity)" 
11. limit 9 to "diagnosis (sensitivity)" 
12. limit 9 to "prognosis (sensitivity)" 
13. 10 or 11 or 12 
14. limit 13 to animals 
15. 13 not 14 
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Appendix 2  
Study selection and data extraction form for diagnostic accuracy of ultrasound in the 
first trimester for the prediction of which MC twin pregnancies will be affected by TTTS. 
Reviewer ID ………… Date   …………………    Paper no ………………… 
Year of publication ………... Language …………….       Region …………………... 
Selection or rejection  (must have all Y) 
a) Population – (pregnant with MC twins)      Y/N 
b) Index test:          Y/N 
c) Reference test/ outcome measure:      Y/N 
d) 2x2 table possible:        Y/N 
   
Select this study?  Y/N  If this is Y – complete this form 
     If N must describe why…….………………………… 
 
Data extraction 
Population 
Total number of patients/fetuses recruited (n)/(n)    (…….)/(…….) 
Confirmation of chorionicity   Y/N 
Method described    Y/ N …………………….  
 
Study Design 
RCT/ Controlled observational study/ Uncontrolled study 
Data collection     retrospective/prospective/unreported/other 
Patient enrolment    consecutive/arbitrary/unreported/other 
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Outcomes 
Complete follow up:        yes/ no/ can’t tell 
Percentage of follow up  (>90%; 81-91%; <81%)  n (…….)/ % ……. 
Comments on data available: 
……………………………………………………………………………………………………
……… 
Index Test 
Describe the interventions for which this form is being used 
……………………………………………………………………………………………… 
Description of test:   a)complete b) incomplete c) can’t tell 
Gestational age at test   i) average    (…….)wks 
     ii) range    (………….)wks 
Timing of measurement …………………………………………………………………… 
Method of measurement …………………………………………………………………… 
No of operators/experience …………………………………………………………………… 
A Eligible Patients 
n=  
C Index Test 
n=  
E Reference Test 
n=  
D Post Enrolment 
Exclusions 
                 n= 
B Excluded 
Patients 
n=  
B reason …………….. 
D reason …………….. 
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Reference standard/ outcome 
Measured blind from diagnostic test        yes/ no/ can’t 
tell 
Reference standard used …………………………………………………………………… 
Threshold …………………………………………………………………… 
Dataset used to establish threshold …………………………………………………………… 
Timing of measurement     
 
Results 
 
 
 
 
 
 
 
 
 
 
 
Population:                          Reference Test: 
                         Threshold: 
 
Index test, 
Measurement: 
 
 
Threshold: 
 Positive 
 
Negative Total 
Positive 
 
TP FP  
Negative 
 
FN TN  
 Total    
Population:                          Reference Test: 
                         Threshold: 
 
Index test, 
Measurement: 
 Positive 
 
Negative Total 
Other Information (ie. other statistics, measures of uncertainty etc) 
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Specify outcome ….…………….. 
 Test 1 
…………………… 
Test 2 
………………….. 
Total 
Present    
 
 
Threshold: 
Positive 
 
TP FP  
Negative 
 
FN TN  
 Total    
Population:                          Reference Test: 
                         Threshold: 
 
Index test, 
Measurement: 
 
 
Threshold: 
 Positive 
 
Negative Total 
Positive 
 
TP FP  
Negative 
 
FN TN  
 Total    
Other Information (ie. other statistics, measures of uncertainty etc) 
Other Information (ie. other statistics, measures of uncertainty etc) 
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Absent    
Total    
 
Specify outcome ….…………….. 
 Test 1 
…………………… 
Test 2 
………………….. 
Total 
Present    
Absent    
Total    
 
Specify outcome ….…………….. 
 Test 1 
…………………… 
Test 2 
………………….. 
Total 
Present    
Absent    
Total    
 
Specify outcome ….…………….. 
 Test 1 
…………………… 
Test 2 
………………….. 
Total 
Present    
Absent    
Total    
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Appendix 3 
Study selection and data extraction form for diagnostic accuracy of ultrasound in the 
prediction of outcome of TTTS after diagnosis.  
Reviewer ID ………… Date   …………………    Paper no ………………… 
Year of publication ………... Language ……………. Region …………………... 
Selection or rejection  (must have all Y) 
a) Population – (pregnant with MC twins and features of TTTS)   Y/N 
b) Index test :          Y/N 
c) Reference test/ outcome measure:      Y/N 
d) 2x2 table possible:        Y/N 
   
Select this study?  Y/N  If this is Y – complete this form 
     If N must describe why…….………………………… 
 
Data extraction 
Population 
Total number of patients/fetuses recruited (n)/(n)    (…….)/(…….) 
Confirmation of chorionicity   Y/N 
Method described    Y/ N …………………….  
Study Design 
RCT/ Controlled observational study/ Uncontrolled study 
Data collection     retrospective/prospective/unreported/other 
Patient enrolment    consecutive/arbitrary/unreported/other 
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Outcomes 
Complete follow up:        yes/ no/ can’t tell 
Percentage of follow up  (>90%; 81-91%; <81%)  n (…….)/ % ……. 
Comments on data available: 
……………………………………………………………………………………………………
……… 
Index Test 
Describe the interventions for which this form is being used 
……………………………………………………………………………………………………
…… 
Description of test:   a)complete b) incomplete c) can’t tell 
Gestational age at test   i) average    (…….)wks 
     ii) range    (………….)wks 
Timing of measurement …………………………………………………………………… 
Method of measurement …………………………………………………………………… 
No of operators/experience …………………………………………………………………… 
A Eligible Patients 
n=  
C Index Test 
n=  
E Reference Test 
n=  
D Post Enrolment 
Exclusions 
                 n= 
B Excluded 
Patients 
n=  
B reason …………….. 
D reason …………….. 
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Reference standard/ outcome 
Measured blind from diagnostic test        yes/ no/ can’t 
tell 
Reference standard used …………………………………………………………………… 
Threshold …………………………………………………………………… 
Dataset used to establish threshold …………………………………………………………… 
Timing of measurement 
     
Results 
 
 
 
 
 
 
 
 
 
 
 
 
 
Population:                          Reference Test: 
                         Threshold: 
 
Index test, 
Measurement: 
 
 
Threshold: 
 Positive 
 
Negative Total 
Positive 
 
TP FP  
Negative 
 
FN TN  
 Total    
Other Information (ie. other statistics, measures of uncertainty etc) 
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Specify outcome ….…………….. 
 Test 1 
…………………… 
Test 2 
………………….. 
Total 
Present    
Absent    
Total    
 
Specify outcome ….…………….. 
 Test 1 
…………………… 
Test 2 
………………….. 
Total 
Present    
Population:                          Reference Test: 
                         Threshold: 
 
Index test, 
Measurement: 
 
 
Threshold: 
 Positive 
 
Negative Total 
Positive 
 
TP FP  
Negative 
 
FN TN  
 Total    
Other Information (ie. other statistics, measures of uncertainty etc) 
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Absent    
Total    
 
Specify outcome ….…………….. 
 Test 1 
…………………… 
Test 2 
………………….. 
Total 
Present    
Absent    
Total    
 
Specify outcome ….…………….. 
 Test 1 
…………………… 
Test 2 
………………….. 
Total 
Present    
Absent    
Total    
 
Specify outcome ………………………… 
 Test 1 
…………………… 
Test 2 
………………….. 
Total 
Present    
Absent    
Total    
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Appendix 4 
Study selection and data extraction form for the review of effectiveness of FLA and 
serial amnioreduction in the treatment of TTTS.  
Reviewer ID ………… Date   …………………    Paper no ………………… 
Year of publication ………... Language ……………. Region …………………... 
Selection or rejection  (must have a) Y and b) two Y) 
a) Population – (pregnant with MC twins and features of TTTS)   Y/N 
b) Interventions  
i. Amnioreduction      Y/N 
ii. Laser        Y/N 
Select this study?   Y/N  If this is Y – complete this form 
      If N must describe why rejected 
……………………………………………………………………………………………… 
 
Data extraction 
Population 
Total number of patients/fetuses recruited (n)/(n)    (…….)/(…….) 
Data collection     retrospective/prospective/unreported/other 
Patient enrolment    consecutive/arbitrary/unreported/other 
Confirmation of chorionicity   Y/N 
Method described    Y/ N …………………….  
Interventions 
Describe the interventions for which this form is being used 
……………………………………………………………………………………………………
…… 
Description  of interventions:   a)complete b) incomplete c) can’t tell 
Gestational age at intervention i) average    (…….)wks 
     ii) range    (………….)wks 
Outcomes 
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Complete follow up:        yes/ no/ can’t tell 
Percentage of follow up  (>90%; 81-91%; <81%)  n (…….)/ % ……. 
Blinding of intervention from outcome     yes/ no/ unreported 
Comments on data available: 
……………………………………………………………………………………………………
……… 
Did anyone not get the intended treatment or who got more than one treatment and why 
……………………………………………………………………………………………………
…….. 
Study Design 
RCT/ Controlled observational study/ Uncontrolled study 
Specify outcome … SURVIVAL- overall 
 Intervention 1 
…………………… 
Intervention 2 
………………….. 
Total 
Present    
Absent    
Total    
 
Specify outcome …SURVIVAL- of at least one 
 Intervention 1 
…………………… 
Intervention 2 
………………….. 
Total 
Present    
Absent    
Total    
 
 
Specify outcome …SURVIVAL- donor 
 Intervention 1 Intervention 2 Total 
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…………………… ………………….. 
Present    
Absent    
Total    
 
Specify outcome …SURVIVAL- recipient 
 Intervention 1 
…………………… 
Intervention 2 
………………….. 
Total 
Present    
Absent    
Total    
 
Specify outcome ………………………… 
 Intervention 1 
…………………… 
Intervention 2 
………………….. 
Total 
Present    
Absent    
Total    
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Appendix 5 
Studies excluded from the review diagnostic accuracy of ultrasound in the first trimester 
for the prediction of which MC twin pregnancies will be affected by TTTS. 
 
1. Cheng,P.J.; Huang,S.Y.; Shaw,S.W.; Hsiao,C.H.; Kao,C.C.; Chueh,H.Y.; Hsieh,T.T. Difference in 
nuchal translucency between monozygotic and dizygotic spontaneously conceived twins. Prenat 
Diagn. 30(3):247-50, 2010 Mar 
2. Lewi,L.; Lewi,P.; Diemert,A.; Jani,J.; Gucciardo,L.; Van,Mieghem T.; Done,E.; Gratacos,E.; 
Huber,A.; Hecher,K.; Deprest,J. The role of ultrasound examination in the first trimester and at 
16 weeks' gestation to predict fetal complications in monochorionic diamniotic twin 
pregnancies. Am J Obstet Gynecol. 199(5):493.e1-7, 2008 Nov 
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Appendix 8  
Morbidity, gestational age and birth weight data for review of effectiveness of FLA and 
serial amniodrainage for treatment of TTTS:  
(where p values are not stated the differences are not statistically significant, p=0.05 
taken to be significant) 
RCT – inclusion after qualifying amnioreduction 
Crombleholme et al 
- Gestational age at delivery (wks) – Mean – laser 30.67; AR 30.29 
- Delivery <32 wks – data not known  
- Fetal morbidity – data not known 
- Maternal morbidity – 
Mini-laparotomy in 7 cases in laser group to expose the surface of the uterus 
Uterine bleeding n=1 Laser (no maternal transfusion needed but procedure had 
to be stopped due to poor visualisation; n=0 AR 
Spinal headache n=1 (group not specified) 
Maternal hospitalisation (including for preterm labour, short cervix, preterm 
prelabour rupture of membranes (PPROM) or to monitor fetal growth) 9.5% each 
arm 
PPROM prior to 28/40 laser 4.8%, AR 0; requirement for additional tocolysis 
laser 0, AR 4.8%; delivery <28/40 laser 9.5% (n=2), AR 4.8% (n=1).  
 RCT – inclusion at diagnosis 
Senat et al 
- Gestational age at delivery (wks) – Median- laser 33.3; SA 29.0 p=0.004 
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- Delivery <32 wks – Laser 30/72 (41.7%); SA 48/70 (68.6%)  
- Fetal morbidity 
Alive without major neurological morbidity at 6/12 overall- Laser 75/144 (52.1%); 
SA 44/140 (31.4%) p=0.003 
Alive without major neurological morbidity at 6/12 donor- Laser 36/72 (50%); SA 
25/70 (357%) p=0.09 
Alive without major neurological morbidity at 6/12 recipient- Laser 39/72 (54.2%); 
SA 19/70 (27.1%) p=0.001 
- Maternal morbidity 
Intra-abdominal fluid leak   n=2 Laser; n=0 SA  
Abruptio placenta n=1 Laser; n=2 SA  
 
Observational studies – inclusion at diagnosis 
Middledorp et al (recruitment only after 26 weeks) 
- Gestational age at delivery (wks) – Median - laser 31; SA 29 
- Interval between intervention and delivery (days) – Median – laser 31, SA 9 
- Birth weight (g) – Mean (SD) – laser 1615 (516); SA 1472 (634) p=0.43 
- Fetal morbidity:  
Major neonatal morbidity (necrotising enterocolitis (NEC) grade III, chronic lung 
disease, terminal renal failure) – laser 0, SA 6 (27%) p=0.02 
Severe cerebral injury – laser 3 (15%), SA 5 (23%) p=0.7 
Adverse outcome (IUD, neonatal death, major neonatal morbidity or severe 
cerebral injury) – laser 3 (15%), SA 8 (36%) p=0.17 
- Maternal morbidity: 
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Need for additional tocolysis – laser 2 (20%), SA 9 (82%) p=0.009 
PPROM within 2 weeks of procedure – laser 0, SA 1 (9%) 
 
Hecher et al 
- Gestational age at delivery (wks) – Median/Range – laser 33.7 / 24.9-40.3; SA 30.7 / 
27.7-37.3 p=0.018 
- Interval between intervention and delivery (days) – Median (range) – laser 90 (2-134); 
SA 72 (27-131) p=0.022  
- Birth weight (g) 
Donor median (range) – laser 1750 (470-2960); SA 1145 (660-2660) p=0.034 
Recipient median (range) – laser 2000 (460-3460); SA 1560  (870-2660) p=0.076 
- Fetal morbidity: 
Incidence of abnormal ultrasound findings in the brain in neonates Laser 5/89 
(6%); SA 8/44 (18%) p=0.03 
 
Quintero et al 
- Gestational age at delivery (wks) – Median/range- Laser 32 / 16.7-40.3); SA 29 / 18.4-
38 p=0.005 
- Interval between intervention and delivery (wks) – Median/range- Laser 10.3 / 0-21.4; 
SA 6.9 / 0-19 p<0.001 
 - Mean birth weight (g) 
Donor- laser 1781  734; SA 1219  644 p<0.001 
Recipient- laser 1940  773; SA 1612  724 p=0.019 
- Fetal morbidity: 
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Neurological morbidity (at least 1 fetus per pregnancy) Laser 4/95 (4.2%); SA 
19/78 (24.4%) including 4 neurological damage both fetuses= total with 
neurological morbidity 23 
Donor neurological morbidity Laser 3/65 (4.7%); SA 12/66 (18.2%) p=0.014 
Recipient neurological morbidity Laser 1/71 (1.4%); SA 11/64 (17.2%) p=0.001 
Intact neurological survival (1NN survivor per pregnancy, neither twin with 
neurological damage) Laser 75/95 (78.9%); SA 40/78 (51.3%) p<0.001 
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